WO2022045273A1 - α-N-アセチルグルコサミニダーゼの変異体 - Google Patents
α-N-アセチルグルコサミニダーゼの変異体 Download PDFInfo
- Publication number
- WO2022045273A1 WO2022045273A1 PCT/JP2021/031431 JP2021031431W WO2022045273A1 WO 2022045273 A1 WO2022045273 A1 WO 2022045273A1 JP 2021031431 W JP2021031431 W JP 2021031431W WO 2022045273 A1 WO2022045273 A1 WO 2022045273A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino acid
- acid sequence
- hnaglu
- acid residues
- combination
- Prior art date
Links
- 108010009380 alpha-N-acetyl-D-glucosaminidase Proteins 0.000 title description 9
- 102100034561 Alpha-N-acetylglucosaminidase Human genes 0.000 title description 7
- 101000924350 Homo sapiens Alpha-N-acetylglucosaminidase Proteins 0.000 claims abstract description 504
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 156
- 230000035772 mutation Effects 0.000 claims abstract description 92
- 125000000539 amino acid group Chemical group 0.000 claims description 382
- 150000001413 amino acids Chemical group 0.000 claims description 242
- 238000006467 substitution reaction Methods 0.000 claims description 176
- 238000012217 deletion Methods 0.000 claims description 171
- 230000037430 deletion Effects 0.000 claims description 171
- 210000004899 c-terminal region Anatomy 0.000 claims description 87
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 68
- 235000004400 serine Nutrition 0.000 claims description 68
- 239000004475 Arginine Substances 0.000 claims description 56
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 56
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims description 55
- 239000013604 expression vector Substances 0.000 claims description 55
- 102000004169 proteins and genes Human genes 0.000 claims description 55
- 235000018102 proteins Nutrition 0.000 claims description 49
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 46
- 102000037865 fusion proteins Human genes 0.000 claims description 46
- 108020001507 fusion proteins Proteins 0.000 claims description 46
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims description 41
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 33
- 239000004472 Lysine Substances 0.000 claims description 33
- 239000004471 Glycine Substances 0.000 claims description 31
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 31
- 210000004962 mammalian cell Anatomy 0.000 claims description 29
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 27
- 235000013922 glutamic acid Nutrition 0.000 claims description 27
- 239000004220 glutamic acid Substances 0.000 claims description 27
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims description 25
- 229960000310 isoleucine Drugs 0.000 claims description 24
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Chemical group CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 24
- 235000014705 isoleucine Nutrition 0.000 claims description 24
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Chemical group OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 23
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 20
- 229960003136 leucine Drugs 0.000 claims description 20
- 235000005772 leucine Nutrition 0.000 claims description 20
- 238000004519 manufacturing process Methods 0.000 claims description 20
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 20
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 claims description 19
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 18
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 18
- 235000004554 glutamine Nutrition 0.000 claims description 18
- 239000004474 valine Substances 0.000 claims description 18
- 229960004295 valine Drugs 0.000 claims description 18
- 235000014393 valine Nutrition 0.000 claims description 18
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 17
- 102000005962 receptors Human genes 0.000 claims description 17
- 108020003175 receptors Proteins 0.000 claims description 17
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical group OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 15
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 15
- 239000004473 Threonine Substances 0.000 claims description 15
- 235000003704 aspartic acid Nutrition 0.000 claims description 15
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 15
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 15
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 15
- 239000012679 serum free medium Substances 0.000 claims description 15
- 235000008521 threonine Nutrition 0.000 claims description 15
- 102000007238 Transferrin Receptors Human genes 0.000 claims description 14
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 14
- 108010033576 Transferrin Receptors Proteins 0.000 claims description 13
- 235000004279 alanine Nutrition 0.000 claims description 13
- 238000012258 culturing Methods 0.000 claims description 12
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims description 12
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims description 12
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 10
- 235000009582 asparagine Nutrition 0.000 claims description 10
- 229960001230 asparagine Drugs 0.000 claims description 10
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 9
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 8
- 230000008499 blood brain barrier function Effects 0.000 claims description 8
- 210000002889 endothelial cell Anatomy 0.000 claims description 8
- 210000001218 blood-brain barrier Anatomy 0.000 claims description 7
- BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical compound NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 claims description 6
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims description 6
- YWAQATDNEKZFFK-BYPYZUCNSA-N Gly-Gly-Ser Chemical compound NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O YWAQATDNEKZFFK-BYPYZUCNSA-N 0.000 claims description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 4
- 230000002490 cerebral effect Effects 0.000 claims description 4
- 210000003556 vascular endothelial cell Anatomy 0.000 claims description 4
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims description 3
- 108010001127 Insulin Receptor Proteins 0.000 claims description 3
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims description 3
- 102000011965 Lipoprotein Receptors Human genes 0.000 claims description 3
- 108010061306 Lipoprotein Receptors Proteins 0.000 claims description 3
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 claims description 3
- XZKQVQKUZMAADP-IMJSIDKUSA-N Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(O)=O XZKQVQKUZMAADP-IMJSIDKUSA-N 0.000 claims description 3
- 102000005861 leptin receptors Human genes 0.000 claims description 3
- 108010019813 leptin receptors Proteins 0.000 claims description 3
- 102100036721 Insulin receptor Human genes 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract description 440
- 230000014509 gene expression Effects 0.000 abstract description 65
- 238000007792 addition Methods 0.000 description 125
- 235000001014 amino acid Nutrition 0.000 description 118
- 229940024606 amino acid Drugs 0.000 description 116
- 210000004027 cell Anatomy 0.000 description 105
- 108020004414 DNA Proteins 0.000 description 65
- 239000012634 fragment Substances 0.000 description 60
- 241000282414 Homo sapiens Species 0.000 description 55
- 239000002609 medium Substances 0.000 description 47
- 238000000034 method Methods 0.000 description 35
- 239000002773 nucleotide Substances 0.000 description 34
- 125000003729 nucleotide group Chemical group 0.000 description 34
- 230000027455 binding Effects 0.000 description 29
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 26
- 239000013598 vector Substances 0.000 description 25
- 239000012228 culture supernatant Substances 0.000 description 24
- 239000013612 plasmid Substances 0.000 description 23
- 230000010474 transient expression Effects 0.000 description 23
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 21
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 21
- 239000000427 antigen Substances 0.000 description 18
- 102000036639 antigens Human genes 0.000 description 18
- 108091007433 antigens Proteins 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- HSHNITRMYYLLCV-UHFFFAOYSA-N 4-methylumbelliferone Chemical compound C1=C(O)C=CC2=C1OC(=O)C=C2C HSHNITRMYYLLCV-UHFFFAOYSA-N 0.000 description 16
- 102000004190 Enzymes Human genes 0.000 description 16
- 108090000790 Enzymes Proteins 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 108010030074 endodeoxyribonuclease MluI Proteins 0.000 description 16
- 239000000499 gel Substances 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 15
- 238000012790 confirmation Methods 0.000 description 14
- 108091008146 restriction endonucleases Proteins 0.000 description 14
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- 241000124008 Mammalia Species 0.000 description 12
- 239000012528 membrane Substances 0.000 description 12
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 11
- 210000004408 hybridoma Anatomy 0.000 description 11
- 102200082921 rs33948615 Human genes 0.000 description 11
- 102220309268 rs904453895 Human genes 0.000 description 11
- 239000012488 sample solution Substances 0.000 description 11
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical group OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 10
- 241000700605 Viruses Species 0.000 description 10
- 239000002299 complementary DNA Substances 0.000 description 10
- 238000001962 electrophoresis Methods 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical group C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 10
- 102220063383 rs786204916 Human genes 0.000 description 10
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 208000025820 Sanfilippo syndrome type B Diseases 0.000 description 9
- 208000012227 mucopolysaccharidosis type IIIB Diseases 0.000 description 9
- 230000000717 retained effect Effects 0.000 description 9
- 230000002441 reversible effect Effects 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- 239000000872 buffer Substances 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 8
- 208000005340 mucopolysaccharidosis III Diseases 0.000 description 8
- 208000011045 mucopolysaccharidosis type 3 Diseases 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 7
- 229920002971 Heparan sulfate Polymers 0.000 description 7
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 7
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 7
- 239000007983 Tris buffer Substances 0.000 description 7
- 210000003169 central nervous system Anatomy 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 7
- 239000012086 standard solution Substances 0.000 description 7
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 7
- 241000251730 Chondrichthyes Species 0.000 description 6
- 101100421450 Drosophila melanogaster Shark gene Proteins 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000000020 Nitrocellulose Substances 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000004422 calculation algorithm Methods 0.000 description 6
- 238000011088 calibration curve Methods 0.000 description 6
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000003028 enzyme activity measurement method Methods 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 229920001220 nitrocellulos Polymers 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- HKZAAJSTFUZYTO-LURJTMIESA-N (2s)-2-[[2-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoic acid Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O HKZAAJSTFUZYTO-LURJTMIESA-N 0.000 description 5
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 5
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 108010076504 Protein Sorting Signals Proteins 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 5
- 239000007853 buffer solution Substances 0.000 description 5
- 201000002491 encephalomyelitis Diseases 0.000 description 5
- 210000003527 eukaryotic cell Anatomy 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 229950010131 puromycin Drugs 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 101000766306 Homo sapiens Serotransferrin Proteins 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 238000000246 agarose gel electrophoresis Methods 0.000 description 4
- 229960003767 alanine Drugs 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000002641 enzyme replacement therapy Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 229960000890 hydrocortisone Drugs 0.000 description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 201000000050 myeloid neoplasm Diseases 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 4
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
- 241000699802 Cricetulus griseus Species 0.000 description 3
- 241000701022 Cytomegalovirus Species 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 3
- 241000283086 Equidae Species 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108091081024 Start codon Proteins 0.000 description 3
- 102000044159 Ubiquitin Human genes 0.000 description 3
- 108090000848 Ubiquitin Proteins 0.000 description 3
- 108010006025 bovine growth hormone Proteins 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 239000007986 glycine-NaOH buffer Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 208000036709 mucopolysaccharidosis type 3B Diseases 0.000 description 3
- QCTHLCFVVACBSA-UHFFFAOYSA-N n-[4,5-dihydroxy-6-(hydroxymethyl)-2-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]acetamide Chemical compound CC(=O)NC1C(O)C(O)C(CO)OC1OC1=CC=C(C(C)=CC(=O)O2)C2=C1 QCTHLCFVVACBSA-UHFFFAOYSA-N 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 description 3
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- 102100027377 HBS1-like protein Human genes 0.000 description 2
- 101001009070 Homo sapiens HBS1-like protein Proteins 0.000 description 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
- 108020005350 Initiator Codon Proteins 0.000 description 2
- 102000003746 Insulin Receptor Human genes 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- UGJBHEZMOKVTIM-UHFFFAOYSA-N N-formylglycine Chemical compound OC(=O)CNC=O UGJBHEZMOKVTIM-UHFFFAOYSA-N 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 239000012124 Opti-MEM Substances 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 108010022394 Threonine synthase Proteins 0.000 description 2
- 241001416177 Vicugna pacos Species 0.000 description 2
- 229930003779 Vitamin B12 Natural products 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- GHWVXCQZPNWFRO-UHFFFAOYSA-N butane-2,3-diamine Chemical compound CC(N)C(C)N GHWVXCQZPNWFRO-UHFFFAOYSA-N 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960001031 glucose Drugs 0.000 description 2
- 229960002743 glutamine Drugs 0.000 description 2
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Chemical compound NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 2
- 206010019847 hepatosplenomegaly Diseases 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 150000002506 iron compounds Chemical class 0.000 description 2
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 2
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 2
- 210000003712 lysosome Anatomy 0.000 description 2
- 230000001868 lysosomic effect Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 239000003471 mutagenic agent Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 125000003835 nucleoside group Chemical group 0.000 description 2
- 239000007793 ph indicator Substances 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- -1 respectively Natural products 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000012723 sample buffer Substances 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 229940054269 sodium pyruvate Drugs 0.000 description 2
- 229960001471 sodium selenite Drugs 0.000 description 2
- 235000015921 sodium selenite Nutrition 0.000 description 2
- 239000011781 sodium selenite Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000011715 vitamin B12 Substances 0.000 description 2
- 235000019163 vitamin B12 Nutrition 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- RLMISHABBKUNFO-WHFBIAKZSA-N Ala-Ala-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O RLMISHABBKUNFO-WHFBIAKZSA-N 0.000 description 1
- CXISPYVYMQWFLE-VKHMYHEASA-N Ala-Gly Chemical compound C[C@H]([NH3+])C(=O)NCC([O-])=O CXISPYVYMQWFLE-VKHMYHEASA-N 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000710190 Cardiovirus Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 108700006830 Drosophila Antp Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000710188 Encephalomyocarditis virus Species 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000014770 Foot disease Diseases 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000899240 Homo sapiens Endoplasmic reticulum chaperone BiP Proteins 0.000 description 1
- 101100434895 Homo sapiens NAGLU gene Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 208000033868 Lysosomal disease Diseases 0.000 description 1
- 208000015439 Lysosomal storage disease Diseases 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 206010056886 Mucopolysaccharidosis I Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241001180873 Saposhnikovia divaricata Species 0.000 description 1
- 201000002883 Scheie syndrome Diseases 0.000 description 1
- 208000036623 Severe mental retardation Diseases 0.000 description 1
- 208000026062 Tissue disease Diseases 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 108010047495 alanylglycine Proteins 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000002349 hydroxyamino group Chemical class [H]ON([H])[*] 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000007981 phosphate-citrate buffer Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920001583 poly(oxyethylated polyols) Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001289 polyvinyl ether Polymers 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/0105—Alpha-N-acetylglucosaminidase (3.2.1.50)
Definitions
- the present invention relates to a mutant of human ⁇ -N-acetylglucosaminidase (hNAGLU). Specifically, by adding a mutation to the amino acid sequence of hNAGLU, the expression level of hNAGLU in a host cell into which a gene encoding hNAGLU has been introduced is determined. It relates to a novel hNAGLU mutant that can be enhanced as compared with the case of introducing a gene encoding wild-type hNAGLU.
- hNAGLU human ⁇ -N-acetylglucosaminidase
- Mucopolysaccharidosis type IIIB which is a type of lysosomal disease, is also known as Sanfilippo syndrome type B and is required for the degradation of heparan sulfate (HS), which is a type of glycosaminoglycan (GAG), in lysosomes.
- HS heparan sulfate
- GAG glycosaminoglycan
- NAGLU ⁇ -N-acetylglucosaminidase
- the accumulation of HS in various organs including the brain causes serious neurological disorders such as cognitive decline and behavioral disorders and tissue disorders around the age of 2 to 6 years, resulting in behavioral disorders such as hyperactivity.
- Enzyme replacement therapy is performed to replace deficient or deficient enzymes in patients with Sanfilippo syndrome type B.
- the enzyme ⁇ -N-acetylglucosaminidase (NAGLU) has the effect of catalyzing the reaction of hydrolyzing the non-reducing terminal ⁇ -N-acetylglucosamine residue of heparan sulfate, and when administered to patients, it is used in lysosomes in patients.
- the accumulated HS can be decomposed.
- HNAGLU wild-type human NAGLU
- An object of the present invention is to increase the expression level of hNAGLU in a host cell into which a gene encoding hNAGLU has been introduced by mutating the amino acid sequence of hNAGLU as compared with the case where a gene encoding wild-type hNAGLU is introduced. It is to provide a novel hNAGLU mutant that can be used.
- the present inventors have introduced a gene encoding the hNAGLU mutant obtained by modifying the amino acid sequence of hNAGLU, which is described in detail in the present specification, as a result of diligent studies.
- the host cell expresses more hNAGLU than the host cell into which the gene encoding the wild-type hNAGLU has been introduced, and completed the present invention. That is, the present invention includes the following. 1. 1.
- a mutant of human ⁇ -N-acetylglucosaminidase selected from the group consisting of the following (1) to (7): (1)
- the wild-type hNAGLU amino acid sequence shown in SEQ ID NO: 1 has the amino acid sequence shown in SEQ ID NO: 3 in which lysine at position 36 is replaced with glutamic acid and proline at position 37 is replaced with serine.
- the wild-type hNAGLU amino acid sequence shown in SEQ ID NO: 1 has the amino acid sequence shown in SEQ ID NO: 5 in which serine is added between leucine at position 44 and glycine at position 45; (3) The wild-type hNAGLU amino acid sequence shown in SEQ ID NO: 1 having the amino acid sequence shown in SEQ ID NO: 9 in which glutamine at position 209 is replaced with arginine; (4) The wild-type hNAGLU amino acid sequence shown in SEQ ID NO: 1 having the amino acid sequence shown in SEQ ID NO: 11 in which glutamic acid at position 228 is replaced with lysine; (5) The wild-type hNAGLU amino acid sequence shown in SEQ ID NO: 1 has the amino acid sequence shown in SEQ ID NO: 15, in which threonine at position 320 is replaced with proline and glutamic acid at position 321 is replaced with aspartic acid.
- (1'-a) The amino acid residues constituting the amino acid sequence are substituted with other amino acid residues, and the number of substituted amino acid residues is 1 to 10, and 1 to 5 Or 1 to 3 pieces, for example, 1 or 2 pieces;
- (1'-b) The amino acid residues constituting the amino acid sequence are deleted, and the number of deleted amino acid residues is 1 to 10, 1 to 5, or 1 to 3 pieces, for example, 1 piece or 2 pieces;
- (1'-d) One or more amino acid residues are added to the amino acid sequence or to the N-terminal side or C-terminal side of the amino acid sequence, and the number of added amino acid residues.
- (2'-a) The amino acid residues constituting the amino acid sequence are substituted with other amino acid residues, and the number of substituted amino acid residues is 1 to 10, and 1 to 5 Or 1 to 3 pieces, for example, 1 or 2 pieces;
- (2'-b) The amino acid residues constituting the amino acid sequence are deleted, and the number of deleted amino acid residues is 1 to 10, 1 to 5, or 1 to 3 pieces, for example, 1 piece or 2 pieces;
- (2'-d) One or more amino acid residues are added to the amino acid sequence or to the N-terminal side or C-terminal side of the amino acid sequence, and the number of added amino acid residues.
- the hNAGLU mutant having the amino acid sequence represented by SEQ ID NO: 9 is a hNAGLU mutant to which the mutation was added while preserving the arginine at position 209 of the amino acid sequence to the hNAGLU mutant of 1 above, which is the following (3'-a).
- amino acid residues constituting the amino acid sequence are substituted with other amino acid residues, and the number of substituted amino acid residues is 1 to 10, and 1 to 5 Or 1 to 3 pieces, for example, 1 or 2 pieces;
- amino acid residues constituting the amino acid sequence are deleted, and the number of deleted amino acid residues is 1 to 10, 1 to 5, or 1 to 3 pieces, for example, 1 piece or 2 pieces;
- One or more amino acid residues are added to the amino acid sequence or to the N-terminal side or C-terminal side of the amino acid sequence, and the number of added amino acid residues.
- the hNAGLU mutant having the amino acid sequence represented by SEQ ID NO: 11 was mutated while preserving the lysine at position 228 of the amino acid sequence to the hNAGLU variant of 1 above, which is the following (4'-a). )-(4'-h) selected from the group: (4'-a) The amino acid residues constituting the amino acid sequence are substituted with other amino acid residues, and the number of substituted amino acid residues is 1 to 10, and 1 to 5 Or 1 to 3 pieces, for example, 1 or 2 pieces; (4'-b) The amino acid residues constituting the amino acid sequence are deleted, and the number of deleted amino acid residues is 1 to 10, 1 to 5, or 1 to 3 pieces, for example, 1 piece or 2 pieces; (4'-c) A combination of the above 4'-a substitution and 4'-b deletion; (4'-d) One or more amino acid residues are added to the amino acid sequence or to the N-terminal side or C-terminal side of the amino acid sequence, and the number of added amino acid residues
- (5'-a) The amino acid residues constituting the amino acid sequence are substituted with other amino acid residues, and the number of substituted amino acid residues is 1 to 10, and 1 to 5 Or 1 to 3 pieces, for example, 1 or 2 pieces;
- (5'-b) The amino acid residues constituting the amino acid sequence are deleted, and the number of deleted amino acid residues is 1 to 10, 1 to 5, or 1 to 3 pieces, for example, 1 piece or 2 pieces;
- (5'-d) One or more amino acid residues are added to the amino acid sequence or to the N-terminal side or C-terminal side of the amino acid sequence, and the number of added amino acid residues.
- the hNAGLU mutant having the amino acid sequence represented by SEQ ID NO: 17 is mutated while preserving alanine at position 505 and valine at position 506 of the amino acid sequence to the hNAGLU mutant according to the following.
- (6'-a) The amino acid residues constituting the amino acid sequence are substituted with other amino acid residues, and the number of substituted amino acid residues is 1 to 10, and 1 to 5 Or 1 to 3 pieces, for example, 1 or 2 pieces;
- (6'-b) The amino acid residues constituting the amino acid sequence are deleted, and the number of deleted amino acid residues is 1 to 10, 1 to 5, or 1 to 3 pieces, for example, 1 piece or 2 pieces;
- (6'-d) One or more amino acid residues are added to the amino acid sequence or to the N-terminal side or C-terminal side of the
- the hNAGLU mutant having the amino acid sequence represented by SEQ ID NO: 19 is a hNAGLU mutant to which a mutation has been added while preserving asparagine at position 526 and threonine at position 528 of the amino acid sequence.
- the hNAGLU mutant of 4 above which is selected from the group consisting of the following (8) to (15): (8)
- the hNAGLU variant having the amino acid sequence shown in SEQ ID NO: 9 the hNAGLU variant to which the mutation was added while preserving the arginine at position 209 of the amino acid sequence, and the lysine at position 36 was converted to glutamate.
- Proline at position 37 has the amino acid sequence shown in SEQ ID NO: 25 substituted with serine, respectively;
- the hNAGLU variant having the amino acid sequence represented by SEQ ID NO: 9 is a hNAGLU variant in which the arginine at position 209 of the amino acid sequence is preserved and mutated, and is at positions 44 and 45.
- Glutamic acid at position 321 has the amino acid sequence shown in SEQ ID NO: 29 substituted with aspartic acid, respectively; (11) In the hNAGLU variant having the amino acid sequence shown in SEQ ID NO: 9, the hNAGLU variant to which the mutation was added while preserving the arginine at position 209 of the amino acid sequence, and the lysine at position 36 was converted to glutamic acid.
- Arginine at position 620 has the amino acid sequence shown in SEQ ID NO: 33 substituted with lysine, respectively; (13)
- valine at position 54 is replaced with isoleucine and arginine at position 620 is replaced with lysine, respectively, and between leucine at position 44 and glycine at position 45.
- the hNAGLU mutant according to 9 above having the amino acid sequence represented by SEQ ID NO: 25 is mutated while preserving arginine at position 209, glutamic acid at position 36, and serine at position 37 of the amino acid sequence.
- the hNAGLU mutant having the amino acid sequence represented by SEQ ID NO: 27 is a hNAGLU mutant in which a mutation is added while preserving arginine at position 210 and serine at position 45 of the amino acid sequence to the hNAGLU mutant according to 9 above.
- (9'-a) The amino acid residues constituting the amino acid sequence are substituted with other amino acid residues, and the number of substituted amino acid residues is 1 to 10, and 1 to 5 Or 1 to 3 pieces, for example, 1 or 2 pieces;
- (9'-b) The amino acid residues constituting the amino acid sequence are deleted, and the number of deleted amino acid residues is 1 to 10, 1 to 5, or 1 to 3 pieces, for example, 1 piece or 2 pieces;
- (9'-c) A combination of the above 9'-a substitution and 9'-b deletion;
- (9'-d) One or more amino acid residues are added to the amino acid sequence or to the N-terminal side or C-terminal side of the amino acid sequence, and the number of added amino acid residues.
- the hNAGLU mutant according to 9 above having the amino acid sequence represented by SEQ ID NO: 29 was mutated while preserving arginine at position 209, proline at position 320, and aspartic acid at position 321 of the amino acid sequence.
- the amino acid residues constituting the amino acid sequence are substituted with other amino acid residues, and the number of substituted amino acid residues is 1 to 10, and 1 to 5 Or 1 to 3 pieces, for example, 1 or 2 pieces;
- (10'-b) The amino acid residues constituting the amino acid sequence are deleted, and the number of deleted amino acid residues is 1 to 10, 1 to 5, or 1 to 3 pieces, for example, 1 piece or 2 pieces;
- One or more amino acid residues are added to the amino acid sequence or to the N-terminal
- the hNAGLU mutant according to 9 above having the amino acid sequence represented by SEQ ID NO: 31 is mutated while preserving arginine at position 210, glutamic acid at position 36, serine at position 37, and serine at position 45 of the amino acid sequence.
- the hNAGLU mutant according to 9 above having the amino acid sequence represented by SEQ ID NO: 33 is mutated while preserving arginine at position 209, isoleucine at position 54, and lysine at position 620 of the amino acid sequence.
- the hNAGLU mutant according to 9 above having the amino acid sequence represented by SEQ ID NO: 35 is mutated while preserving arginine at position 210, isoleucine at position 55, and serine at position 45 of the amino acid sequence.
- (13'-a) The amino acid residues constituting the amino acid sequence are substituted with other amino acid residues, and the number of substituted amino acid residues is 1 to 10, and 1 to 5 Or 1 to 3 pieces, for example, 1 or 2 pieces;
- (13'-b) The amino acid residues constituting the amino acid sequence are deleted, and the number of deleted amino acid residues is 1 to 10, 1 to 5, or 1 to 3 pieces, for example, 1 piece or 2 pieces;
- One or more amino acid residues are added to the amino acid sequence or to the N-terminal side or C-terminal
- the hNAGLU mutant according to 9 above having the amino acid sequence represented by SEQ ID NO: 37 is mutated while preserving arginine at position 210, lysine at position 621, and serine at position 45 of the amino acid sequence.
- (14'-a) The amino acid residues constituting the amino acid sequence are substituted with other amino acid residues, and the number of substituted amino acid residues is 1 to 10, and 1 to 5 Or 1 to 3 pieces, for example, 1 or 2 pieces;
- (14'-b) The amino acid residues constituting the amino acid sequence are deleted, and the number of deleted amino acid residues is 1 to 10, 1 to 5, or 1 to 3 pieces, for example, 1 piece or 2 pieces;
- One or more amino acid residues are added to the amino acid sequence or to the N-terminal side or C-terminal
- the hNAGLU variant according to 9 above having the amino acid sequence represented by SEQ ID NO: 39 is mutated while preserving arginine at position 210, isoleucine at position 55, lysine at position 621, and serine at position 45 of the amino acid sequence.
- (15'-a) The amino acid residues constituting the amino acid sequence are substituted with other amino acid residues, and the number of substituted amino acid residues is 1 to 10, and 1 to 5 Or 1 to 3 pieces, for example, 1 or 2 pieces;
- (15'-b) The amino acid residues constituting the amino acid sequence are deleted, and the number of deleted amino acid residues is 1 to 10, 1 to 5, or 1 to 3 pieces, for example, 1 piece or 2 pieces;
- (15'-d) One or more amino acid residues are added to the amino acid sequence or to the N-terminal side or C-terminal side of the amino acid sequence, and the number of added amino acid residues.
- a method for producing an hNAGLU variant which comprises the step of culturing the above 20 mammalian cells in a serum-free medium. 22.
- BBB blood-brain barrier
- the hNAGLU mutant is bound to either the C-terminal side or the N-terminal side of the light chain of the antibody, or to either the C-terminal side or the N-terminal side of the heavy chain via a linker sequence.
- the fusion protein according to any one of 22 to 27 above. 29. 28.
- the fusion protein according to 28 above, wherein the linker sequence consists of 1 to 50 amino acid residues.
- the linker sequence includes one glycine, one serine, amino acid sequence Gly-Ser, amino acid sequence Ser-Ser, amino acid sequence Gly-Gly-Ser, amino acid sequence of SEQ ID NO: 3, amino acid sequence of SEQ ID NO: 4, and sequence. 29.
- the fusion protein according to 29 above which comprises the amino acid sequence of No. 5 and an amino acid sequence selected from the group consisting of 1 to 10 consecutive amino acid sequences.
- 31. A DNA comprising a gene encoding the fusion protein according to any one of 22 to 30 above.
- 32. An expression vector comprising the DNA according to 31 above.
- 33. Mammalian cells transformed with the expression vector according to 32 above.
- 34. 33. A method for producing a fusion protein of an hNAGLU variant and an antibody, which comprises the step of culturing the mammalian cells in a serum-free medium.
- hNAGLU which can be administered as enzyme replacement therapy for the treatment of patients with mucopolysaccharidosis type IIIB, can be efficiently produced by using gene recombination technology.
- the figure which shows the result of the confirmation experiment of the hNAGLU mutant expression level by transient expression (Example 6).
- the vertical axis of the bar graph shows the fluorescence intensity.
- (1) is K36E / P37S hNAGLU mutant, (2) is L44_G45insS hNAGLU mutant, (3) is R129Q hNAGLU mutant, (4) is Q209R hNAGLU mutant, (5) is E228K hNAGLU mutant, (6) Is a T240V hNAGLU mutant, (7) is a T320P / E321D hNAGLU mutant, (8) is an S505A / I506V hNAGLU mutant, (9) is an S526N / A528T hNAGLU mutant, and (10) is a D613Q hNAGLU mutant.
- (1) is K36E / P37S hNAGLU mutant, (2) is L44_G45insS hNAGLU mutant, (3) is R129Q hNAGLU mutant, (4) is Q209R hNAGLU mutant, (5) is E228K hNAGLU mutant, (6) Is a T240V hNAGLU mutant, (7) is a T320P / E321D hNAGLU mutant, (8) is an S505A / I506V hNAGLU mutant, (9) is an S526N / A528T hNAGLU mutant, (10) is a D613Q hNAGLU mutant, (11).
- (1) is wild-type hNAGLU, (2) is Q209R hNAGLU mutant, (3) is K36E / P37S / Q209R hNAGLU mutant, (4) is L44_G45insS / Q209R hNAGLU mutant, (5) is Q209R / T320P / E321D.
- the hNAGLU mutant and (6) show the expression level data of K36E / P37S / L44_G45insS / Q209R hNAGLU mutant, respectively.
- the figure which shows the result of the confirmation experiment of the hNAGLU mutant expression level by transient expression (Example 16).
- the vertical axis of the bar graph shows the fluorescence intensity.
- (a) shows the pattern on the SDS-page of the band corresponding to the wild-type hNAGLU or hNAGLU mutant.
- (1) is wild-type hNAGLU
- (2) is Q209R hNAGLU mutant
- (3) is L44_G45insS / Q209R hNAGLU mutant
- (4) is V54I / Q209R / R620K hNAGLU mutant
- (5) is L44_G45insS / V54I / Q209R.
- the hNAGLU mutant, (6) is the L44_G45insS / Q209R / R620K hNAGLU mutant, (7) is the L44_G45insS / V54I / Q209R / R620K hNAGLU mutant, and (8) is the expression level data of the negative control.
- hNAGLU human ⁇ -N-acetylglucosaminidase
- hNAGLU heparan sulfate is decomposed in addition to the usual wild-type hNAGLU consisting of 720 amino acid residues shown in SEQ ID NO: 1.
- hNAGLU a normal wild-type hNAGLU such as having an enzymatic activity capable of
- one or more amino acid residues are substituted or deleted from the amino acid sequence shown in SEQ ID NO: 1.
- variants of hNAGLU corresponding to those that have been lost and / or added in the present specification, "addition" of an amino acid residue means adding a residue to the end or inside of the sequence).
- the wild-type hNAGLU is encoded by, for example, a gene having the base sequence shown in SEQ ID NO: 2.
- the number of amino acid residues to be replaced is 1 to 10, 1 to 5, or 1 to 3, for example, 1 or 1.
- the number of amino acid residues to be deleted is 1 to 10, 1 to 5, or 1 to 3, for example, 1 or 2.
- the N-terminal amino acid residue may be deleted. In that case, the number of amino acid residues to be deleted is 1 to 10, and 1 to 5 is used. Yes, or 1 to 3, for example, 1 or 2.
- substitutions and deletions of these amino acid residues may be combined.
- the amino acid residue is one or more amino acids in the amino acid sequence of hNAGLU or on the N-terminal side or C-terminal side of the amino acid sequence. Residues are added.
- the number of amino acid residues added at this time is 1 to 10, 1 to 5, or 1 to 3, for example, 1 or 2. Further, the addition and substitution of amino acid residues may be combined, the addition and deletion of amino acid residues may be combined, and the addition, substitution and deletion of amino acid residues may be combined.
- the normal wild-type hNAGLU is biosynthesized as a precursor consisting of 743 amino acid residues, and the leader peptide consisting of 23 amino acid residues is removed from the N-terminal shown in SEQ ID NO: 67 to obtain hNAGLU.
- the amino acid may be derived from a leader peptide.
- the amino acid added to the N-terminal is Gly when there is one amino acid, Ala-Gly when there are two amino acids, and Ala-Ala-Gly when there are two amino acids. ..
- the hNAGLU mutants introduced by combining at least two types of mutations include (i) to (iv) shown below. Not limited: (I) For the amino acid sequence shown in SEQ ID NO: 1, deletion of 0 to 10 amino acid residues, substitution of 0 to 10 amino acid residues with other amino acid residues, and further 0 to 10 Those having an amino acid sequence consisting of addition of amino acid residues; (Ii) For the amino acid sequence represented by SEQ ID NO: 1, deletion of 0 to 5 amino acid residues, substitution of 0 to 5 amino acid residues with other amino acid residues, and further 0 to 5 Those having an amino acid sequence consisting of addition of amino acid residues; (Iii) For the amino acid sequence represented by SEQ ID NO: 1, deletion of 0 to 3 amino acid residues, substitution of 0 to 3 amino acid residues with other amino acid residues, and further 0 to 3 Those having an amino acid sequence consisting of addition of amino acid residues;
- the above-mentioned wild-type or mutant hNAGLU in which the amino acids constituting the hNAGLU are modified with sugar chains, is also hNAGLU.
- the above-mentioned wild-type or mutant hNAGLU in which the amino acids constituting the hNAGLU are modified with phosphoric acid, is also hNAGLU.
- HNAGLU is also modified with substances other than sugar chains and phosphoric acid.
- the above-mentioned wild-type or mutant hNAGLU in which the side chains of the amino acids constituting the hNAGLU are converted by a substitution reaction or the like, is also hNAGLU.
- Such conversions include, but are not limited to, conversion of cysteine residues to formylglycine.
- hNAGLU modified by a sugar chain shall be included in hNAGLU having the amino acid sequence before the modification.
- hNAGLU modified with phosphoric acid shall be included in hNAGLU having the original amino acid sequence before being modified with phosphoric acid.
- those modified with substances other than sugar chains and phosphoric acid shall also be included in hNAGLU having the original amino acid sequence before the modification.
- the side chains of amino acids constituting hNAGLU that have been converted by a substitution reaction or the like are also included in hNAGLU that has the original amino acid sequence before the conversion. Such conversions include, but are not limited to, conversion of cysteine residues to formylglycine.
- hNAGLU variant human ⁇ -N-acetylglucosaminidase variant
- hNAGLU variant is one or more with respect to the amino acid sequence of normal wild-type hNAGLU (amino acid sequence shown by SEQ ID NO: 1). Amino acid residues are substituted, deleted, and / or added (in the present specification, "addition" of an amino acid residue means adding a residue to the end or inside of the sequence). Moreover, it has a function as a normal wild-type hNAGLU, such as having an enzymatic activity capable of decomposing heparan sulfate.
- the preferred hNAGLU variant in the present invention is an amino acid sequence in which one or more amino acid residues are replaced with other amino acid residues, deleted or added to the amino acid sequence shown in SEQ ID NO: 1. Including those that are.
- the number of amino acid residues to be replaced is 1 to 10, 1 to 5, or 1 to 3.
- the number of amino acid residues to be deleted is 1 to 10, 1 to 5, or 1 to 3, for example, 1 or 2. ..
- the hNAGLU mutant may be a combination of substitutions and deletions of these amino acid residues.
- the amino acid residue is one or more amino acids in the amino acid sequence of hNAGLU or on the N-terminal side or C-terminal side of the amino acid sequence. Residues are added.
- the number of amino acid residues added at this time is 1 to 10, 1 to 5, or 1 to 3, for example, 1 or 2.
- the addition and substitution of amino acid residues may be combined, the addition and deletion of amino acid residues may be combined, and the addition, substitution and deletion of amino acid residues may be combined. That is, the hNAGLU mutant is introduced by combining at least two types of mutations out of the three types of amino acid substitutions, deletions, and additions into the amino acid sequence shown in SEQ ID NO: 1.
- the hNAGLU mutants introduced by combining at least two types of mutations include (i) to (iv) shown below. Not limited: (I) For the amino acid sequence shown in SEQ ID NO: 1, deletion of 0 to 10 amino acid residues, substitution of 0 to 10 amino acid residues with other amino acid residues, and further 0 to 10 Those having an amino acid sequence consisting of the addition of individual amino acid residues (excluding wild-type hNAGLU); (Ii) For the amino acid sequence represented by SEQ ID NO: 1, deletion of 0 to 5 amino acid residues, substitution of 0 to 5 amino acid residues with other amino acid residues, and further 0 to 5 Those having an amino acid sequence consisting of the addition of individual amino acid residues (excluding wild-type hNAGLU); (Iii) For the amino acid sequence represented by SEQ ID NO: 1, deletion of 0 to 3 amino acid residues, substitution of 0 to 3 amino acid residues with other amino
- the amino acid sequence of the hNAGLU variant preferably shows 80% or more identity, 85% or more identity, and 90% or more identity with the amino acid sequence of the normal wild-type hNAGLU shown in SEQ ID NO: 1. , Or show 95% or more identity, for example, 98% or more, or 99% identity.
- the identity between the amino acid sequence of the wild-type hNAGLU and the amino acid sequence of the hNAGLU mutant can be easily calculated using a well-known homology calculation algorithm.
- BLAST Altschul SF. J Mol. Biol. 215. 403-10, (1990)
- Pearson and Lipman similarity search method Proc. Natl. Acad. Sci. USA. 85. 2444 (1988)
- Smith and Waterman's local homology algorithm (Adv. Appl. Math. 2. 482-9 (1981)).
- substitution of amino acids in the amino acid sequence of wild-type hNAGLU or hNAGLU variants with other amino acids occurs, for example, within their side chains and chemistries of the amino acids. Substitutions within such amino acid families are not expected to result in significant changes in the function of the original protein (ie, conservative amino acid substitutions).
- Such amino acid families include, for example, those represented by the following (1) to (12): (1) Acidic amino acids aspartic acid and glutamic acid, (2) The basic amino acids histidine, lysine, and arginine (3) The aromatic amine acids phenylalanine, tyrosine, and tryptophan, (4) Serine and threonine, which are amino acids having hydroxyl groups (hydroxy amino acids), (5) Hydrophobic amino acids methionine, alanine, valine, leucine, and isoleucine, (6) Neutral hydrophilic amino acids cysteine, serine, threonine, asparagine, and glutamine, (7) Glycine and proline, which are amino acids that affect the orientation of peptide chains, (8) Asparagine and glutamine, which are amide-type amino acids (polar amino acids), (9) Aliphatic amino acids, alanine, leucine, isoleucine, and valine, (10) Alanine, glycine, serine, and th
- the highly expressed hNAGLU mutant is when expressed in a host cell as a recombinant protein and when wild-type hNAGLU is expressed in the host cell as a recombinant protein under the same conditions. At least 1.1 times or more, 1.5 times or more, 2 times or more, 4 times or more, 5 times or more, or 6 times or more, for example, 1.5 to 4 times, 2 to 5 times, 2 It is an hNAGLU mutant characterized by obtaining an expression level of up to 8 times.
- the same conditions mean that the expression vector, host cells, culture conditions, etc. are the same.
- Preferred embodiments of such a highly expressed hNAGLU mutant include the following (1) to (7): (1) In the amino acid sequence of wild-type hNAGLU shown in SEQ ID NO: 1, lysine at position 36 is replaced with glutamic acid and proline at position 37 is replaced with serine, respectively, having the amino acid sequence shown in SEQ ID NO: 3. (2) Those having the amino acid sequence shown in SEQ ID NO: 5 in which serine is added between leucine at position 44 and glycine at position 45 in the amino acid sequence of wild-type hNAGLU shown in SEQ ID NO: 1.
- the wild-type hNAGLU amino acid sequence shown in SEQ ID NO: 1 having the amino acid sequence shown in SEQ ID NO: 9 in which glutamine at position 209 is replaced with arginine.
- the wild-type hNAGLU amino acid sequence shown in SEQ ID NO: 1 having the amino acid sequence shown in SEQ ID NO: 11 in which glutamic acid at position 228 is replaced with lysine.
- the wild-type hNAGLU amino acid sequence shown in SEQ ID NO: 1 has the amino acid sequence shown in SEQ ID NO: 15, in which threonine at position 320 is replaced with proline and glutamic acid at position 321 is replaced with aspartic acid.
- preferred embodiments of the highly expressed hNAGLU mutant include the following (1') to (7').
- (1') Without mutating glutamic acid at position 36 and serine at position 37 of the amino acid sequence shown in SEQ ID NO: 3:
- (1'-a) The amino acid residues constituting the amino acid sequence are substituted with other amino acid residues, and the number of substituted amino acid residues is 1 to 10, and 1 to 5 Or 1 to 3 pieces, for example, 1 piece or 2 pieces;
- (1'-b) The amino acid residues constituting the amino acid sequence are deleted, and the number of deleted amino acid residues is 1 to 10, 1 to 5, or 1 to 3 pieces, for example, 1 piece or 2 pieces;
- (1'-c) A combination of the above 1'-a substitution and 1'-b deletion;
- One or more amino acid residues are added to the amino acid sequence or to the N-terminal side or C-terminal side of the amino acid sequence, and the number of added amino acid residues.
- amino acid residues constituting the amino acid sequence are substituted with other amino acid residues, and the number of substituted amino acid residues is 1 to 10, and 1 to 5 Or 1 to 3 pieces, for example, 1 or 2 pieces;
- amino acid residues constituting the amino acid sequence are deleted, and the number of deleted amino acid residues is 1 to 10, 1 to 5, or 1 to 3 pieces, for example, 1 piece or 2 pieces;
- 5'-c A combination of the above 5'-a substitution and 5'-b deletion;
- One or more amino acid residues are added to the amino acid sequence or to the N-terminal side or C-terminal side of the amino acid sequence, and the number of added amino acid residues.
- (6') Without mutating alanine at position 505 and valine at position 506 of the amino acid sequence set forth in SEQ ID NO: 17: (6'-a) The amino acid residues constituting the amino acid sequence are substituted with other amino acid residues, and the number of substituted amino acid residues is 1 to 10, and 1 to 5 Or 1 to 3 pieces, for example, 1 piece or 2 pieces; (6'-b) The amino acid residues constituting the amino acid sequence are deleted, and the number of deleted amino acid residues is 1 to 10, 1 to 5, or 1 to 3 pieces, for example, 1 piece or 2 pieces; (6'-c) A combination of the above 6'-a substitution and 6'-b deletion; (6'-d) One or more amino acid residues are added to the amino acid sequence or to the N-terminal side or C-terminal side of the amino acid sequence, and the number of added amino acid residues.
- hNAGLU mutant having the amino acid sequence shown in SEQ ID NO: 9 in which glutamine at position 209 in the amino acid sequence of wild-type hNAGLU shown in SEQ ID NO: 1 of (1) above is replaced with arginine.
- Specific embodiments of the introduced highly expressed hNAGLU mutant include the following (8) to (15): (8) In the amino acid sequence of wild-type hNAGLU shown in SEQ ID NO: 1, glutamine at position 209 is replaced with arginine, lysine at position 36 is replaced with glutamic acid, and proline at position 37 is replaced with serine.
- preferred embodiments of the highly expressed hNAGLU mutant include the following (8') to (15').
- amino acid residues constituting the amino acid sequence are substituted with other amino acid residues, and the number of substituted amino acid residues is 1 to 10, and 1 to 5 Or 1 to 3 pieces, for example, 1 or 2 pieces;
- amino acid residues constituting the amino acid sequence are deleted, and the number of deleted amino acid residues is 1 to 10, 1 to 5, or 1 to 3 pieces, for example, 1 piece or 2 pieces;
- One or more amino acid residues are added to the amino acid sequence or to the N-terminal side or C-terminal side of the amino acid sequence, and the number of added amino acid residues.
- (11') Without mutating arginine at position 210, glutamic acid at position 36, serine at position 37, and serine at position 45 of the amino acid sequence shown in SEQ ID NO: 31 :, (11'-a)
- the amino acid residues constituting the amino acid sequence are substituted with other amino acid residues, and the number of substituted amino acid residues is 1 to 10, and 1 to 5 Or 1 to 3 pieces, for example, 1 piece or 2 pieces;
- (11'-b) The amino acid residues constituting the amino acid sequence are deleted, and the number of deleted amino acid residues is 1 to 10, 1 to 5, or 1 to 3 pieces, for example, 1 piece or 2 pieces; (11'-c) A combination of the above 11'-a substitution and the 11'-b deletion; (11'-d)
- One or more amino acid residues are added to the amino acid sequence or to the N-terminal side or C-terminal side of the amino acid sequence, and the number of added amino acid residues.
- (12') Without mutations to arginine at position 209, isoleucine at position 54, and lysine at position 620 of the amino acid sequence set forth in SEQ ID NO: 33: (12'-a)
- the amino acid residues constituting the amino acid sequence are substituted with other amino acid residues, and the number of substituted amino acid residues is 1 to 10, and 1 to 5 Or 1 to 3 pieces, for example, 1 or 2 pieces;
- (12'-b) The amino acid residues constituting the amino acid sequence are deleted, and the number of deleted amino acid residues is 1 to 10, 1 to 5, or 1 to 3 pieces, for example, 1 piece or 2 pieces;
- (12'-c) A combination of the above 12'-a substitution and the 12'-b deletion;
- (12'-d) One or more amino acid residues are added to the amino acid sequence or to the N-terminal side or C-terminal side of the amino acid sequence, and the number of added amino acid residues.
- the hNAGLU mutant in one embodiment of the present invention is compared with the case where wild-type hNAGLU is expressed as a recombinant protein in a host cell under the same conditions when expressed in a host cell as a recombinant protein. It is characterized by a high expression level.
- this type of hNAGLU mutant is referred to as a highly expressed hNAGLU mutant.
- the highly expressed hNAGLU mutant is produced as a recombinant protein, the production efficiency can be increased as compared with the wild-type hNAGLU, so that the production cost can be reduced.
- the same conditions mean that the expression vector, host cells, culture conditions, etc. are the same.
- the gene encoding the hNAGLU mutant whose expression level is increased as compared with the wild-type hNAGLU when expressed as a recombinant protein in a host cell can be obtained by the following method.
- the mutant-introduced hNAGLU and the wild-type hNAGLU-encoding gene were integrated into the same type of expression vector, and the same type of host cell was transformed using this to transform the cells into which each expression vector was introduced. To get. Then, these cells are cultured under the same conditions, and the hNAGLU obtained in the culture supernatant is quantified.
- the gene introduced into the cells showing a large quantified value compared with the quantified value of the cell into which the gene encoding the wild-type hNAGLU was introduced was identified as the gene encoding the target highly expressed hNAGLU mutant.
- the enzyme activity value of hNAGLU can be used in addition to the quantitative value of hNAGLU as a protein.
- the total amount of hNAGLU enzyme activity contained in the culture supernatant can be used as a quantitative value.
- the introduction of mutations into wild-type hNAGLU can be performed by using a method of randomly introducing mutations into the gene encoding wild-type hNAGLU.
- a gene encoding wild-type hNAGLU is integrated into a vector, and a mutagen (radiation, mutagenic substance, etc.) is allowed to act on a host cell transformed using this gene to encode wild-type hNAGLU. Mutations can be introduced into the gene.
- the introduction of the mutation into the wild-type hNAGLU can also be performed by using the method of introducing the mutation into a predetermined location of the gene encoding the wild-type hNAGLU.
- a gene mutation can be introduced by chemically synthesizing a gene having a mutation at a predetermined location.
- the highly expressed hNAGLU mutant can be produced as a recombinant protein by culturing a host cell transformed with an expression vector incorporating a gene encoding the mutant.
- the host cell used at this time is not particularly limited as long as it can express a highly expressed hNAGLU variant by introducing such an expression vector, and is not particularly limited, and is a mammalian cell, yeast, plant cell, or insect cell. It may be any of eukaryotic cells such as Eukaryotic cells such as Eukaryotic cells and prokaryotic cells such as Escherichia coli and Bacillus subtilis, but mammalian cells are particularly suitable.
- the type of the mammalian cell is not particularly limited, but human, mouse, and Chinese hamster-derived cells are preferable, and Chinese hamster ovary cell-derived CHO cells or mouse myeloma are particularly preferable.
- NS / 0 cells derived from are preferred.
- the expression vector used for incorporating and expressing the DNA fragment encoding the highly expressed hNAGLU mutant may be used without particular limitation as long as it brings about the expression of the gene when introduced into mammalian cells. can.
- the gene integrated into the expression vector is placed downstream of a DNA sequence (gene expression control site) capable of regulating the frequency of gene transcription in mammalian cells.
- Examples of the gene expression control site that can be used in the present invention include a cytomegalovirus-derived promoter, an SV40 early promoter, a human elongation factor-1 ⁇ (EF-1 ⁇ ) promoter, a human ubiquitin C promoter, and the like.
- GS glutamine synthase
- IVS internal ribosome entry site
- an expression vector for expressing a target protein which is a first gene expression control site, a gene encoding the protein downstream thereof, an internal ribosome binding site further downstream, and glutamine synthesis further downstream.
- An expression vector containing a gene encoding an enzyme and further containing a dihydrofolate reductase gene or a drug resistance gene downstream of the first gene expression control site or another second gene expression control site. Can be suitably used for the production of highly expressed hNAGLU variants.
- the first gene expression control site or the second gene expression control site includes a promoter derived from cytomegalovirus, an SV40 initial promoter, a human elongation factor-1 ⁇ promoter (hEF-1 ⁇ promoter), and human ubiquitin C.
- a promoter is preferably used, but the hEF-1 ⁇ promoter is particularly preferred.
- the internal ribosome binding site includes viruses of the family Picornavirus, mouth-foot disease virus, hepatitis A virus, hepatitis C virus, corona virus, bovine intestinal virus, siler murine encephalomyelitis virus, and coxsackie B virus.
- a virus genome selected from the group consisting of, or a gene derived from the 5'untranslated region of a gene selected from the group consisting of human immunoglobulin heavy chain binding protein gene, Drosophila antennapedia gene, and Drosophila ultrabitrax gene is preferable.
- an internal ribosome binding site derived from the 5'untranslated region of the mouse encephalomyelitis virus genome is particularly suitable.
- the drug resistance gene preferably used in this expression vector is preferably a puromycin or neomycin resistance gene, and more preferably a puromycin resistance gene.
- an expression vector for expressing a target protein which is a human elongation factor-1 ⁇ promoter, a gene encoding the protein downstream thereof, and a 5'untranslated region of the mouse encephalomyelitis virus genome further downstream.
- An expression vector in which a part of a plurality of initiation codons contained in a wild-type internal ribosome binding site is disrupted can be suitably used for producing a highly expressed hNAGLU mutant.
- Examples of such an expression vector include the expression vector described in WO2013 / 161958.
- an expression vector for expressing a target protein which is a human elongation factor-1 ⁇ promoter, a gene encoding the protein downstream thereof, and a 5'untranslated region of the mouse encephalomyelitis virus genome further downstream.
- an expression vector in which a part of a plurality of initiation codons contained in the wild-type internal ribosome binding site is disrupted can be suitably used for the production of a highly-expressed hNAGLU mutant. Examples of such expression vectors include pE-mIRES-GS-puro described in WO2012 / 063799 and pE-mIRES-GS-mNeo described in WO2013 / 161958.
- ATGs Three start codons (ATGs) are present at the 3'end of the internal ribosome binding site derived from the 5'untranslated region of the wild-type mouse cardiovirus virus genome.
- the above pE-mIRES-GS-puro and pE-mIRES-GS-mNeo are expression vectors having IRES in which some of the start codons are disrupted.
- the hNAGLU mutant (including the highly expressed hNAGLU mutant) can be expressed in cells or in a medium by culturing a host cell into which an expression vector incorporating a gene encoding the hNAGLU mutant has been introduced.
- the expression method of the hNAGLU mutant when the mammalian cell is a host cell is described in detail below.
- any medium can be used as long as it can cultivate and proliferate the mammalian cells, but a serum-free medium is preferably used.
- a serum-free medium used as the medium for producing recombinant protein, for example, amino acids are 3 to 700 mg / L, vitamins are 0.001 to 50 mg / L, and monosaccharides are 0.3 to 10 g / L.
- Inorganic salts 0.1 to 10000 mg / L, trace elements 0.001 to 0.1 mg / L, nucleosides 0.1 to 50 mg / L, amino acids 0.001 to 10 mg / L, biotin 0.01 ⁇ 1 mg / L, hydrocortisone 0.1-20 ⁇ g / L, insulin 0.1-20 mg / L, vitamin B12 0.1-10 mg / L, ptolessin 0.01-1 mg / L, sodium pyruvate
- a medium containing 10 to 500 mg / L and a water-soluble iron compound is preferably used. If desired, thymidine, hypoxanthine, conventional pH indicators, antibiotics and the like may be added to the medium.
- DMEM / F12 medium mixed medium of DMEM and F12
- the serum-free medium contains sodium hydrogencarbonate, L-glutamine, D-glucose, insulin, sodium selenite, diaminobutane, hydrocortisone, iron (II) sulfate, asparagine, aspartic acid, serine and polyvinyl alcohol, DMEM.
- HG HAM improved (R5) medium may be used.
- serum-free medium for example, CD OptiCHO TM medium, CHO-S-SFM II medium or CD CHO medium (Thermo Fisher Scientific, formerly Life Technologies), IS cho- VTM medium (Irvine Scientific), EX-CELL TM 302 medium or EX-CELL TM 325-PF medium (SAFC Biosciences) or the like can also be used as the basic medium.
- the highly expressed hNAGLU mutant is a wild-type under the same conditions when mammalian cells into which an expression vector incorporating a gene encoding it has been introduced are cultured in the above serum-free medium and expressed as a recombinant protein. At least 1.1 times or more, 1.5 times or more, 2 times or more, 4 times or more, 5 times or more, or 6 times or more, for example, 1.5 times or more, as compared with the case where hNAGLU is expressed as a recombinant protein. It is characterized in that an expression level of up to 4 times, 2 to 5 times, 2 to 8 times, etc. can be obtained.
- the mammalian cells used at this time are CHO cells, NS / 0 cells and the like, and are particularly CHO cells.
- the recombinant hNAGLU mutant expressed in the cell or medium can be separated from impurities by a method such as column chromatography and purified.
- the purified hNAGLU mutant can be used as a pharmaceutical.
- the hNAGLU mutant can be used as a drug for the target disease of mucopolysaccharidosis type IIIB (MPS-IIIB) known as Sanfilippo syndrome type B.
- MPS-IIIB mucopolysaccharidosis type IIIB
- a drug containing the hNAGLU mutant as an active ingredient can be administered intravenously, intramuscularly, intraperitoneally, subcutaneously or intraventricularly as an injection.
- injections can be supplied as lyophilized preparations or aqueous liquids.
- it When it is an aqueous solution, it may be filled in a vial, or it may be supplied as a prefilled-type preparation that is pre-filled in a syringe. In the case of lyophilized preparation, dissolve it in an aqueous medium and restore it before use.
- the hNAGLU mutant in one embodiment of the present invention can be bound to an antibody.
- the hNAGLU mutant in one embodiment of the present invention can be a conjugate with an antibody capable of specifically binding to a receptor on cerebrovascular endothelial cells.
- the hNAGLU variant is made to cross the blood-brain barrier (BBB) and in the central nervous system (CNS). It can be made to exert its function.
- BBB blood-brain barrier
- CNS central nervous system
- the receptor is preferably a human-derived receptor.
- the term "antibody” mainly refers to human antibody, mouse antibody, humanized antibody, antibody derived from camel family (including alpaca), chimeric antibody between human antibody and antibody of other mammals, and mouse.
- a chimeric antibody between an antibody and an antibody of another mammal but is not limited to these as long as it has the property of specifically binding to a specific antigen, and is not limited to the animal species of the antibody. There are no particular restrictions on.
- human antibody refers to an antibody in which the entire protein is encoded by a human-derived gene.
- human antibodies also include antibodies encoded by genes that have been mutated from the original human gene without changing the original amino acid sequence for the purpose of increasing the expression efficiency of the gene. ..
- An antibody produced by combining two or more genes encoding human antibodies and replacing a part of one human antibody with a part of another human antibody is also a "human antibody”.
- Human antibodies have three complementarity determining regions (CDRs) of the light chain and three complementarity determining regions (CDRs) of the heavy chain. The three CDRs of the light chain are referred to as CDR1, CDR2 and CDR3 in order from the one on the N-terminal side.
- the three CDRs of the heavy chain are also referred to as CDR1, CDR2 and CDR3 in order from the one on the N-terminal side.
- An antibody obtained by modifying the antigen specificity, affinity, etc. of a human antibody by replacing the CDR of a human antibody with the CDR of another human antibody is also included in the human antibody.
- an antibody in which a mutation such as substitution, deletion, or addition is added to the amino acid sequence of the original antibody by modifying the gene of the original human antibody is also included in the "human antibody".
- the amino acid in the amino acid sequence of the original antibody is replaced with another amino acid, the number of amino acids to be replaced is preferably 1 to 20, more preferably 1 to 5, and even more preferably 1 to 3.
- the number of amino acids to be deleted is preferably 1 to 20, more preferably 1 to 5, and even more preferably 1 to 3.
- Antibodies to which mutations are added by combining substitutions and deletions of these amino acids are also human antibodies.
- amino acids preferably 1 to 20, more preferably 1 to 5, and even more preferably 1 to 3 amino acids are added to the amino acid sequence of the original antibody or to the N-terminal or C-terminal.
- Antibodies to which mutations are added by combining additions, substitutions and deletions of these amino acids are also human antibodies.
- the amino acid sequence of the mutated antibody preferably exhibits 80% or more identity, more preferably 90% or more identity, and even more preferably 95% or more identity with the amino acid sequence of the original antibody. It exhibits sex, and even more preferably 98% or more identity.
- the mutation can be added to the variable region of the antibody.
- the mutation may be added to either the CDR or the framework region of the variable region, but is particularly added to the framework region. That is, in the present invention, the term "human-derived gene” includes not only the original human-derived gene but also a gene obtained by modifying it.
- the term "humanized antibody” means that the amino acid sequence of a part of the variable region (for example, all or part of CDR) is derived from a non-human mammal, and the other region is derived from a human. It refers to a certain antibody.
- a humanized antibody the three complementarity determining regions (CDRs) of the light chain and the three complementarity determining regions (CDRs) of the heavy chain constituting the human antibody are replaced with CDRs of other mammals. Examples of the antibody produced by.
- the species of other mammals from which the CDRs to be implanted at appropriate positions of human antibodies are derived are not particularly limited as long as they are non-human mammals, but are preferably mice, rats, rabbits, horses, or Non-human primates, more preferably mice and rats, and even more preferably mice.
- an antibody in which a mutation similar to the mutation that can be added to the above-mentioned human antibody is added to the amino acid sequence of the original humanized antibody is also included in the "humanized antibody".
- chimeric antibody refers to an antibody in which fragments of two or more different antibodies derived from two or more different species are linked.
- a chimeric antibody between a human antibody and an antibody of another mammal is an antibody in which a part of the human antibody is replaced by a part of the antibody of a non-human mammal.
- the antibody consists of an Fc region, a Fab region and a hinge region described below.
- Specific examples of such chimeric antibodies include chimeric antibodies in which the Fc region is derived from a human antibody while the Fab region is derived from an antibody of another mammal.
- the hinge portion is derived from either a human antibody or another mammalian antibody.
- a chimeric antibody in which the Fc region is derived from another mammal while the Fab region is derived from a human antibody can be mentioned.
- the hinge portion is derived from either a human antibody or another mammalian antibody.
- the antibody consists of a variable region and a constant region.
- the constant region of the heavy chain ( CH ) and the constant region of the light chain ( CL ) are derived from the human antibody, while the variable region of the heavy chain ( VH ) and the light chain.
- the variable region ( VL ) is derived from antibodies of other mammals, and conversely, the constant region of heavy chain ( CH ) and the constant region of light chain ( CL ) are derived from antibodies of other mammals.
- the variable region of the heavy chain ( VH ) and the variable region of the light chain ( VL ) may be derived from a human antibody.
- the species of other mammals is not particularly limited as long as it is a mammal other than humans, but is preferably mice, rats, rabbits, horses, or primates other than humans, for example, mice. ..
- the antibody in one embodiment of the invention consists of two immunoglobulin light chains (or simply “light chains”) and two immunoglobulin heavy chains (or simply “heavy chains”), for a total of four polypeptide chains.
- the term "antibody” is used in addition to those having this basic structure. (1) A total of two polypeptide chains, one light chain and one heavy chain, (2) Those consisting of a Fab region in which the Fc region is deleted from the basic structure of the antibody in the original sense, and those consisting of the Fab region and all or part of the hinge portion (Fab, F (ab').
- It consists of an Fc region in which the Fab region is deleted from the basic structure of the antibody in the original sense, and the amino acid sequence of the Fc region specifically binds to a specific antigen. Modified to have (Fc antibody), (6) A single domain antibody described later is also included in the "antibody" in the present invention.
- the antibody in one embodiment of the present invention is an antibody derived from a camelid (including alpaca). Some camelid antibodies consist of two heavy chains linked by disulfide bonds. An antibody consisting of these two heavy chains is called a heavy chain antibody.
- VHH is an antibody consisting of one heavy chain containing a variable region of a heavy chain constituting a heavy chain antibody, or an antibody consisting of a single heavy chain lacking a constant region (CH) constituting a heavy chain antibody.
- VHH is also one of the antibodies in the embodiment of the present invention.
- an antibody consisting of two light chains linked by a disulfide bond is also one of the antibodies in the embodiment of the present invention. An antibody consisting of these two light chains is called a light chain antibody.
- an antibody having a mutation in the amino acid sequence of the camelid antibody is also an antibody in one embodiment of the present invention. Is. When a mutation is added to an amino acid of an antibody of a camelid, a mutation similar to the mutation that can be added to the antibody described herein can be added.
- the antibody in one embodiment of the present invention is a shark-derived antibody.
- Shark antibodies consist of two heavy chains linked by disulfide bonds. An antibody consisting of these two heavy chains is called a heavy chain antibody.
- VNAR is an antibody consisting of one heavy chain containing a variable region of a heavy chain constituting a heavy chain antibody, or an antibody consisting of a single heavy chain lacking a constant region (CH) constituting a heavy chain antibody.
- VNAR is also one of the antibodies in the embodiment of the present invention.
- An antibody in one embodiment of the present invention is also obtained by modifying the amino acid sequence of a shark antibody in order to reduce the antigenicity when a shark-derived antibody (including VNAR) is administered to a human. When mutating the amino acids of a shark antibody, the same mutations that can be added to the antibodies described herein can be mutated.
- a humanized shark antibody is also one of the antibodies in the embodiment of the present invention.
- An antibody having a basic structure consisting of two light chains and two heavy chains, for a total of four polypeptide chains, has three complementarity determining regions (CDRs) in the variable region ( VL ) of the light chain. It has three complementarity determining regions (CDRs) in the variable region ( VH ) of the chain.
- the three CDRs of the light chain are referred to as CDR1, CDR2 and CDR3 in order from the one on the N-terminal side.
- the three CDRs of the heavy chain are also referred to as CDR1, CDR2 and CDR3 in order from the one on the N-terminal side.
- FR framework regions
- FR1 FR2, FR3 and FR4 in order from the one on the N-terminal side.
- CDR and FR exist in the order of FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4 from the N-terminal side.
- the antibody also includes an antibody in which mutations such as substitution, deletion, and addition are added to the amino acid sequence of the original antibody.
- mutations such as substitution, deletion, and addition are added to the amino acid sequence of the original antibody.
- the number of amino acids to be replaced is preferably 1 to 20, more preferably 1 to 5, and even more preferably 1 to 3.
- the number of amino acids to be deleted is preferably 1 to 20, more preferably 1 to 5, and even more preferably 1 to 3.
- Antibodies are also mutated by combining substitutions and deletions of these amino acids.
- amino acids preferably 1 to 20, more preferably 1 to 5, and even more preferably 1 to 3 amino acids are added to the amino acid sequence of the original antibody or to the N-terminal or C-terminal.
- Antibodies are also mutated by combining additions, substitutions and deletions of these amino acids.
- the amino acid sequence of the mutated antibody preferably exhibits 80% or more identity with the amino acid sequence of the original antibody, more preferably 85% or more, and even more preferably 90% or more, 95. % Or more, or 98% or more identity.
- the antibody also includes an antibody in which mutations such as substitution, deletion, and addition are added to the amino acid sequence of the variable region of the original antibody.
- mutations such as substitution, deletion, and addition are added to the amino acid sequence of the variable region of the original antibody.
- the number of amino acids to be replaced is preferably 1 to 10, more preferably 1 to 5, and even more preferably 1 to 3.
- the number of amino acids to be deleted is preferably 1 to 10, more preferably 1 to 5, and even more preferably 1 to 3.
- Antibodies are also mutated by combining substitutions and deletions of these amino acids.
- amino acids preferably 1 to 10, more preferably 1 to 5, and even more preferably 1 to 3 amino acids are added to the amino acid sequence of the original antibody or to the N-terminal or C-terminal.
- Antibodies are also mutated by combining additions, substitutions and deletions of these amino acids.
- the amino acid sequence of the mutated antibody preferably exhibits 80% or more identity with the amino acid sequence of the original antibody, more preferably 85% or more, and even more preferably 90% or more, 95. % Or more, or 98% or more identity.
- the mutation may be added to either the CDR or the framework region of the variable region, but in particular to the framework region.
- the antibody also includes an antibody in which mutations such as substitutions, deletions, and additions are added to the amino acid sequence in the framework region of the variable region of the original antibody.
- mutations such as substitutions, deletions, and additions are added to the amino acid sequence in the framework region of the variable region of the original antibody.
- the number of amino acids to be replaced is preferably 1 to 10, more preferably 1 to 5, and even more preferably 1 to 3.
- the number of amino acids to be deleted is preferably 1 to 10, more preferably 1 to 5, and even more preferably 1 to 3.
- Antibodies are also mutated by combining substitutions and deletions of these amino acids.
- amino acids preferably 1 to 10, more preferably 1 to 5, and even more preferably 1 to 3 amino acids are added to the amino acid sequence of the original antibody or to the N-terminal or C-terminal.
- Antibodies are also mutated by combining additions, substitutions and deletions of these amino acids.
- the amino acid sequence of the mutated antibody preferably exhibits 80% or more identity with the amino acid sequence of the original antibody, more preferably 85% or more, and even more preferably 90% or more, 95. % Or more, or 98% or more identity.
- the antibody also includes an antibody in which mutations such as substitutions, deletions, and additions to amino acid sequences are added to the CDR regions of the variable regions of the original antibody.
- mutations such as substitutions, deletions, and additions to amino acid sequences are added to the CDR regions of the variable regions of the original antibody.
- the number of amino acids to be replaced is preferably 1 to 5, more preferably 1 to 3, and even more preferably 1 or 2.
- the number of amino acids to be deleted is preferably 1 to 5, more preferably 1 to 3, and even more preferably 1 or 2.
- Antibodies are also mutated by combining substitutions and deletions of these amino acids.
- amino acids preferably 1 to 5, more preferably 1 to 3, and even more preferably 1 or 2 amino acids are added to the amino acid sequence of the original antibody or to the N-terminal or C-terminal.
- Antibodies are also mutated by combining additions, substitutions and deletions of these amino acids.
- the amino acid sequence of the mutated antibody preferably exhibits 80% or more identity with the amino acid sequence of the original antibody, more preferably 85% or more, and even more preferably 90% or more, 95. % Or more, or 98% or more identity.
- the identity between the amino acid sequence of the original antibody and the amino acid sequence of the mutated antibody can be easily calculated using a well-known homology calculation algorithm.
- BLAST Altschul SF. J Mol. Biol. 215. 403-10, (1990)
- Pearson and Lipman similarity search method Proc. Natl. Acad. Sci. USA. 85. 2444 (1988)
- Smith and Waterman's local homology algorithm (Adv. Appl. Math. 2. 482-9 (1981)).
- a Fab is a light chain that includes a variable region and a CL region (constant region of a light chain), and a variable region and a CH 1 region (part 1 of the constant region of a heavy chain).
- the heavy chain may further include a part of the hinge portion in addition to the variable region and the CH 1 region (part 1 of the constant region of the heavy chain), but in this case, the hinge portion is in the hinge portion. It lacks the cysteine residue that is present and binds the heavy chains of the antibody to each other.
- the light chain and the heavy chain are a cysteine residue existing in the constant region ( CL region) of the light chain and a cysteine residue existing in the constant region ( CH 1 region) or the hinge portion of the heavy chain. It is bound by the disulfide bond formed between them.
- the heavy chain that forms a Fab is called a Fab heavy chain.
- Fab is composed of one light chain and one heavy chain because it is present in the hinge portion and lacks a cysteine residue that binds the heavy chains of the antibody to each other.
- the light chain constituting the Fab includes a variable region and a CL region.
- the heavy chain constituting the Fab may be composed of a variable region and a CH 1 region, or may include a part of a hinge portion in addition to the variable region and the CH 1 region.
- the hinge portion is selected so as not to contain a cysteine residue that binds between the heavy chains so that a disulfide bond is not formed between the two heavy chains at the hinge portion.
- the heavy chain contains all or part of the hinge portion containing the cysteine residue that binds the heavy chains together, in addition to the variable region and the CH1 region.
- F (ab') 2 refers to a molecule in which two F (ab') are bonded by a disulfide bond between cysteine residues existing at the hinge portions of each other.
- a heavy chain that forms F (ab') or F (ab') 2 is called a Fab'heavy chain.
- a polymer such as a dimer or a trimer in which a plurality of antibodies are bound directly or via a linker is also an antibody.
- any antibody that contains a part of an antibody molecule and has a property of specifically binding to an antigen is included in the "antibody" in the present invention.
- the term "light chain” in the present invention includes those derived from the light chain and having an amino acid sequence of all or part of the variable region thereof.
- the term heavy chain includes those derived from the heavy chain and having an amino acid sequence of all or part of the variable region. Therefore, as long as it has the amino acid sequence of all or part of the variable region, for example, the one in which the Fc region is deleted is also a heavy chain.
- the Fc or Fc region is a fragment of the antibody molecule consisting of a CH 2 region (part 2 of the heavy chain constant region) and a CH 3 region (part 3 of the heavy chain constant region). It refers to the area that includes it.
- the antibody in one embodiment of the present invention is (7)
- the light chain and heavy chain constituting Fab, F (ab') or F (ab') 2 shown in (2) above were bound via a linker sequence to form a single-chain antibody.
- Also included are scFab, scF (ab'), and scF (ab') 2 .
- scFab, scF (ab'), and scF (ab') 2 a linker sequence is bound to the C-terminal side of the light chain, and a heavy chain is further bound to the C-terminal side thereof.
- a linker sequence may be bound to the C-terminal side of the variable region of the light chain, and a variable region of the heavy chain may be further bound to the C-terminal side thereof, or C of the variable region of the heavy chain may be bound. It may consist of a linker sequence attached to the terminal side and a variable region of the light chain attached to the C-terminal side thereof.
- antibody as used herein is a broader concept that includes (1) to (7) in addition to the full-length antibody and those shown in (1) to (7) above. Any form of an antigen-binding fragment (antibody fragment) in which a part of a long antibody is deleted is included. Antigen-binding fragments also include heavy chain antibodies, light chain antibodies, VHH, VNAR, and those lacking some of them.
- antigen-binding fragment refers to a fragment of an antibody that retains at least a portion of its specific binding activity to an antigen.
- binding fragments include Fab, Fab', F (ab') 2 , variable region (Fv), heavy chain variable region ( VH ) and light chain variable region ( VL ) linked with an appropriate linker.
- a linker sequence is bound to the C-terminal side of an amino acid sequence containing all or part of the variable region of the light chain, and the linker sequence is further attached to the C-terminal side.
- the linker sequence is bound to the C-terminal side of the amino acid sequence containing all or part of the variable region of the heavy chain, and the amino acid sequence containing all or part of the variable region of the light chain is further bound to the C-terminal side.
- the protein capable of specifically binding to a specific antigen is also the "single-chain antibody" in the present invention.
- the heavy chain In a single-chain antibody in which a light chain is bound to the C-terminal side of the heavy chain via a linker sequence, the heavy chain usually lacks the Fc region.
- the variable region of the light chain has three complementarity determining regions (CDRs) involved in the antigen specificity of the antibody.
- the variable region of the heavy chain also has three CDRs. These CDRs are the main regions that determine the antigen specificity of an antibody. Therefore, it is preferable that the single-chain antibody contains all three CDRs of the heavy chain and all three CDRs of the light chain. However, as long as the antigen-specific affinity of the antibody is maintained, it may be a single-chain antibody in which one or more CDRs are deleted.
- the number of linker sequences arranged between the light chain and the heavy chain of the antibody is preferably 2 to 50, more preferably 8 to 50, still more preferably 10 to 30, and even more preferably. It is a peptide chain composed of 12 to 18 or 15 to 25 amino acid residues, for example, 15 or 25 amino acid residues.
- Such a linker sequence is not limited in its amino acid sequence as long as the anti-hTfR antibody to which both chains are linked retains the affinity for hTfR, but is preferably composed of glycine alone or glycine and serine.
- amino acid sequence Gly-Ser amino acid sequence Gly-Gly-Ser, amino acid sequence Gly-Gly-Ser, amino acid sequence Gly-Gly-Gly, amino acid sequence Gly-Gly-Gly, amino acid sequence Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 3), amino acid sequence Gly- Gly-Gly-Gly-Ser (SEQ ID NO: 4), amino acid sequence Ser-Gly-Gly-Gly (SEQ ID NO: 5), or these amino acid sequences are repeated 2 to 10 times or 2 to 5 times. It contains an array.
- variable region of the light chain is bound to the C-terminal side of the amino acid sequence consisting of the entire variable region of the heavy chain via the linker sequence
- amino acid sequence Gly-Gly-Gly-Gly-Ser SEQ ID NO: 3
- a linker sequence containing a total of 15 amino acids corresponding to 3 consecutive amino acids in is suitable.
- a single domain antibody refers to an antibody having the property of specifically binding to an antigen in a single variable region.
- Single domain antibodies include antibodies whose variable region consists only of heavy chain variable regions (heavy chain single domain antibodies) and antibodies whose variable regions consist only of light chain variable regions (light chain single domain antibodies). Is done. VHH and VNAR are a kind of single domain antibody.
- the term "human transferrin receptor” refers to a membrane protein having the amino acid sequence set forth in SEQ ID NO: 57.
- the antibody of the present invention is applied to the portion from the cysteine residue 89th from the N-terminal side to phenylalanine at the C-terminal (extracellular region of the transferrin receptor) in the amino acid sequence shown in SEQ ID NO: 57.
- it is not limited to this.
- a recombinant protein is produced using a cell into which an expression vector incorporating a gene encoding the protein has been introduced, and the recombinant protein is used to immunize an animal such as a mouse.
- the method of obtaining the protein is common.
- the animal species from which the immune system cells are derived is not particularly limited, but primates including mice, rats, rabbits, guinea pigs, dogs, cats, horses, and humans are preferable. It is preferably mice, rats and humans, and more preferably mice and humans.
- the immune system cells of the mouse for example, splenocytes prepared from the spleen of the mouse can be used.
- the human immune system cells cells prepared from human peripheral blood, bone marrow, spleen and the like can be used.
- hybridoma cells capable of producing antibodies can be produced by fusing the cells with myeloma cells.
- mRNA is extracted from post-immunized cells to synthesize cDNA, and DNA fragments containing genes encoding the light and heavy chains of immunoglobulin are amplified by PCR reaction using this cDNA as a template, and artificially used. It is also possible to reconstruct the antibody gene.
- hybridoma cells as obtained by the above method also include cells that produce antibodies that recognize unintended proteins as antigens. Further, not all hybridoma cells that produce an antibody against a desired protein produce an antibody that exhibits desired characteristics such as having a high affinity for the protein.
- the artificially reconstructed antibody gene also includes a gene encoding an antibody that recognizes an unintended protein as an antigen. Further, not all genes encoding an antibody against a desired protein encode an antibody exhibiting desired properties such as having a high affinity for the protein.
- a step of selecting a hybridoma cell that produces an antibody having a desired characteristic from the hybridoma cell as obtained above is required.
- a step of selecting a gene encoding an antibody having a desired characteristic from the antibody gene is required.
- the method described in detail below is effective. be.
- the protein when selecting a hybridoma cell that produces an antibody having high affinity for a desired protein, the protein is added to a plate and retained in the plate, and then the culture supernatant of the hybridoma cell is added, and then the said.
- a method is used in which the antibody that is not bound to the protein is removed from the plate and the amount of antibody retained on the plate is measured. According to this method, the higher the affinity of the antibody contained in the culture supernatant of the hybridoma cells added to the plate to the protein, the greater the amount of antibody retained on the plate. Therefore, the amount of antibody retained on the plate is measured, and the hybridoma cell corresponding to the plate on which more antibody is retained is used as a cell line that produces an antibody having a relatively high affinity for the protein.
- the cells used as host cells may be proto-nuclear cells or eukaryotic cells as long as they can express the antibody gene by introducing an expression vector incorporating an artificially reconstructed antibody gene.
- cells derived from mammals such as humans, mice, and Chinese hamsters are preferable, and CHO cells derived from Chinese hamster ovary or NS / 0 cells derived from mouse myeloma are particularly preferable.
- the expression vector used for incorporating and expressing the gene encoding the antibody gene can be used without particular limitation as long as it expresses the gene when introduced into a mammalian cell.
- the gene integrated into the expression vector is placed downstream of a DNA sequence (gene expression control site) capable of regulating the frequency of gene transcription in mammalian cells.
- a DNA sequence capable of regulating the frequency of gene transcription in mammalian cells.
- the gene expression control site that can be used in the present invention include a cytomegalovirus-derived promoter, an SV40 early promoter, a human elongation factor-1alpha (EF-1 ⁇ ) promoter, a human ubiquitin C promoter, and the like.
- Mammalian cells into which such an expression vector has been introduced will express the above-mentioned artificially reconstructed antibody incorporated into the expression vector.
- the protein is added to the plate.
- the method is to contact the protein with the culture supernatant of the cells, then remove the antibody that is not bound to the protein from the plate, and measure the amount of antibody retained on the plate. Be done. According to this method, the higher the affinity of the antibody contained in the cell culture supernatant for the protein, the greater the amount of antibody retained on the plate.
- the amount of antibody retained on the plate is measured, and the cell corresponding to the plate on which more antibody is retained is selected as a cell line that produces an antibody having a relatively high affinity for the protein.
- a gene encoding an antibody having a high affinity for the protein can be selected.
- a gene encoding a high affinity antibody can also be isolated by amplifying a DNA fragment containing a gene encoding an antibody against the protein from the cell line selected in this manner by using the PCR method. ..
- Non-peptide linkers include polyethylene glycol, polypropylene glycol, copolymers of ethylene glycol and propylene glycol, polyoxyethylated polyols, polyvinyl alcohol, polysaccharides, dextran, polyvinyl ether, biodegradable polymers, lipid polymers, etc. Chitins and hyaluronic acid, derivatives thereof, or a combination thereof can be used.
- a peptide linker is a peptide chain consisting of 1 to 50 amino acids bound to a peptide or a derivative thereof, and its N-terminal and C-terminal respectively form a covalent bond with any of the antibodies of the hNAGLU variant. , It binds the hNAGLU variant to the antibody.
- the antibody and the hNAGLU variant bind the N-terminal or C-terminal of the hNAGLU variant to the C-terminal or N-terminal side of the heavy or light chain of the antibody via a linker sequence or directly, respectively, by peptide bond. You can also do it.
- the conjugate formed by binding the antibody to the hNAGLU variant in this way is a DNA fragment encoding the linker sequence directly on the 3'end side or the 5'end side of the cDNA encoding the heavy chain or the light chain of the antibody.
- a DNA fragment in which the cDNA encoding the hNAGLU variant is arranged in frame is incorporated into an expression vector for mammalian cells, and the mammalian cells into which this expression vector has been introduced are cultured as a fusion protein. Obtainable.
- the expression vector for the mammalian cell incorporating the cDNA fragment encoding the light chain of the antibody is also the same host.
- An expression vector for mammalian cells that can be introduced into cells and that incorporates a cDNA fragment encoding the heavy chain of an antibody when the DNA fragment encoding the hNAGLU variant is bound to the light chain.
- the fusion protein that binds the antibody to the hNAGLU variant encodes the linker sequence directly or on the 5'end or 3'end of the cDNA encoding the hNAGLU variant.
- a DNA fragment in which a cDNA encoding a single-chain antibody is ligated is incorporated into an expression vector (for mammalian cells, eukaryotic cells such as yeast, or prokaryotic cells such as Escherichia coli), and this expression is expressed. It can be obtained by expression in these cells into which the vector has been introduced.
- the fusion protein of the antibody and the hNAGLU mutant can be produced as a recombinant protein by the above method.
- any medium can be used as long as the animal cells can be cultured and proliferated, but a serum-free medium is preferably used. Be done.
- the serum-free medium used as the medium for producing recombinant protein for example, amino acids are 3 to 700 mg / L, vitamins are 0.001 to 50 mg / L, and monosaccharides are 0.3 to 10 g / L.
- Inorganic salts 0.1 to 10000 mg / L, trace elements 0.001 to 0.1 mg / L, nucleosides 0.1 to 50 mg / L, amino acids 0.001 to 10 mg / L, biotin 0.01 ⁇ 1 mg / L, hydrocortisone 0.1-20 ⁇ g / L, insulin 0.1-20 mg / L, vitamin B12 0.1-10 mg / L, ptolessin 0.01-1 mg / L, sodium pyruvate
- a medium containing 10 to 500 mg / L and a water-soluble iron compound is preferably used. If desired, thymidine, hypoxanthine, conventional pH indicators, antibiotics and the like may be added to the medium.
- DMEM / F12 medium (mixed medium of DMEM and F12) may be used as the basic medium as the serum-free medium used as the medium for producing the fusion protein of the antibody and the hNAGLU variant, and each of these media is well known to those skilled in the art. be.
- the serum-free medium contains sodium hydrogencarbonate, L-glutamine, D-glucose, insulin, sodium selenite, diaminobutane, hydrocortisone, iron (II) sulfate, asparagine, aspartic acid, serine and polyvinyl alcohol, DMEM.
- HG HAM improved (R5) medium may be used.
- serum-free medium for example, CD OptiCHO TM medium, CHO-S-SFM II medium or CD CHO medium (Thermo Fisher Scientific, formerly Life Technologies), IS cho- VTM medium (Irvine Scientific), EX-CELL TM 302 medium or EX-CELL TM 325-PF medium (SAFC Biosciences) or the like can also be used as the basic medium.
- Preferred embodiments of the fusion protein of the antibody and the hNAGLU mutant include the following (1) to (7). That is: (1) A conjugate containing the hNAGLU mutant bound directly to the C-terminal of the heavy chain of the antibody or via a linker, and the light chain of the antibody; (2) A conjugate containing the hNAGLU mutant bound directly to the N-terminal of the heavy chain of the antibody or via a linker, and the light chain of the antibody; (3) A conjugate containing the hNAGLU mutant bound directly to the C-terminal of the light chain of the antibody or via a linker, and the heavy chain of the antibody; (4) A conjugate containing a conjugate in which the hNAGLU mutant is bound to the N-terminal of the light chain of the antibody directly or via a linker, and a heavy chain of the antibody.
- the number of linker sequences arranged between the antibody and the hNAGLU mutant is preferably 1 to 60 or 1 to 50, more preferably 1 to 1. It is a peptide chain composed of 17, more preferably 1 to 10, and even more preferably 1 to 5 amino acids, but the number of amino acids constituting the linker sequence is 1, 2, or 3. It can be appropriately adjusted from 1 to 17, 1 to 10, 10 to 40, 20 to 34, 23 to 31, 25 to 29, 27 and the like.
- Such a linker sequence is such that the ligated antibody retains its affinity for the receptor on cerebrovascular endothelial cells, and the hNAGLU variant ligated by the linker sequence is such hNAGLU under physiological conditions.
- its amino acid sequence is not limited, but it is preferably composed of glycine and serine.
- amino acid sequence Gly-Ser amino acid sequence Ser-Ser, amino acid sequence Gly-Gly-Ser, amino acid sequence Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 58), amino acid sequence Gly-Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 59), amino acid sequence Ser-Gly-Gly-Gly-Gly (SEQ ID NO: 60), or 1 to 10 of these amino acid sequences, Alternatively, those containing 2 to 5 consecutive sequences can be mentioned.
- those containing the amino acid sequence Gly-Ser can be suitably used as a linker sequence.
- a linker sequence containing a total of 27 amino acid sequences in which the amino acid sequence Gly-Ser is followed by the amino acid sequence Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 58) is preferably used.
- a linker sequence containing a total of 25 amino acid sequences having five consecutive amino acid sequences Gly-Gly-Gly-Gly-Ser can be preferably used.
- each linker sequence is named as a first linker sequence and a second linker sequence in order from the N-terminal side for convenience.
- anti-hTfR antibody anti-human transferrin receptor antibody
- An anti-hTfR antibody wherein the light chain of the antibody comprises the amino acid sequence of SEQ ID NO: 61 and the heavy chain comprises the amino acid sequence of SEQ ID NO: 62
- anti-hTfR anti-human transferrin receptor antibody
- An antibody that is an antibody and is a Fab antibody wherein the light chain of the antibody comprises the amino acid sequence of SEQ ID NO: 61 and the heavy chain comprises the amino acid sequence of SEQ ID NO: 63. Is.
- the anti-hTfR antibody of the above (1) and (2) is a humanized anti-hTfR antibody.
- the number of amino acids to be replaced is preferably 1 to 10, and more preferably 1 to 5. , More preferably 1 to 3, and even more preferably 1 or 2.
- the number of amino acids to be deleted is preferably 1 to 10, more preferably 1 to 5, and even more preferably 1 to 3. , Even more preferably one or two. Mutations that combine substitutions and deletions of these amino acids can also be added.
- amino acid When an amino acid is added to the amino acid sequence of the light chain of the above anti-human transferrin receptor antibody, preferably 1 to 10 amino acids, more preferably 1 to 5 in the amino acid sequence of the light chain or on the N-terminal side or the C-terminal side. 13 amino acids, more preferably 1 to 3, and even more preferably 1 or 2 amino acids are added. Mutations that combine additions, substitutions and deletions of these amino acids can also be added.
- the mutated light chain amino acid sequence has preferably 80% or more identity, more preferably 90% or more identity, and even more preferably 95% identity with the original light chain amino acid sequence. The above identity is shown.
- the number of amino acids to be substituted is preferably 1 to 10, and more preferably 1 to 5. , More preferably 1 to 3, and even more preferably 1 or 2.
- the number of amino acids to be deleted is preferably 1 to 10, more preferably 1 to 5, and even more preferably 1 to 3. , Even more preferably one or two. Mutations that combine substitutions and deletions of these amino acids can also be added.
- amino acid When an amino acid is added to the amino acid sequence of the heavy chain of the above anti-human transferrin receptor antibody, preferably 1 to 10 amino acids, more preferably 1 to 5 in the amino acid sequence of the heavy chain or on the N-terminal side or the C-terminal side. 13 amino acids, more preferably 1 to 3, and even more preferably 1 or 2 amino acids are added. Mutations that combine additions, substitutions and deletions of these amino acids can also be added.
- the mutated heavy chain amino acid sequence has preferably 80% or more identity with the original heavy chain amino acid sequence, more preferably 90% or more identity, and even more preferably 95%. The above identity is shown.
- the hNAGLU variant of the present invention is caused by NAGLU deficiency because it can cross the blood-brain barrier and exert its function in the brain by binding to an antibody against a receptor on cerebrovascular endothelial cells. It can be used for the production of drugs for blood administration for the treatment of disease states of the central nervous system.
- the hNAGLU mutant bound to the antibody is administered in the blood to the relevant patient in a therapeutically effective amount for the disease state of the central nervous system caused by NAGLU deficiency (including intravenous injection such as intravenous drip infusion). Can be used in therapeutic methods, including.
- the hNAGLU mutant bound to the antibody administered in the blood can reach not only the brain but also other organs / organs expressing NAGLU.
- the drug can also be used to prevent the onset of the disease state.
- the hNAGLU variant of the present invention can be administered into the blood and used as a drug to exert its medicinal effect in the central nervous system (CNS) by binding to an antibody against a receptor on cerebrovascular endothelial cells.
- CNS central nervous system
- Such a drug is generally administered to a patient by intravenous injection such as intravenous drip injection, subcutaneous injection, or intramuscular injection, but the route of administration is not particularly limited.
- the hNAGLU mutant in one embodiment of the present invention is not limited to an antibody, but can also be a conjugate with other proteins.
- the other proteins are not particularly limited, but the proteins are, for example, human-derived proteins.
- a conjugate of the hNAGLU mutant and the other protein can be obtained by the above-mentioned method for producing a conjugate of the hNAGLU mutant and an antibody.
- the fusion protein of the hNAGLU mutant and the other protein can be obtained as a recombinant protein by the method for producing the fusion protein with the above-mentioned antibody.
- One embodiment of the invention includes a gene encoding a fusion protein of a hNAGLU variant and another protein, an expression vector incorporating the gene, and a host cell into which the expression vector has been introduced.
- the hNAGLU mutant in one embodiment of the present invention is not limited to the anti-hTfR antibody, but can also be a conjugate with a substance capable of binding to human hTfR.
- the substance is not particularly limited, but the protein is, for example, human transferrin.
- Human transferrin is not limited to the wild type, and may be a partial fragment or a mutant thereof as long as it has an affinity for hTfR.
- conjugates can cross the blood-brain barrier and exert their functions in the brain.
- the fusion protein of the hNAGLU mutant and human transferrin can be obtained as a recombinant protein by the method for producing the fusion protein with the above-mentioned antibody.
- One embodiment of the present invention includes a gene encoding a fusion protein of an hNAGLU variant and human transferase, an expression vector incorporating the gene, and a host cell into which the expression vector has been introduced.
- Example 1 Construction of expression vector for hNAGLU mutant A DNA fragment having the nucleotide sequence shown by SEQ ID NO: 41 containing the wild-type hNAGLU gene was synthesized. Using this as a template, the MluI-added 5'primer having the base sequence shown in SEQ ID NO: 42 as a forward primer, and the primers shown in Table 1 as a reverse primer, PCR of Nos. 1 to 7 and 11 shown in Table 1 is used. Was done. Table 1 shows the sequence numbers corresponding to the base sequences of each reverse primer.
- PCR products obtained by PCR of Nos. 1 to 7 and 11 shown in Table 1 as forward primers are shown in SEQ ID NO: 43 as reverse primers.
- PCR was performed using the His tag-Not I addition 3'primer having the same nucleotide sequence, and a PCR product containing the gene encoding the hNAGLU variant shown in Table 2 was obtained.
- Table 2 shows the sequence number corresponding to the amino acid sequence of each hNAGLU mutant, the sequence number corresponding to the base sequence encoding them, and the number (mutant number) of each hNAGLU mutant.
- PCR was performed using the PCR product obtained by the above-mentioned PCR to obtain a PCR product containing the gene encoding the hNAGLU variant shown in Table 4.
- Table 4 shows the sequence number corresponding to the amino acid sequence of each hNAGLU mutant, the sequence number corresponding to the base sequence encoding them, and the number (mutant number) of each hNAGLU mutant.
- the PCR products obtained by PCR of Nos. 1 to 11 and the DNA fragment having the base sequence represented by SEQ ID NO: 41 encoding wild-type hNAGLU were treated with restriction enzymes with MluI and NotI (Takara Bio). , Separated by agarose gel electrophoresis. After EtBr staining, a band containing the target DNA fragment was excised under UV irradiation, and DNA was extracted from the gel using the QIAEX II Gel Extraction Kit (QIAGEN). Similarly, the pCI-neo vector (Promega) and the pEI-puro vector were also treated with restriction enzymes with MluI and NotI, and gel extraction and purification were performed.
- Each PCR product treated with the restriction enzyme was mixed with each vector treated with the restriction enzyme, and a ligation reaction was carried out at 16 ° C. for 30 to 60 minutes using Ligation Mix (Takara Bio Inc.). A ligation reaction was also carried out for the DNA fragment containing the base sequence shown by SEQ ID NO: 41 containing the wild-type hNAGLU gene.
- the pEI-puro vector was prepared by the following procedure.
- the pEF / myc / nuc vector (Invitrogen) is digested with restriction enzymes (KpnI and NcoI), a DNA fragment containing the EF-1a promoter and its first intron is excised, and this DNA fragment is blunt-ended with T4 DNA polymerase.
- restriction enzymes KpnI and NcoI
- pCI-neo (Invitrogen) was digested with restriction enzymes (BglII and EcoRI), the region containing the enhancer / promoter and intron of CMV was excised, and then blunt-terminated with T4 DNA polymerase.
- the pCAGIpuro vector (Miyahara M. et.al., J. Biol. Chem. 275, 613-618 (2000)) is digested with restriction enzymes (NotI and BamHI) and derived from mouse encephalomyopathy virus (EMCV).
- EMCV mouse encephalomyopathy virus
- the pE-neo vector was digested with restriction enzymes (NotI and BamHI) to excise the region of about 2 kbp containing the neomycin resistance gene (Neo r ).
- restriction enzymes NotI and BamHI
- a DNA fragment containing polyA derived from the above IRES, PuroR and bGH was inserted into this. This was named the pEI-puro vector.
- Escherichia coli (ECOS TM X Competent E. coli DH5 ⁇ , Nippon Gene Co., Ltd.) was transformed with each ligation reaction solution.
- LB liquid medium LB Broth, Sigma-Aldrich
- FastGene plasmid Mini Kit Nippon Genetics
- the purified plasmid DNA was treated with restriction enzymes MluI and NotI, and separated by agarose gel electrophoresis. It was confirmed that the desired insert DNA was inserted. In addition, it was confirmed by Sanger sequence analysis that the desired modification was introduced into each hNAGLU gene.
- Each plasmid confirmed to incorporate the target hNAGLU mutant or wild-type hNAGLU was purified by a conventional method.
- Example 2 Transient expression of hNAGLU mutant
- a plasmid in which a gene encoding each hNAGLU mutant was incorporated into the purified pCI-neo vector obtained in Example 1 was used. I went.
- a plasmid in which a gene encoding wild-type NAGLU was incorporated into a pCI-neo vector was used.
- ExpiCHO cells were transformed using a plasmid incorporating a gene encoding an hNAGLU mutant and a plasmid incorporating a gene encoding a wild-type hNAGLU according to the High titer protocol of the ExpiCHO Expression System (Thermo Fisher Scientific). .. After transformation, cells were cultured for 8 days, and each hNAGLU mutant and wild-type hNAGLU were expressed in the culture supernatant. After culturing, the culture broth was centrifuged to collect the culture supernatant.
- Example 3 Confirmation of hNAGLU mutant expression level by transient expression (SDS page electrophoresis) 10 ⁇ L of the culture supernatant obtained in Example 2 was mixed with 8 ⁇ L of 2 ⁇ Sample Buffer (Biorad) and 2 ⁇ L of 2-Mercaptoethanol, and kept warm at 100 ° C. for 3 minutes under reducing conditions. It was heat-denatured. Place the heat-denatured sample in 5 ⁇ L each in wells of a 5-20% polyacrylamide gel placed in 50 mM Tris buffer / 380 mM glycine buffer (pH 8.3) containing 0.1% SDS, 25 mA. It was electrophoresed at a constant current.
- the gel after electrophoresis was immersed in Oriole Fluorescent Gel Stain (Biorad) and shaken at room temperature for 90 minutes. After washing the gel with pure water, a protein band was detected with a lumino image analyzer (Amersham Imager 600RGB, Citiva).
- Example 4 Confirmation of hNAGLU mutant expression level by transient expression (Western blotting method) Electrophoresis was performed in the same manner as in Example 3, and the nitrocellulose membrane and the gel after electrophoresis were sandwiched between blotting papers dipped in 25 mM Tris buffer / 192 mM glycine buffer containing 20% methanol. The protein was transferred to the nitrocellulose membrane by energizing with a blotting device at 1.0 A and 25 V for 10 minutes.
- Example 5 Confirmation of hNAGLU mutant expression level by transient expression (enzyme activity measurement)
- the culture supernatant obtained in Example 2 was diluted 10-fold with 100 mM citric acid buffer (pH 4.2) containing 0.1% BSA.
- 4-MU 4-Methylumbelliferone, Sigma-Aldrich
- the fluorescence intensity of 4-MU (4-Methylumbelliferone) released by a fluorescent plate reader was measured (excitation wavelength 355 nm, fluorescence wavelength 460 nm).
- a calibration curve was prepared based on the measurement results of the standard solution, and the measured values of each sample solution were intercalated into the calibration curve to determine the amount of enzyme activity.
- FIG. 1 shows the measurement results of the hNAGLU mutant expression level by transient expression measured in Examples 2 to 4.
- Table 5 shows the expression level of each hNAGLU mutant based on the enzyme activity measurement result shown by the bar graph in FIG. 1 as a relative value when the expression level of the wild type is 1.
- the expression level of the Q209R hNAGLU mutant (mutant No. 3) was 4.4 times higher than that of the wild-type hNAGLU.
- the R129Q hNAGLU mutant (mutant number 16), S526N / A528T hNAGLU mutant (mutant number 17), D613Q hNAGLU mutant (mutant number 18), and H204K hNAGLU mutant (mutant number 19) are It showed a low transient expression compared to the wild type.
- Example 7 Preparation of hNAGLU mutant-expressing bulk cells Using a gene transfer apparatus (super electroporator NEPA21, Neppagene), each hNAGLU obtained in Example 1 was applied to a serum-free conditioned strain of CHO-K1 cells. Expression plasmids incorporating mutants or genes encoding wild-type hNAGLU were introduced, and selective culture was performed on CD OptiCHO medium (Thermo Fisher Scientific) containing 10 ⁇ g / mL Puromycin (Thermo Fisher Scientific).
- the volume of the culture medium was gradually increased by repeating the medium exchange every 3 to 4 days, and the cells were collected when the viability of the cells in culture exceeded 90%, and these were collected as hNAGLU mutant-expressing bulk cells and wild-type cells.
- the hNAGLU-expressing bulk cells were used.
- Example 8 Culturing of hNAGLU mutant-expressing bulk cells Two hNAGLU mutant-expressing bulk cells and wild-type hNAGLU-expressing bulk cells obtained in Example 7 were placed in a CD OptiCHO medium containing 10 ⁇ g / mL Puromycin. The cells were seeded at a cell density of ⁇ 10 5 cells / mL and statically cultured in the presence of 5% CO 2 at 37 ° C. Nine days after the start of the culture, the culture supernatant was centrifuged and the culture supernatant was collected.
- Example 9 Confirmation of hNAGLU mutant expression level by bulk cells (enzyme activity measurement)
- the culture supernatant obtained in Example 8 was diluted 10-fold with a citric acid buffer solution (pH 4.2) containing 0.1% BSA to prepare a sample solution.
- a citric acid buffer solution pH 4.2
- 4-Methylumbelliferyl-N-acetyl- ⁇ -D-glucosaminide which is an artificial substrate of hNAGLU, was diluted with citric acid buffer (pH 4.2) to 1 mmol / L.
- a calibration curve was prepared based on the measurement results of the standard solution, and the measured values of each sample solution were intercalated into the calibration curve to determine the amount of enzyme activity.
- the amount of enzyme activity was determined for each hNAGLU variant as the amount of hNAGLU enzyme activity (nmol / h / 1 ⁇ 10 6 cells) expressed from 1 ⁇ 10 6 cells during culture.
- FIG. 2 shows the measurement results of the hNAGLU mutant expression level by the bulk cells measured in Example 9.
- Table 6 shows the expression level of each hNAGLU mutant based on the enzyme activity measurement result shown by the bar graph in FIG. 2 as a relative value when the expression level of the wild type is 1. The bulk cell culture was repeated 4 times, and the enzyme activity was measured for each.
- the expression levels of the seven mutants of the S526N / A528T hNAGLU mutant (mutant numbers 1 to 7) were higher than those of the wild type.
- the expression level of the Q209R hNAGLU mutant (mutant No. 3) was 2.2 times higher than that of the wild-type hNAGLU.
- mutant number 16 R129Q hNAGLU mutant
- S526N / A528T hNAGLU mutant mutant number 17
- D613Q hNAGLU mutant mutant number 18
- H204K hNAGLU H204K hNAGLU
- Example 11 Mutation introduction into Q209R hNAGLU mutant and construction of expression vector From the experimental results of Examples 1 to 10, it was found that the Q209R hNAGLU mutant showed the highest expression level among the hNAGLU mutants. .. Therefore, in order to obtain a higher expression hNAGLU mutant, further mutations were introduced into the Q209R hNAGLU mutant.
- the MluI-added 5'primer having the base sequence shown by SEQ ID NO: 42 as a forward primer is shown in Table 7 as a reverse primer. PCR of Nos. 12 to 15 shown in Table 7 was performed using primers. Table 7 shows the SEQ ID NOs corresponding to the base sequences of each reverse primer.
- the His tag having the primer shown in Table 8 as a forward primer and the nucleotide sequence shown by SEQ ID NO: 43 as a reverse primer- PCR of No. 16 shown in Table 8 was performed using the NotI-added 3'primer.
- Table 8 shows the SEQ ID NOs corresponding to the base sequences of the forward primers.
- Table 10 shows the sequence number corresponding to the amino acid sequence of each hNAGLU mutant, the sequence number corresponding to the base sequence encoding them, and the number (mutant number) of each hNAGLU mutant.
- each PCR product obtained by PCR of Nos. 17-19, 21, and 23-26 was treated with restriction enzymes by MluI and NotI (Takara Bio Inc.), and separated by agarose gel electrophoresis. After EtBr staining, a band containing the target DNA fragment was excised under UV irradiation, and DNA was extracted from the gel using the QIAEX II Gel Extraction Kit (QIAGEN). Similarly, the pCI-neo vector (Promega) and the pEI-puro vector were also treated with restriction enzymes with MluI and NotI, and gel extraction and purification were performed. Each PCR product treated with the restriction enzyme was mixed with each vector treated with the restriction enzyme, and a ligation reaction was carried out at 16 ° C. for 30 to 60 minutes using Ligation Mix (Takara Bio Inc.).
- Escherichia coli (ECOS TM X Competent E. coli DH5 ⁇ , Nippon Gene Co., Ltd.) was transformed with each ligation reaction solution.
- LB liquid medium LB Broth, Sigma-Aldrich
- FastGene plasmid Mini Kit Nippon Genetics
- the purified plasmid DNA was treated with restriction enzymes MluI and NotI, and separated by agarose gel electrophoresis. It was confirmed that the desired insert DNA was inserted. In addition, it was confirmed by Sanger sequence analysis that the desired modification was introduced into each hNAGLU gene.
- Each plasmid confirmed to incorporate the desired hNAGLU mutant was purified by a conventional method.
- Example 12 Transient expression of hNAGLU mutant Transient expression of hNAGLU mutant was performed using a plasmid in which the hNAGLU mutant was incorporated into the pCI-neo vector purified in Example 11. As a control, a plasmid in which wild-type hNAGLU was incorporated into a pCI-neo vector was used.
- ExpiCHO cells were transformed using a plasmid incorporating a gene encoding an hNAGLU mutant and a plasmid incorporating a gene encoding a wild-type hNAGLU according to the High titer protocol of the ExpiCHO Expression System (Thermo Fisher Scientific). .. After transformation, cells were cultured for 8 days, and each hNAGLU mutant and wild-type hNAGLU were expressed in the culture supernatant. After culturing, the culture broth was centrifuged to collect the culture supernatant. In addition, as a negative control, the culture supernatant of untransformed cells was collected in the same manner.
- Example 13 Confirmation of hNAGLU mutant expression level by transient expression (SDS page electrophoresis) 10 ⁇ L of the culture supernatant obtained in Example 12 was mixed with 8 ⁇ L of 2 ⁇ Sample Buffer and 2 ⁇ L of 2-Mercaptoethanol, and heat-denatured under reducing conditions by keeping the temperature at 100 ° C. for 3 minutes. Apply 5 ⁇ L each of the heat-denatured sample to the wells of a 5-20% polyacrylamide gel placed in 50 mM Tris buffer / 380 mM glycine buffer (pH 8.3) containing 0.1% SDS, 25 mA. It was electrophoresed at a constant current. The gel after electrophoresis was immersed in Oriole Fluorescent Gel Stain (Biorad) and shaken at room temperature for 90 minutes. After washing the gel with pure water, a protein band was detected with a lumino image analyzer.
- Example 14 Confirmation of hNAGLU mutant expression level by transient expression (Western blotting method) Electrophoresis was performed in the same manner as in Example 13, and the nitrocellulose membrane and the gel after electrophoresis were sandwiched between blotting papers dipped in 25 mM Tris buffer / 192 mM glycine buffer containing 20% methanol. The protein was transferred to the nitrocellulose membrane by energizing with a blotting device at 1.0 A and 25 V for 10 minutes.
- the transferred nitrocellulose membrane was immersed in PBS containing 5% skim milk and shaken for 1 hour, and then immersed in Mouse anti-His tag mAb solution diluted to 0.4 ⁇ g / mL and shaken for 1 hour. After washing the membrane with PBST, the membrane was immersed in Anti-mouse IgG (H + L) and HRP Conjugate solution diluted to 0.4 ⁇ g / mL, shaken for 30 minutes, and washed again with PBST. The HRP detection reagent was added dropwise to the transfer surface of the membrane, reacted for 5 minutes, and detected with a lumino image analyzer.
- Example 15 Confirmation of hNAGLU mutant expression level by transient expression (enzyme activity measurement)
- the culture supernatant obtained in Example 12 was diluted 10-fold with a citric acid buffer solution (pH 4.2) containing 0.1% BSA to prepare a sample solution.
- a citric acid buffer solution pH 4.2
- 4-Methylumbelliferyl-N-acetyl- ⁇ -D-glucosaminide which is an artificial substrate of hNAGLU, was diluted with citric acid buffer (pH 4.2) to 1 mmol / L.
- Example 16 Confirmation of hNAGLU mutant expression level by transient expression (result) 3 and 4 show the measurement results of the hNAGLU mutant expression level by transient expression measured in Examples 12 to 15.
- Table 11 shows the expression levels of each hNAGLU mutant based on the enzyme activity measurement results shown in the bar graphs in FIGS. 3 and 4 as relative values when the wild-type expression level is 1.
- the V54I / Q209R / R620K hNAGLU mutant showed a transient expression of about 1.8 times (5.9 times that of the wild type) compared with the Q209R hNAGLU mutant.
- a positive correlation was observed between the amount of enzyme activity and the expression level of the hNAGLU mutant confirmed by SDS page electrophoresis shown in FIGS. 3 (b) and 4 (a).
- a positive correlation was observed between the amount of enzyme activity and the expression level of the hNAGLU mutant confirmed by the Western blotting method shown in FIG. 4 (b).
- Example 17 The above results indicate that when the recombinant hNAGLU is produced, the production amount can be 2 to 5 times higher by producing the recombinant Q209R hNAGLU mutant instead of the recombinant wild-type hNAGLU. show.
- Example 18 Construction of cells for expression of fusion protein of anti-human transferrin receptor antibody (anti-hTfR antibody) and hNAGLU variant
- the fusion protein of anti-human transferrin receptor antibody (anti-hTfR antibody) and hNAGLU variant is as follows. It can be manufactured by the method described in detail in.
- the expression vectors pE-neo vector and pE-hygr vector are constructed by the method described in the patent document (WO2018 / 124121).
- the pE-neo and pE-hygr vectors are digested with MluI and NotI, respectively.
- An amino acid sequence represented by SEQ ID NO: 3 is connected to the C-terminal of the Fab heavy chain of the anti-hTfR antibody containing the amino acid sequence of SEQ ID NO: 63 via a linker sequence consisting of a total of 15 amino acids.
- a MluI sequence and a sequence encoding a leader peptide that functions as a secretory signal are arranged in order from the 5'end, and a NotI sequence is arranged on the 3'side.
- This DNA fragment is digested with MluI and NotI and incorporated between MluI and NotI of the pE-neo vector to construct pE-neo (HC-mhNAGLU).
- amino acid sequence represented by SEQ ID NO: 3 is connected to the C-terminal of the L44_G45insS / Q209R hNAGLU mutant (mutant No. 9) via a linker sequence consisting of a total of 15 amino acids in a row of SEQ ID NO: 63.
- the DNA fragment encoding the protein represented by SEQ ID NO: 65 to which the Fab heavy chain of the anti-hTfR antibody comprising the amino acid sequence of is bound is synthesized. On the 5'side of this DNA fragment, a MluI sequence and a sequence encoding a leader peptide that functions as a secretory signal are arranged in order from the 5'end, and a NotI sequence is arranged on the 3'side.
- This DNA fragment is digested with MluI and NotI and incorporated between MluI and NotI of the pE-neo vector to construct pE-neo (mhNAGLU-HC).
- CHO cells obtained from CHO-K1: American Type Culture Collection
- GenePulser Bio-Rad
- pE-neo HC-mhNAGLU
- pE-neo HC-mhNAGLU
- transform with pE-neo HC-mhNAGLU
- pE-neo mhNAGLU-HC
- Cell transformation is generally performed by the following method. 5X10 5 CHO-K1 cells are seeded in a 3.5 cm culture dish supplemented with CD OptiCHO TM medium (Life Technologies) and cultured overnight at 37 ° C. and 5% CO 2 .
- Opti-MEM TM I medium Life Technologies
- Opti-MEM TM I medium Life Technologies
- the cells selected in the selective culture are seeded on a 96-well plate so that one or less cells are seeded per well, and each cell is about to form a monoclonal colony. Incubate for 10 days. The culture supernatant of the well in which the monoclonal colony was formed is collected, the humanized antibody content in the culture supernatant is examined by the ELISA method, and a cell line highly expressing humanized antibody is selected.
- the ELISA method at this time is generally implemented by the following method.
- a goat anti-human IgG polyclonal antibody solution diluted to 4 ⁇ g / mL with 0.05 M bicarbonate buffer (pH 9.6) at room temperature.
- the antibody was adsorbed on the plate by allowing it to stand for at least 1 hour.
- PBS Starting Block
- Blocking Buffer Thermo Fisher Scientific
- culture supernatant or human IgG standard product diluted to an appropriate concentration with PBS supplemented with 0.5% BSA and 0.05% Tween 20 (PBS-BT) was added to each well.
- PBS-BT culture supernatant or human IgG standard product diluted to an appropriate concentration with PBS supplemented with 0.5% BSA and 0.05% Tween 20
- Example 19 Production of fusion protein of anti-hTfR antibody and hNAGLU mutant
- the fusion protein of anti-hTfR antibody and hNAGLU mutant can be produced by the following method.
- the highly expressed cell line described in Example 18 was diluted with CD OptiCHO TM medium so that the cell concentration was about 2 ⁇ 10 5 cells / mL, and 200 mL of the cell suspension was added to a 1 L triangular flask. Incubate at 37 ° C. in a moist environment consisting of 5% CO 2 and 95% air at a stirring rate of about 70 rpm for 6-7 days.
- the culture supernatant is collected by centrifugation and filtered through a 0.22 ⁇ m filter (Millipore) to collect the culture supernatant.
- To the culture supernatant add 20 mM Tris buffer (pH 8.0) containing 150 mL NaCl, which is 5 times the volume of the column, and add 20 mM Tris buffer (pH 8.0), which contains 150 mL NaCl, which is 3 times the volume of the column.
- Load the Protein A column (column volume: 1 mL, Bio-Rad) pre-equilibrated in 8.0).
- the column was washed by supplying the same buffer solution having a volume of 5 times the volume of the column, and then adsorbed fusion protein with a 50 mM glycine buffer solution (pH 2.8) having a volume 4 times the volume of the column containing 150 mM NaCl. Elute.
- the pH of the eluate containing this fusion protein is adjusted to pH 7.0 by adding 1 M Tris buffer (pH 8.0).
- the solution thus obtained is stored as a refined product of the fusion protein at 4 ° C or frozen.
- hNAGLU mutant that can be administered as enzyme replacement therapy for the treatment of patients with mucopolysaccharidosis type IIIB, and is more as a recombinant protein than wild-type hNAGLU. It is possible to provide hNAGLU mutants for efficient production.
- SEQ ID NO: 1 Nucleotide sequence of wild-type hNAGLU
- SEQ ID NO: 2 Nucleotide sequence of DNA fragment encoding wild-type hNAGLU
- synthetic sequence SEQ ID NO: 3: Amino acid sequence of hNAGLU variant No. 1
- SEQ ID NO: 4 hNAGLU variant No. 1.
- Synthetic sequence SEQ ID NO: 7 hNAGLU variant number 16 amino acid sequence
- SEQ ID NO: 8 Nucleotide sequence of DNA fragment encoding hNAGLU variant No. 16
- Synthetic sequence SEQ ID NO: 9 Amino acid sequence of hNAGLU variant No. 3
- SEQ ID NO: 10 DNA fragment encoding hNAGLU variant No. 3
- SEQ ID NO: 12 Nucleotide sequence of DNA fragment encoding hNAGLU variant No. 4
- Synthetic sequence SEQ ID NO: 13 Amino acid sequence of hNAGLU variant No.
- SEQ ID NO: 14 Nucleotide sequence of DNA fragment encoding hNAGLU variant No. 17
- Synthetic sequence SEQ ID NO: 15 Nucleotide sequence of hNAGLU variant No. 5
- SEQ ID NO: 16 Nucleotide sequence of DNA fragment encoding hNAGLU variant No. 5.
- Synthetic sequence SEQ ID NO: 17 Nucleotide sequence of hNAGLU variant No. 6
- SEQ ID NO: 18 Nucleotide sequence of DNA fragment encoding hNAGLU variant No. 6
- Nucleotide sequence SEQ ID NO: 19 Amino acid sequence of hNAGLU variant No. 7
- SEQ ID NO: 28 Nucleotide sequence of DNA fragment encoding hNAGLU variant No. 9, synthetic sequence SEQ ID NO: 29: hNAGLU mutation
- Nucleotide sequence of body number 10 SEQ ID NO: 30: Nucleotide sequence of DNA fragment encoding hNAGLU variant No. 10, Nucleotide sequence SEQ ID NO: 31: hNAGLU mutation Amino acid sequence of body number 11
- SEQ ID NO: 32 Nucleotide sequence of DNA fragment encoding hNAGLU variant number 11, synthetic sequence SEQ ID NO: 33: Amino acid sequence of hNAGLU variant number 12
- SEQ ID NO: 34 encodes hNAGLU variant number 12.
- Synthetic sequence SEQ ID NO: 41 Nucleotide sequence containing the gene encoding hNAGLU
- Synthetic sequence SEQ ID NO: 42 MluI addition 5'primer
- Synthetic sequence SEQ ID NO: 43 His tag-NotI addition 3'primer
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
1.下記の(1)~(7)からなる群から選択されるヒトα-N-アセチルグルコサミニダーゼ(hNAGLU)の変異体:
(1)配列番号1で示される野生型のhNAGLUのアミノ酸配列中36位のリシンがグルタミン酸に,かつ37位のプロリンがセリンに,それぞれ置換された配列番号3で示されるアミノ酸配列を有するもの;
(2)配列番号1で示される野生型のhNAGLUのアミノ酸配列中44位のロイシンと45位のグリシンの間にセリンが付加された配列番号5で示されるアミノ酸配列を有するもの;
(3)配列番号1で示される野生型のhNAGLUのアミノ酸配列中209位のグルタミンがアルギニンに置換された配列番号9で示されるアミノ酸配列を有するもの;
(4)配列番号1で示される野生型のhNAGLUのアミノ酸配列中228位のグルタミン酸がリシンに置換された配列番号11で示されるアミノ酸配列を有するもの;
(5)配列番号1で示される野生型のhNAGLUのアミノ酸配列中320位のトレオニンがプロリンに,かつ321位のグルタミン酸がアスパラギン酸に,それぞれ置換された配列番号15で示されるアミノ酸配列を有するもの;
(6)配列番号1で示される野生型のhNAGLUのアミノ酸配列中505位のセリンがアラニンに,かつ506位のイソロイシンがバリンに,それぞれ置換された配列番号17で示されるアミノ酸配列を有するもの;及び
(7)配列番号1で示される野生型のhNAGLUのアミノ酸配列中526位のセリンがアスパラギンに,かつ528位のアラニンがトレオニンに,それぞれ置換された配列番号19で示されるアミノ酸配列を有するもの。
2.配列番号3で示されるアミノ酸配列を有する上記1のhNAGLU変異体に,該アミノ酸配列の36位のグルタミン酸及び37位のセリンを保存しつつ,変異が加えられたhNAGLU変異体であって,以下の(1’-a)~(1’-h)からなる群から選択されるもの:
(1’-a)該アミノ酸配列を構成するアミノ酸残基を他のアミノ酸残基で置換されたものであり,置換されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(1’-b)該アミノ酸配列を構成するアミノ酸残基を欠失されたものであり,欠失されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(1’-c)上記1’-aの置換と1’-bの欠失を組み合わせたもの;
(1’-d)該アミノ酸配列中に又は該アミノ酸配列のN末端側若しくはC末端側に,1個又は複数個のアミノ酸残基が付加されたものであり,付加されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(1’-e)上記1’-aの置換と1’-dの付加を組み合わせたもの;
(1’-f)上記1’-bの欠失と1’-dの付加を組み合わせたもの;
(1’-g)上記1’-aの置換と,1’-bの欠失と及び1’-dの付加を組み合わせたもの;及び
(1’-h)該アミノ酸配列と80%以上,85%以上,90%以上,95%以上の同一性,98%以上,又は99%の同一性を示すもの。
3.配列番号5で示されるアミノ酸配列を有する上記1のhNAGLU変異体(1)に,該アミノ酸配列の45位のセリンを保存しつつ,変異が加えられたhNAGLU変異体であって,以下の(2’-a)~(2’-h)からなる群から選択されるもの:
(2’-a)該アミノ酸配列を構成するアミノ酸残基を他のアミノ酸残基で置換されたものであり,置換されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(2’-b)該アミノ酸配列を構成するアミノ酸残基を欠失されたものであり,欠失されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(2’-c)上記2’-aの置換と2’-bの欠失を組み合わせたもの;
(2’-d)該アミノ酸配列中に又は該アミノ酸配列のN末端側若しくはC末端側に,1個又は複数個のアミノ酸残基が付加されたものであり,付加されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(2’-e)上記2’-aの置換と2’-dの付加を組み合わせたもの;
(2’-f)上記2’-bの欠失と2’-dの付加を組み合わせたもの;
(2’-g)上記2’-aの置換と,2’-bの欠失と及び2’-dの付加を組み合わせたもの;及び
(2’-h)該アミノ酸配列と80%以上,85%以上,90%以上,95%以上の同一性,98%以上,又は99%の同一性を示すもの。
4.配列番号9で示されるアミノ酸配列を有する上記1のhNAGLU変異体に,該アミノ酸配列の209位のアルギニンを保存しつつ,変異が加えられたhNAGLU変異体であって,以下の(3’-a)~(3’-h)からなる群から選択されるもの:
(3’-a)該アミノ酸配列を構成するアミノ酸残基を他のアミノ酸残基で置換されたものであり,置換されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(3’-b)該アミノ酸配列を構成するアミノ酸残基を欠失されたものであり,欠失されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(3’-c)上記3’-aの置換と3’-bの欠失を組み合わせたもの;
(3’-d)該アミノ酸配列中に又は該アミノ酸配列のN末端側若しくはC末端側に,1個又は複数個のアミノ酸残基が付加されたものであり,付加されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(3’-e)上記3’-aの置換と3’-dの付加を組み合わせたもの;
(3’-f)上記3’-bの欠失と3’-dの付加を組み合わせたもの;
(3’-g)上記3’-aの置換と,3’-bの欠失と及び3’-dの付加を組み合わせたもの;及び
(3’-h)該アミノ酸配列と80%以上,85%以上,90%以上,95%以上の同一性,98%以上,又は99%の同一性を示すもの。
5.配列番号11で示されるアミノ酸配列を有する上記1のhNAGLU変異体に,該アミノ酸配列の228位のリジンを保存しつつ,変異が加えられたhNAGLU変異体であって,以下の(4’-a)~(4’-h)からなる群から選択されるもの:
(4’-a)該アミノ酸配列を構成するアミノ酸残基を他のアミノ酸残基で置換されたものであり,置換されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(4’-b)該アミノ酸配列を構成するアミノ酸残基を欠失されたものであり,欠失されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(4’-c)上記4’-aの置換と4’-bの欠失を組み合わせたもの;
(4’-d)該アミノ酸配列中に又は該アミノ酸配列のN末端側若しくはC末端側に,1個又は複数個のアミノ酸残基が付加されたものであり,付加されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(4’-e)上記4’-aの置換と4’-dの付加を組み合わせたもの;
(4’-f)上記4’-bの欠失と4’-dの付加を組み合わせたもの;
(4’-g)上記4’-aの置換と,4’-bの欠失と及び4’-dの付加を組み合わせたもの;及び
(4’-h)該アミノ酸配列と80%以上,85%以上,90%以上,95%以上の同一性,98%以上,又は99%の同一性を示すもの。
6.配列番号15で示されるアミノ酸配列を有する上記1のhNAGLU変異体に,該アミノ酸配列の320位のプロリン及び321位のアスパラギン酸を保存しつつ,変異が加えられたhNAGLU変異体であって,以下の(5’-a)~(5’-h)からなる群から選択されるもの:
(5’-a)該アミノ酸配列を構成するアミノ酸残基を他のアミノ酸残基で置換されたものであり,置換されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(5’-b)該アミノ酸配列を構成するアミノ酸残基を欠失されたものであり,欠失されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(5’-c)上記5’-aの置換と5’-bの欠失を組み合わせたもの;
(5’-d)該アミノ酸配列中に又は該アミノ酸配列のN末端側若しくはC末端側に,1個又は複数個のアミノ酸残基が付加されたものであり,付加されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(5’-e)上記5’-aの置換と5’-dの付加を組み合わせたもの;
(5’-f)上記5’-bの欠失と5’-dの付加を組み合わせたもの;
(5’-g)上記5’-aの置換と,5’-bの欠失と及び5’-dの付加を組み合わせたもの;及び
(5’-h)該アミノ酸配列と80%以上,85%以上,90%以上,95%以上の同一性,98%以上,又は99%の同一性を示すもの。
7.配列番号17で示されるアミノ酸配列を有する上記1のhNAGLU変異体に,該アミノ酸配列の505位のアラニン及び506位のバリンを保存しつつ,変異が加えられたhNAGLU変異体であって,以下の(6’-a)~(6’-h)からなる群から選択されるもの:
(6’-a)該アミノ酸配列を構成するアミノ酸残基を他のアミノ酸残基で置換されたものであり,置換されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(6’-b)該アミノ酸配列を構成するアミノ酸残基を欠失されたものであり,欠失されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(6’-c)上記6’-aの置換と6’-bの欠失を組み合わせたもの;
(6’-d)該アミノ酸配列中に又は該アミノ酸配列のN末端側若しくはC末端側に,1個又は複数個のアミノ酸残基が付加されたものであり,付加されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(6’-e)上記6’-aの置換と6’-dの付加を組み合わせたもの;
(6’-f)上記6’-bの欠失と6’-dの付加を組み合わせたもの;
(6’-g)上記6’-aの置換と,6’-bの欠失と及び6’-dの付加を組み合わせたもの;及び
(6’-h)該アミノ酸配列と80%以上,85%以上,90%以上,95%以上の同一性,98%以上,又は99%の同一性を示すもの。
8.配列番号19で示されるアミノ酸配列を有する上記1のhNAGLU変異体に,該アミノ酸配列の526位のアスパラギン及び528位のトレオニンを保存しつつ,変異が加えられたhNAGLU変異体であって,以下の(7’-a)~(7’-h)からなる群から選択されるもの:
(7’-a)該アミノ酸配列を構成するアミノ酸残基を他のアミノ酸残基で置換されたものであり,置換されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(7’-b)該アミノ酸配列を構成するアミノ酸残基を欠失されたものであり,欠失されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(7’-c)上記7’-aの置換と7’-bの欠失を組み合わせたもの;
(7’-d)該アミノ酸配列中に又は該アミノ酸配列のN末端側若しくはC末端側に,1個又は複数個のアミノ酸残基が付加されたものであり,付加されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(7’-e)上記7’-aの置換と7’-dの付加を組み合わせたもの;
(7’-f)上記7’-bの欠失と7’-dの付加を組み合わせたもの;
(7’-g)上記7’-aの置換と,7’-bの欠失と及び7’-dの付加を組み合わせたもの;及び
(7’-h)該アミノ酸配列と80%以上,85%以上,90%以上,95%以上の同一性,98%以上,又は99%の同一性を示すもの。
9.以下の(8)~(15)からなる群から選択されるものである上記4のhNAGLU変異体:
(8)配列番号9で示されるアミノ酸配列を有するhNAGLU変異体に,該アミノ酸配列の209位のアルギニンを保存しつつ,変異が加えられたhNAGLU変異体であって,36位のリシンがグルタミン酸に,37位のプロリンがセリンに,それぞれ置換された配列番号25で示されるアミノ酸配列を有するもの;
(9)配列番号9で示されるアミノ酸配列を有するhNAGLU変異体に,該アミノ酸配列の209位のアルギニンを保存しつつ,変異が加えられたhNAGLU変異体であって,44位のロイシンと45位のグリシンの間にセリンが付加された配列番号27で示されるアミノ酸配列を有するもの;
(10)配列番号9で示されるアミノ酸配列を有するhNAGLU変異体に,該アミノ酸配列の209位のアルギニンを保存しつつ,変異が加えられたhNAGLU変異体であって,320位のトレオニンがプロリンに,321位のグルタミン酸がアスパラギン酸に,それぞれ置換された配列番号29で示されるアミノ酸配列を有するもの;
(11)配列番号9で示されるアミノ酸配列を有するhNAGLU変異体に,該アミノ酸配列の209位のアルギニンを保存しつつ,変異が加えられたhNAGLU変異体であって,36位のリシンがグルタミン酸に,37位のプロリンがセリンに,それぞれ置換され,かつ,44位のロイシンと45位のグリシンの間にセリンが付加された配列番号31で示されるアミノ酸配列を有するもの;
(12)配列番号9で示されるアミノ酸配列を有するhNAGLU変異体に,該アミノ酸配列の209位のアルギニンを保存しつつ,変異が加えられたhNAGLU変異体であって,54位のバリンがイソロイシンに,620位のアルギニンがリシンに,それぞれ置換された配列番号33で示されるアミノ酸配列を有するもの;
(13)配列番号9で示されるアミノ酸配列を有するhNAGLU変異体に,該アミノ酸配列の209位のアルギニンを保存しつつ,変異が加えられたhNAGLU変異体であって,54位のバリンがイソロイシンに置換され,かつ,44位のロイシンと45位のグリシンの間にセリンが付加された配列番号35で示されるアミノ酸配列を有するもの;
(14)配列番号9で示されるアミノ酸配列を有するhNAGLU変異体に,該アミノ酸配列の209位のアルギニンを保存しつつ,変異が加えられたhNAGLU変異体であって,620位のアルギニンがリシンに置換され,かつ,44位のロイシンと45位のグリシンの間にセリンが付加された配列番号37で示されるアミノ酸配列を有するもの;及び
(15)配列番号9で示されるアミノ酸配列を有するhNAGLU変異体に,該アミノ酸配列の209位のアルギニンを保存しつつ,54位のバリンがイソロイシンに,620位のアルギニンがリシンに,それぞれ置換され,かつ,44位のロイシンと45位のグリシンの間にセリンが付加された配列番号39で示されるアミノ酸配列を有するもの。
10.配列番号25で示されるアミノ酸配列を有する上記9に記載のhNAGLU変異体に,該アミノ酸配列の209位のアルギニン,36位のグルタミン酸,及び37位のセリンを保存しつつ,変異が加えられたhNAGLU変異体であって,以下の(8’-a)~(8’-h)からなる群から選択されるもの:
(8’-a)該アミノ酸配列を構成するアミノ酸残基を他のアミノ酸残基で置換されたものであり,置換されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(8’-b)該アミノ酸配列を構成するアミノ酸残基を欠失されたものであり,欠失されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(8’-c)上記8’-aの置換と8’-bと欠失を組み合わせたもの;
(8’-d)該アミノ酸配列中に又は該アミノ酸配列のN末端側若しくはC末端側に,1個又は複数個のアミノ酸残基が付加されたものであり,付加されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(8’-e)上記8’-aの置換と8’-dの付加を組み合わせたもの;
(8’-f)上記8’-bの欠失と8’-dの付加を組み合わせたもの;
(8’-g)上記8’-aの置換と,8’-bの欠失と及び8’-dの付加を組み合わせたもの;
(8’-h)該アミノ酸配列と80%以上,85%以上,90%以上,95%以上の同一性,98%以上,又は99%の同一性を示すもの。
11.配列番号27で示されるアミノ酸配列を有する上記9に記載のhNAGLU変異体に,該アミノ酸配列の210位のアルギニン,及び45位のセリンを保存しつつ,変異が加えられたhNAGLU変異体であって,以下の(9’-a)~(9’-h)からなる群から選択されるもの:
(9’-a)該アミノ酸配列を構成するアミノ酸残基を他のアミノ酸残基で置換されたものであり,置換されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(9’-b)該アミノ酸配列を構成するアミノ酸残基を欠失されたものであり,欠失されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(9’-c)上記9’-aの置換と9’-bの欠失を組み合わせたもの;
(9’-d)該アミノ酸配列中に又は該アミノ酸配列のN末端側若しくはC末端側に,1個又は複数個のアミノ酸残基が付加されたものであり,付加されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(9’-e)上記9’-aの置換と9’-dの付加を組み合わせたもの;
(9’-f)上記9’-bの欠失と9’-dの付加を組み合わせたもの;
(9’-g)上記9’-aの置換と,9’-bの欠失と及び9’-dの付加を組み合わせたもの;
(9’-h)該アミノ酸配列と80%以上,85%以上,90%以上,95%以上の同一性,98%以上,又は99%の同一性を示すもの。
12.配列番号29で示されるアミノ酸配列を有する上記9に記載のhNAGLU変異体に,該アミノ酸配列の209位のアルギニン,320位のプロリン,及び321位のアスパラギン酸を保存しつつ,変異が加えられたhNAGLU変異体であって,以下の(10’-a)~(10’-h)からなる群から選択されるもの:
(10’-a)該アミノ酸配列を構成するアミノ酸残基を他のアミノ酸残基で置換されたものであり,置換されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(10’-b)該アミノ酸配列を構成するアミノ酸残基を欠失されたものであり,欠失されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(10’-c)上記10’-aの置換と10’-bの欠失を組み合わせたもの;
(10’-d)該アミノ酸配列中に又は該アミノ酸配列のN末端側若しくはC末端側に,1個又は複数個のアミノ酸残基が付加されたものであり,付加されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(10’-e)上記10’-aの置換と10’-dの付加を組み合わせたもの;
(10’-f)上記10’-bの欠失と10’-dの付加を組み合わせたもの;
(10’-g)上記10’-aの置換と,10’-bの欠失と及び10’-dの付加を組み合わせたもの;
(10’-h)該アミノ酸配列と80%以上,85%以上,90%以上,95%以上の同一性,98%以上,又は99%の同一性を示すもの。
13.配列番号31で示されるアミノ酸配列を有する上記9に記載のhNAGLU変異体に,該アミノ酸配列の210位のアルギニン,36位のグルタミン酸,37位のセリン,及び45位のセリンを保存しつつ,変異が加えられたhNAGLU変異体であって,以下の(11’-a)~(11’-h)からなる群から選択されるもの:
(11’-a)該アミノ酸配列を構成するアミノ酸残基を他のアミノ酸残基で置換されたものであり,置換されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(11’-b)該アミノ酸配列を構成するアミノ酸残基を欠失されたものであり,欠失されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(11’-c)上記11’-aの置換と11’-bの欠失を組み合わせたもの;
(11’-d)該アミノ酸配列中に又は該アミノ酸配列のN末端側若しくはC末端側に,1個又は複数個のアミノ酸残基が付加されたものであり,付加されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(11’-e)上記11’-aの置換と11’-dの付加を組み合わせたもの;
(11’-f)上記11’-bの欠失と11’-dの付加を組み合わせたもの;
(11’-g)上記11’-aの置換と,11’-bの欠失と及び11’-dの付加を組み合わせたもの;
(11’-h)該アミノ酸配列と80%以上,85%以上,90%以上,95%以上の同一性,98%以上,又は99%の同一性を示すもの。
14.配列番号33で示されるアミノ酸配列を有する上記9に記載のhNAGLU変異体に,該アミノ酸配列の209位のアルギニン,54位のイソロイシン,及び620位のリシンを保存しつつ,変異が加えられたhNAGLU変異体であって,以下の(12’-a)~(12’-h)からなる群から選択されるもの:
(12’-a)該アミノ酸配列を構成するアミノ酸残基を他のアミノ酸残基で置換されたものであり,置換されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(12’-b)該アミノ酸配列を構成するアミノ酸残基を欠失されたものであり,欠失されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(12’-c)上記12’-aの置換と12’-bの欠失を組み合わせたもの;
(12’-d)該アミノ酸配列中に又は該アミノ酸配列のN末端側若しくはC末端側に,1個又は複数個のアミノ酸残基が付加されたものであり,付加されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(12’-e)上記12’-aの置換と12’-dの付加を組み合わせたもの;
(12’-f)上記12’-bの欠失と12’-dの付加を組み合わせたもの;
(12’-g)上記12’-aの置換と,12’-bの欠失と及び12’-dの付加を組み合わせたもの;
(12’-h)該アミノ酸配列と80%以上,85%以上,90%以上,95%以上の同一性,98%以上,又は99%の同一性を示すもの。
15.配列番号35で示されるアミノ酸配列を有する上記9に記載のhNAGLU変異体に,該アミノ酸配列の210位のアルギニン,55位のイソロイシン,及び45位のセリンを保存しつつ,変異が加えられたhNAGLU変異体であって,以下の(13’-a)~(13’-h)からなる群から選択されるもの:
(13’-a)該アミノ酸配列を構成するアミノ酸残基を他のアミノ酸残基で置換されたものであり,置換されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(13’-b)該アミノ酸配列を構成するアミノ酸残基を欠失されたものであり,欠失されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(13’-c)上記13’-aの置換と13’-bの欠失を組み合わせたもの;
(13’-d)該アミノ酸配列中に又は該アミノ酸配列のN末端側若しくはC末端側に,1個又は複数個のアミノ酸残基が付加されたものであり,付加されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(13’-e)上記13’-aの置換と13’-dの付加を組み合わせたもの;
(13’-f)上記13’-bの欠失と13’-dの付加を組み合わせたもの;
(13’-g)上記13’-aの置換と,13’-bの欠失と及び13’-dの付加を組み合わせたもの;
(13’-h)該アミノ酸配列と80%以上,85%以上,90%以上,95%以上の同一性,98%以上,又は99%の同一性を示すもの。
16.配列番号37で示されるアミノ酸配列を有する上記9に記載のhNAGLU変異体に,該アミノ酸配列の210位のアルギニン,621位のリシン,及び45位のセリンを保存しつつ,変異が加えられたhNAGLU変異体であって,以下の(14’-a)~(14’-h)からなる群から選択されるもの:
(14’-a)該アミノ酸配列を構成するアミノ酸残基を他のアミノ酸残基で置換されたものであり,置換されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(14’-b)該アミノ酸配列を構成するアミノ酸残基を欠失されたものであり,欠失されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(14’-c)上記14’-aの置換と14’-bの欠失を組み合わせたもの;
(14’-d)該アミノ酸配列中に又は該アミノ酸配列のN末端側若しくはC末端側に,1個又は複数個のアミノ酸残基が付加されたものであり,付加されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(14’-e)上記14’-aの置換と14’-dの付加を組み合わせたもの;
(14’-f)上記14’-bの欠失と14’-dの付加を組み合わせたもの;
(14’-g)上記14’-aの置換と,14’-bの欠失と及び14’-dの付加を組み合わせたもの;
(14’-h)該アミノ酸配列と80%以上,85%以上,90%以上,95%以上の同一性,98%以上,又は99%の同一性を示すもの。
17.配列番号39で示されるアミノ酸配列を有する上記9に記載のhNAGLU変異体に,該アミノ酸配列の210位のアルギニン,55位のイソロイシン,621位のリシン,及び45位のセリンを保存しつつ,変異が加えられたhNAGLU変異体であって,以下の(15’-a)~(15’-h)からなる群から選択されるもの:
(15’-a)該アミノ酸配列を構成するアミノ酸残基を他のアミノ酸残基で置換されたものであり,置換されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(15’-b)該アミノ酸配列を構成するアミノ酸残基を欠失されたものであり,欠失されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(15’-c)上記15’-aの置換と15’-bの欠失を組み合わせたもの;
(15’-d)該アミノ酸配列中に又は該アミノ酸配列のN末端側若しくはC末端側に,1個又は複数個のアミノ酸残基が付加されたものであり,付加されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(15’-e)上記15’-aの置換と15’-dの付加を組み合わせたもの;
(15’-f)上記15’-bの欠失と15’-dの付加を組み合わせたもの;
(15’-g)上記15’-aの置換と,15’-bの欠失と及び15’-dの付加を組み合わせたもの;
(15’-h)該アミノ酸配列と80%以上,85%以上,90%以上,95%以上の同一性,98%以上,又は99%の同一性を示すもの。
18.上記1~17の何れかのhNAGLU変異体をコードする遺伝子を含んでなるDNA。
19.上記18のDNAを含んでなる発現ベクター。
20.上記19の発現ベクターで形質転換された哺乳動物細胞。
21.上記20の哺乳動物細胞を無血清培地で培養するステップを含む,hNAGLU変異体の製造方法。
22.上記1~17の何れかに記載のhNAGLU変異体と,抗体との融合蛋白質であって,該抗体が脳血管内皮細胞上の受容体と結合することにより,該融合蛋白質が血液脳関門(BBB)を通過することのできるものである,融合蛋白質。
23.該脳血管内皮細胞上の受容体が,インスリン受容体,トランスフェリン受容体,レプチン受容体,リポタンパク質受容体,及びIGF受容体からなる群から選択されるものである,上記22に記載の融合蛋白質。
24.該脳血管内皮細胞上の受容体が,トランスフェリン受容体である,上記22に記載の融合蛋白質。
25.該抗体が,Fab抗体,F(ab’)2抗体,F(ab’)抗体,単一ドメイン抗体,一本鎖抗体,又はFc抗体の何れかである,上記22~24の何れかに記載の融合蛋白質。
26.該hNAGLU変異体が,該抗体の軽鎖のC末端側若しくはN末端側の何れかに結合しているものである,上記22~25の何れか一項に記載の融合蛋白質。
27.該hNAGLU変異体が,該抗体の重鎖のC末端側若しくはN末端側の何れかに結合しているものである,上記22~25の何れか一項に記載の融合蛋白質。
28.該hNAGLU変異体が,該抗体の軽鎖のC末端側若しくはN末端側の何れか,又は重鎖のC末端側若しくはN末端側の何れかに,リンカー配列を介して結合しているものである,上記22~27の何れか一項に記載の融合蛋白質。
29.該リンカー配列が,1~50個のアミノ酸残基からなるものである,上記28に記載の融合蛋白質。
30.該リンカー配列が,1個のグリシン,1個のセリン,アミノ酸配列Gly-Ser,アミノ酸配列Ser-Ser,アミノ酸配列Gly-Gly-Ser,配列番号3のアミノ酸配列,配列番号4のアミノ酸配列,配列番号5のアミノ酸配列,及びこれらのアミノ酸配列が1~10個連続してなるアミノ酸配列からなる群より選ばれるアミノ酸配列を含んでなるものである,上記29に記載の融合蛋白質。
31.上記22~30の何れかに記載の融合蛋白質をコードする遺伝子を含んでなるDNA。
32.上記31に記載のDNAを含んでなる発現ベクター。
33.上記32に記載の発現ベクターで形質転換された哺乳動物細胞。
34.上記33に記載の哺乳動物細胞を無血清培地で培養するステップを含む,hNAGLU変異体と抗体との融合蛋白質の製造方法。
(i)配列番号1で示されるアミノ酸配列に対し,0~10個のアミノ酸残基の欠失と,0~10個のアミノ酸残基の他のアミノ酸残基への置換と,更に0~10個のアミノ酸残基の付加とを行ってなるアミノ酸配列を有するもの;
(ii)配列番号1で示されるアミノ酸配列に対し,0~5個のアミノ酸残基の欠失と,0~5個のアミノ酸残基の他のアミノ酸残基への置換と,更に0~5個のアミノ酸残基の付加とを行ってなるアミノ酸配列を有するもの;
(iii)配列番号1で示されるアミノ酸配列に対し,0~3個のアミノ酸残基の欠失と,0~3個のアミノ酸残基の他のアミノ酸残基への置換と,更に0~3個のアミノ酸残基の付加とを行ってなるアミノ酸配列を有するもの;
(iv)配列番号1で示されるアミノ酸配列に対し,0~2個のアミノ酸残基の欠失と,0~2個のアミノ酸残基の他のアミノ酸残基への置換と,更に0~2個のアミノ酸残基の付加とを行ってなるアミノ酸配列を有するもの。
(i)配列番号1で示されるアミノ酸配列に対し,0~10個のアミノ酸残基の欠失と,0~10個のアミノ酸残基の他のアミノ酸残基への置換と,更に0~10個のアミノ酸残基の付加とを行ってなるアミノ酸配列を有するもの(但し野生型のhNAGLUは除く);
(ii)配列番号1で示されるアミノ酸配列に対し,0~5個のアミノ酸残基の欠失と,0~5個のアミノ酸残基の他のアミノ酸残基への置換と,更に0~5個のアミノ酸残基の付加とを行ってなるアミノ酸配列を有するもの(但し野生型のhNAGLUは除く);
(iii)配列番号1で示されるアミノ酸配列に対し,0~3個のアミノ酸残基の欠失と,0~3個のアミノ酸残基の他のアミノ酸残基への置換と,更に0~3個のアミノ酸残基の付加とを行ってなるアミノ酸配列を有するもの(但し野生型のhNAGLUは除く);
(iv)配列番号1で示されるアミノ酸配列に対し,0~2個のアミノ酸残基の欠失と,0~2個のアミノ酸残基の他のアミノ酸残基への置換と,更に0~2個のアミノ酸残基の付加とを行ってなるアミノ酸配列を有するもの(但し野生型のhNAGLUは除く)。
,例えば,アミノ酸のそれらの側鎖および化学的性質で関連性のあるアミノ酸ファミリー内で起こるものである。このようなアミノ酸ファミリー内での置換は,元の蛋白質の機能に大きな変化をもたらさない(即ち,保存的アミノ酸置換である)ことが予測される。かかるアミノ酸ファミリーとしては,例えば以下の(1)~(12)で示されるものがある:
(1)酸性アミノ酸であるアスパラギン酸とグルタミン酸,
(2)塩基性アミノ酸であるヒスチジン,リシン,及びアルギニン
(3)芳香族アミン酸であるフェニルアラニン,チロシン,及びトリプトファン,
(4)水酸基を有するアミノ酸(ヒドロキシアミノ酸)であるセリンとトレオニン,
(5)疎水性アミノ酸であるメチオニン,アラニン,バリン,ロイシン,及びイソロイシン,
(6)中性の親水性アミノ酸であるシステイン,セリン,トレオニン,アスパラギン,及びグルタミン,
(7)ペプチド鎖の配向に影響するアミノ酸であるグリシンとプロリン,
(8)アミド型アミノ酸(極性アミノ酸)であるアスパラギンとグルタミン,
(9)脂肪族アミノ酸である,アラニン,ロイシン,イソロイシン,及びバリン,
(10)側鎖の小さいアミノ酸であるアラニン,グリシン,セリン,及びトレオニン,
(11)側鎖の特に小さいアミノ酸であるアラニンとグリシン,
(12)分岐鎖を有するアミノ酸であるバリン,ロイシン,及びイソロイシン。
(1)配列番号1で示される野生型のhNAGLUのアミノ酸配列中36位のリシンがグルタミン酸に,かつ37位のプロリンがセリンに,それぞれ置換された配列番号3で示されるアミノ酸配列を有するもの,
(2)配列番号1で示される野生型のhNAGLUのアミノ酸配列中44位のロイシンと45位のグリシンの間にセリンが付加された配列番号5で示されるアミノ酸配列を有するもの,
(3)配列番号1で示される野生型のhNAGLUのアミノ酸配列中209位のグルタミンがアルギニンに置換された配列番号9で示されるアミノ酸配列を有するもの,
(4)配列番号1で示される野生型のhNAGLUのアミノ酸配列中228位のグルタミン酸がリシンに置換された配列番号11で示されるアミノ酸配列を有するもの,
(5)配列番号1で示される野生型のhNAGLUのアミノ酸配列中320位のトレオニンがプロリンに,かつ321位のグルタミン酸がアスパラギン酸に,それぞれ置換された配列番号15で示されるアミノ酸配列を有するもの,
(6)配列番号1で示される野生型のhNAGLUのアミノ酸配列中505位のセリンがアラニンに,かつ506位のイソロイシンがバリンに,それぞれ置換された配列番号17で示されるアミノ酸配列を有するもの,
(7)配列番号1で示される野生型のhNAGLUのアミノ酸配列中526位のセリンがアスパラギンに,かつ528位のアラニンがトレオニンに,それぞれ置換された配列番号19で示されるアミノ酸配列を有するもの。
(1’)配列番号3で示されるアミノ酸配列の36位のグルタミン酸及び37位のセリンに変異を加えることなく:
(1’-a)該アミノ酸配列を構成するアミノ酸残基を他のアミノ酸残基で置換させたものであり,置換されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(1’-b)該アミノ酸配列を構成するアミノ酸残基を欠失させたものであり,欠失させたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(1’-c)上記1’-aの置換と1’-bの欠失を組み合わせたもの;
(1’-d)該アミノ酸配列中に又は該アミノ酸配列のN末端側若しくはC末端側に,1個又は複数個のアミノ酸残基が付加されたものであり,付加されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(1’-e)上記1’-aの置換と1’-dの付加を組み合わせたもの;
(1’-f)上記1’-bの欠失と1’-dの付加を組み合わせたもの;
(1’-g)上記1’-aの置換と,1’-bの欠失と及び1’-dの付加を組み合わせたもの;
(1’-h)該アミノ酸配列と80%以上,85%以上,90%以上,95%以上の同一性,98%以上,又は99%の同一性を示すもの。
(2’-a)該アミノ酸配列を構成するアミノ酸残基を他のアミノ酸残基で置換させたものであり,置換されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(2’-b)該アミノ酸配列を構成するアミノ酸残基を欠失させたものであり,欠失させたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(2’-c)上記2’-aの置換と2’-bの欠失を組み合わせたもの;
(2’-d)該アミノ酸配列中に又は該アミノ酸配列のN末端側若しくはC末端側に,1個又は複数個のアミノ酸残基が付加されたものであり,付加されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(2’-e)上記2’-aの置換と2’-dの付加を組み合わせたもの;
(2’-f)上記2’-bの欠失と2’-dの付加を組み合わせたもの;
(2’-g)上記2’-aの置換と,2’-bの欠失と及び2’-dの付加を組み合わせたもの;
(2’-h)該アミノ酸配列と80%以上,85%以上,90%以上,95%以上の同一性,98%以上,又は99%の同一性を示すもの。
(3’-a)該アミノ酸配列を構成するアミノ酸残基を他のアミノ酸残基で置換させたものであり,置換されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(3’-b)該アミノ酸配列を構成するアミノ酸残基を欠失させたものであり,欠失させたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(3’-c)上記3’-aの置換と3’-bの欠失を組み合わせたもの;
(3’-d)該アミノ酸配列中に又は該アミノ酸配列のN末端側若しくはC末端側に,1個又は複数個のアミノ酸残基が付加されたものであり,付加されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(3’-e)上記3’-aの置換と3’-dの付加を組み合わせたもの;
(3’-f)上記3’-bの欠失と3’-dの付加を組み合わせたもの;
(3’-g)上記3’-aの置換と,3’-bの欠失と及び3’-dの付加を組み合わせたもの;
(3’-h)該アミノ酸配列と80%以上,85%以上,90%以上,95%以上の同一性,98%以上,又は99%の同一性を示すもの。
(4’-a)該アミノ酸配列を構成するアミノ酸残基を他のアミノ酸残基で置換させたものであり,置換されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(4’-b)該アミノ酸配列を構成するアミノ酸残基を欠失させたものであり,欠失させたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(4’-c)上記4’-aの置換と4’-bの欠失を組み合わせたもの;
(4’-d)該アミノ酸配列中に又は該アミノ酸配列のN末端側若しくはC末端側に,1個又は複数個のアミノ酸残基が付加されたものであり,付加されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(4’-e)上記4’-aの置換と4’-dの付加を組み合わせたもの;
(4’-f)上記4’-bの欠失と4’-dの付加を組み合わせたもの;
(4’-g)上記4’-aの置換と,4’-bの欠失と及び4’-dの付加を組み合わせたもの;
(4’-h)該アミノ酸配列と80%以上,85%以上,90%以上,95%以上の同一性,98%以上,又は99%の同一性を示すもの。
(5’-a)該アミノ酸配列を構成するアミノ酸残基を他のアミノ酸残基で置換させたものであり,置換されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(5’-b)該アミノ酸配列を構成するアミノ酸残基を欠失させたものであり,欠失させたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(5’-c)上記5’-aの置換と5’-bの欠失を組み合わせたもの;
(5’-d)該アミノ酸配列中に又は該アミノ酸配列のN末端側若しくはC末端側に,1個又は複数個のアミノ酸残基が付加されたものであり,付加されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(5’-e)上記5’-aの置換と5’-dの付加を組み合わせたもの;
(5’-f)上記5’-bの欠失と5’-dの付加を組み合わせたもの;
(5’-g)上記5’-aの置換と,5’-bの欠失と及び5’-dの付加を組み合わせたもの;。
(5’-h)該アミノ酸配列と80%以上,85%以上,90%以上,95%以上の同一性,98%以上,又は99%の同一性を示すもの。
(6’-a)該アミノ酸配列を構成するアミノ酸残基を他のアミノ酸残基で置換させたものであり,置換されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(6’-b)該アミノ酸配列を構成するアミノ酸残基を欠失させたものであり,欠失させたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(6’-c)上記6’-aの置換と6’-bの欠失を組み合わせたもの;
(6’-d)該アミノ酸配列中に又は該アミノ酸配列のN末端側若しくはC末端側に,1個又は複数個のアミノ酸残基が付加されたものであり,付加されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(6’-e)上記6’-aの置換と6’-dの付加を組み合わせたもの;
(6’-f)上記6’-bの欠失と6’-dの付加を組み合わせたもの;
(6’-g)上記6’-aの置換と,6’-bの欠失と及び6’-dの付加を組み合わせたもの;
(6’-h)該アミノ酸配列と80%以上,85%以上,90%以上,95%以上の同一性,98%以上,又は99%の同一性を示すもの。
(7’-a)該アミノ酸配列を構成するアミノ酸残基を他のアミノ酸残基で置換させたものであり,置換されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(7’-b)該アミノ酸配列を構成するアミノ酸残基を欠失させたものであり,欠失させたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(7’-c)上記7’-aの置換と7’-bの欠失を組み合わせたもの;
(7’-d)該アミノ酸配列中に又は該アミノ酸配列のN末端側若しくはC末端側に,1個又は複数個のアミノ酸残基が付加されたものであり,付加されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(7’-e)上記7’-aの置換と7’-dの付加を組み合わせたもの;
(7’-f)上記7’-bの欠失と7’-dの付加を組み合わせたもの;
(7’-g)上記7’-aの置換と,7’-bの欠失と及び7’-dの付加を組み合わせたもの;
(7’-h)該アミノ酸配列と80%以上,85%以上,90%以上,95%以上の同一性,98%以上,又は99%の同一性を示すもの。
(8)配列番号1で示される野生型のhNAGLUのアミノ酸配列中209位のグルタミンがアルギニンに,36位のリシンがグルタミン酸に,37位のプロリンがセリンに,それぞれ置換された配列番号25で示されるアミノ酸配列を有するもの,
(9)配列番号1で示される野生型のhNAGLUのアミノ酸配列中209位のグルタミンがアルギニンに置換され,かつ,44位のロイシンと45位のグリシンの間にセリンが付加された配列番号27で示されるアミノ酸配列を有するもの,
(10)配列番号1で示される野生型のhNAGLUのアミノ酸配列中209位のグルタミンがアルギニンに,320位のトレオニンがプロリンに,321位のグルタミン酸がアスパラギン酸に,それぞれ置換された配列番号29で示されるアミノ酸配列を有するもの,
(11)配列番号1で示される野生型のhNAGLUのアミノ酸配列中209位のグルタミンがアルギニンに,36位のリシンがグルタミン酸に,37位のプロリンがセリンに,それぞれ置換され,かつ,44位のロイシンと45位のグリシンの間にセリンが付加された配列番号31で示されるアミノ酸配列を有するもの,
(12)配列番号1で示される野生型のhNAGLUのアミノ酸配列中209位のグルタミンがアルギニンに,54位のバリンがイソロイシンに,620位のアルギニンがリシンに,それぞれ置換された配列番号33で示されるアミノ酸配列を有するもの,
(13)配列番号1で示される野生型のhNAGLUのアミノ酸配列中209位のグルタミンがアルギニンに,54位のバリンがイソロイシンに,それぞれ置換され,かつ,44位のロイシンと45位のグリシンの間にセリンが付加された配列番号35で示されるアミノ酸配列を有するもの,
(14)配列番号1で示される野生型のhNAGLUのアミノ酸配列中209位のグルタミンがアルギニンに,620位のアルギニンがリシンに,それぞれ置換され,かつ,44位のロイシンと45位のグリシンの間にセリンが付加された配列番号37で示されるアミノ酸配列を有するもの,
(15)配列番号1で示される野生型のhNAGLUのアミノ酸配列中209位のグルタミンがアルギニンに,54位のバリンがイソロイシンに,620位のアルギニンがリシンに,それぞれ置換され,かつ,44位のロイシンと45位のグリシンの間にセリンが付加された配列番号39で示されるアミノ酸配列を有するもの。
(8’-a)該アミノ酸配列を構成するアミノ酸残基を他のアミノ酸残基で置換させたものであり,置換されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(8’-b)該アミノ酸配列を構成するアミノ酸残基を欠失させたものであり,欠失させたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(8’-c)上記8’-aの置換と8’-bの欠失を組み合わせたもの;
(8’-d)該アミノ酸配列中に又は該アミノ酸配列のN末端側若しくはC末端側に,1個又は複数個のアミノ酸残基が付加されたものであり,付加されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(8’-e)上記8’-aの置換と8’-dの付加を組み合わせたもの;
(8’-f)上記8’-bの欠失と8’-dの付加を組み合わせたもの;
(8’-g)上記8’-aの置換と,8’-bの欠失と及び8’-dの付加を組み合わせたもの;
(8’-h)該アミノ酸配列と80%以上,85%以上,90%以上,95%以上の同一性,98%以上,又は99%の同一性を示すもの。
(9’-a)該アミノ酸配列を構成するアミノ酸残基を他のアミノ酸残基で置換させたものであり,置換されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(9’-b)該アミノ酸配列を構成するアミノ酸残基を欠失させたものであり,欠失させたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(9’-c)上記9’-aの置換と9’-bの欠失を組み合わせたもの;
(9’-d)該アミノ酸配列中に又は該アミノ酸配列のN末端側若しくはC末端側に,1個又は複数個のアミノ酸残基が付加されたものであり,付加されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(9’-e)上記9’-aの置換と9’-dの付加を組み合わせたもの;
(9’-f)上記9’-bの欠失と9’-dの付加を組み合わせたもの;
(9’-g)上記9’-aの置換と,9’-bの欠失と及び9’-dの付加を組み合わせたもの;
(9’-h)該アミノ酸配列と80%以上,85%以上,90%以上,95%以上の同一性,98%以上,又は99%の同一性を示すもの。
(10’-a)該アミノ酸配列を構成するアミノ酸残基を他のアミノ酸残基で置換させたものであり,置換されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(10’-b)該アミノ酸配列を構成するアミノ酸残基を欠失させたものであり,欠失させたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(10’-c)上記10’-aの置換と10’-bの欠失を組み合わせたもの;
(10’-d)該アミノ酸配列中に又は該アミノ酸配列のN末端側若しくはC末端側に,1個又は複数個のアミノ酸残基が付加されたものであり,付加されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(10’-e)上記10’-aの置換と10’-dの付加を組み合わせたもの;
(10’-f)上記10’-bの欠失と10’-dの付加を組み合わせたもの;
(10’-g)上記10’-aの置換と,10’-bの欠失と及び10’-dの付加を組み合わせたもの;
(10’-h)該アミノ酸配列と80%以上,85%以上,90%以上,95%以上の同一性,98%以上,又は99%の同一性を示すもの。
(11’-a)該アミノ酸配列を構成するアミノ酸残基を他のアミノ酸残基で置換させたものであり,置換されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(11’-b)該アミノ酸配列を構成するアミノ酸残基を欠失させたものであり,欠失させたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(11’-c)上記11’-aの置換と11’-bの欠失を組み合わせたもの;
(11’-d)該アミノ酸配列中に又は該アミノ酸配列のN末端側若しくはC末端側に,1個又は複数個のアミノ酸残基が付加されたものであり,付加されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(11’-e)上記11’-aの置換と11’-dの付加を組み合わせたもの;
(11’-f)上記11’-bの欠失と11’-dの付加を組み合わせたもの;
(11’-g)上記11’-aの置換と,11’-bの欠失と及び11’-dの付加を組み合わせたもの;
(11’-h)該アミノ酸配列と80%以上,85%以上,90%以上,95%以上の同一性,98%以上,又は99%の同一性を示すもの。
(12’-a)該アミノ酸配列を構成するアミノ酸残基を他のアミノ酸残基で置換させたものであり,置換されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(12’-b)該アミノ酸配列を構成するアミノ酸残基を欠失させたものであり,欠失させたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(12’-c)上記12’-aの置換と12’-bの欠失を組み合わせたもの;
(12’-d)該アミノ酸配列中に又は該アミノ酸配列のN末端側若しくはC末端側に,1個又は複数個のアミノ酸残基が付加されたものであり,付加されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(12’-e)上記12’-aの置換と12’-dの付加を組み合わせたもの;
(12’-f)上記12’-bの欠失と12’-dの付加を組み合わせたもの;
(12’-g)上記12’-aの置換と,12’-bの欠失と及び12’-dの付加を組み合わせたもの;
(12’-h)該アミノ酸配列と80%以上,85%以上,90%以上,95%以上の同一性,98%以上,又は99%の同一性を示すもの。
(13’-a)該アミノ酸配列を構成するアミノ酸残基を他のアミノ酸残基で置換させたものであり,置換されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(13’-b)該アミノ酸配列を構成するアミノ酸残基を欠失させたものであり,欠失させたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(13’-c)上記13’-aの置換と13’-bの欠失を組み合わせたもの;
(13’-d)該アミノ酸配列中に又は該アミノ酸配列のN末端側若しくはC末端側に,1個又は複数個のアミノ酸残基が付加されたものであり,付加されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(13’-e)上記13’-aの置換と13’-dの付加を組み合わせたもの;
(13’-f)上記13’-bの欠失と13’-dの付加を組み合わせたもの;
(13’-g)上記13’-aの置換と,13’-bの欠失と及び13’-dの付加を組み合わせたもの;
(13’-h)該アミノ酸配列と80%以上,85%以上,90%以上,95%以上の同一性,98%以上,又は99%の同一性を示すもの。
(14’-a)該アミノ酸配列を構成するアミノ酸残基を他のアミノ酸残基で置換させたものであり,置換されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(14’-b)該アミノ酸配列を構成するアミノ酸残基を欠失させたものであり,欠失させたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(14’-c)上記14’-aの置換と14’-bの欠失を組み合わせたもの;
(14’-d)該アミノ酸配列中に又は該アミノ酸配列のN末端側若しくはC末端側に,1個又は複数個のアミノ酸残基が付加されたものであり,付加されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(14’-e)上記14’-aの置換と14’-dの付加を組み合わせたもの;
(14’-f)上記14’-bの欠失と14’-dの付加を組み合わせたもの;
(14’-g)上記14’-aの置換と,14’-bの欠失と及び14’-dの付加を組み合わせたもの;
(14’-h)該アミノ酸配列と80%以上,85%以上,90%以上,95%以上の同一性,98%以上,又は99%の同一性を示すもの。
(15’-a)該アミノ酸配列を構成するアミノ酸残基を他のアミノ酸残基で置換させたものであり,置換されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(15’-b)該アミノ酸配列を構成するアミノ酸残基を欠失させたものであり,欠失させたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(15’-c)上記15’-aの置換と15’-bの欠失を組み合わせたもの;
(15’-d)該アミノ酸配列中に又は該アミノ酸配列のN末端側若しくはC末端側に,1個又は複数個のアミノ酸残基が付加されたものであり,付加されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(15’-e)上記15’-aの置換と15’-dの付加を組み合わせたもの;
(15’-f)上記15’-bの欠失と15’-dの付加を組み合わせたもの;
(15’-g)上記15’-aの置換と,15’-bの欠失と及び15’-dの付加を組み合わせたもの;
(15’-h)該アミノ酸配列と80%以上,85%以上,90%以上,95%以上の同一性,98%以上,又は99%の同一性を示すもの。
(1)1本の軽鎖と1本の重鎖の計2本のポリペプチド鎖からなるもの,
(2)本来の意味での抗体の基本構造からFc領域が欠失したものであるFab領域からなるもの及びFab領域とヒンジ部の全部若しくは一部とからなるもの(Fab,F(ab’)及びF(ab’)2を含む),
(3)軽鎖のC末端側にリンカー配列を,そして更にそのC末端側に重鎖を結合させてなるものである一本鎖抗体,
(4)重鎖のC末端側にリンカー配列を,そして更にそのC末端側に軽鎖を結合させてなるものである一本鎖抗体,
(5)本来の意味での抗体の基本構造からFab領域が欠失したものであるFc領域からなるものであって,且つ当該Fc領域のアミノ酸配列が特定の抗原に特異的に結合する性質を有するように改変されたもの(Fc抗体),
(6)後述する単一ドメイン抗体も,本発明における「抗体」に含まれる。
(7)上記(2)で示したFab,F(ab’)又はF(ab’)2を構成する軽鎖と重鎖を,リンカー配列を介して結合させて,それぞれ一本鎖抗体としたscFab,scF(ab’),及びscF(ab’)2も含まれる。ここで,scFab,scF(ab’),及びscF(ab’)2にあっては,軽鎖のC末端側にリンカー配列を,そして更にそのC末端側に重鎖を結合させてなるものでもよく,また,重鎖のC末端側にリンカー配列を,そして更にそのC末端側に軽鎖を結合させてなるものでもよい。更には,軽鎖の可変領域と重鎖の可変領域をリンカー配列を介して結合させて一本鎖抗体としたscFvも,本発明における抗体に含まれる。scFvにあっては,軽鎖の可変領域のC末端側にリンカー配列を,そして更にそのC末端側に重鎖の可変領域を結合させてなるものでもよく,また,重鎖の可変領域のC末端側にリンカー配列を,そして更にそのC末端側に軽鎖の可変領域を結合させてなるものでもよい。
(1)抗体の重鎖のC末端に直接又はリンカーを介してhNAGLU変異体が結合した結合体と,抗体の軽鎖とを含むもの;
(2)抗体の重鎖のN末端に直接又はリンカーを介してhNAGLU変異体が結合した結合体と,抗体の軽鎖とを含むもの;
(3)抗体の軽鎖のC末端に直接又はリンカーを介してhNAGLU変異体が結合した結合体と,抗体の重鎖とを含むもの;
(4)抗体の軽い鎖のN末端に直接又はリンカーを介してhNAGLU変異体が結合した結合体と,抗体の重鎖とを含むもの。
(1)抗hTfR抗体であって,該抗体の軽鎖が,配列番号61のアミノ酸配列を含んでなり,重鎖が,配列番号62のアミノ酸配列を含んでなる抗体,及び
(2)抗hTfR抗体であって,かつFab抗体であって,該抗体の軽鎖が,配列番号61のアミノ酸配列を含んでなり,重鎖が,配列番号63のアミノ酸配列を含んでなる抗体,
である。ただし,これらに限られず,上記アミノ酸配列に対しては適宜,置換,欠失,付加等の変異を加えることができる。なお,上記(1)及び(2)の抗hTfR抗体はヒト化抗hTfR抗体である。
野生型hNAGLU遺伝子を含む配列番号41で示される塩基配列を有するDNA断片を合成した。これを鋳型として,フォワードプライマーとして配列番号42で示される塩基配列を有するMluI付加5’プライマーを,リバースプライマーとして表1で示すプライマーを用いて,表1に示すNo. 1~7及び11のPCRを行った。表1に各リバースプライマーの塩基配列に対応する配列番号を示す。
hNAGLU変異体の一過性発現は,実施例1で得た精製したpCI-neoベクターに各hNAGLU変異体をコードする遺伝子を組み込んだプラスミドを用いて行った。コントロールとしてpCI-neoベクターに野生型NAGLUをコードする遺伝子を組み込んだプラスミドを用いた。
実施例2で得られた培養上清10 μLを,8 μLの2×Sample Buffer(バイオラッド社)及び2 μLの2-Mercaptoethanolと混合し,100℃で3分間保温することで還元条件下で熱変性させた。熱変性後の試料を,0.1% SDSを含む50 mM Tris緩衝液/380 mM グリシン緩衝液(pH8.3)内に設置した5-20%ポリアクリルアミドゲルのウェルに5 μLずつ付し,25 mA定電流にて電気泳動した。電気泳動後のゲルをOriole Fluorescent Gel Stain(バイオラッド社)に浸し,室温で90分間振とうした。ゲルを純水で洗浄した後,ルミノイメージアナライザー(Amersham Imager 600RGB,サイティバ社)で蛋白質のバンドを検出した。
実施例3に記載した方法と同様に電気泳動を行い,ニトロセルロース膜と電気泳動後のゲルを,20%メタノールを含む25 mM Tris緩衝液/192 mM グリシン緩衝液に浸したブロッティングペーパーで挟み,ブロッティング装置で1.0 A,25 Vで10分間通電することで,蛋白質をニトロセルロース膜に転写した。転写後のニトロセルロース膜を5%スキムミルクを含むPBSTに浸して1時間振とうした後,0.4 μg/mLに希釈したMouse anti-His tag mAb(医学生物学研究所)溶液に浸して1時間振とうした。PBSTで膜を洗浄後,0.4 μg/mLに希釈したAnti-mouse IgG (H+L), HRP Conjugate(プロメガ社)溶液に浸して30分間振とうし,再度PBSTで洗浄した。膜の転写面にHRP検出試薬(バイオラッド社)を滴下して5分間反応させ,各hNAGLU変異体及び野生型hNAGLUに相当するバンドをルミノイメージアナライザーで検出した。
試料溶液として,実施例2で得られた培養上清を0.1% BSAを含む100 mM クエン酸緩衝液(pH4.2)で10倍希釈したものを調製した。標準溶液として,4-MU(4-Methylumbelliferone,シグマアルドリッチ社)を0.1% BSAを含む100 mM クエン酸緩衝液(pH4.2)で400~35.12 μMに段階希釈したものを調製した。基質溶液として,NAGLUの人工基質である4-Methylumbelliferyl-N-acetyl-α-D-glucosaminide(シグマアルドリッチ社)を0.1% BSAを含む100 mM クエン酸緩衝液(pH4.2)で1 mmol/Lに希釈したものを調製した。マイクロプレートに試料溶液又は標準溶液を各ウェルに25 μLずつ添加し,更に基質溶液を25 μL/well添加してプレートシェイカーで撹拌し混合した。プレートを37℃で1時間保温した後,200 mmol/L グリシン-NaOH緩衝液(pH10.7)を各ウェルに150 μLずつ添加して反応を停止させた。蛍光プレートリーダー(Gemini XPS,モレキュラーデバイス社)で遊離した4-MU(4-Methylumbelliferone)の蛍光強度を測定した(励起波長355 nm,蛍光波長460 nm)。標準溶液の測定結果に基づき検量線を作成し,これに各試料溶液の測定値を内挿して,酵素活性量を求めた。
図1に,実施例2~4で測定した一過性発現によるhNAGLU変異体発現量の測定結果を示す。表5は,図1において棒グラフで示される酵素活性測定結果に基づく各hNAGLU変異体の発現量を,野生型の発現量を1としたときの相対値として示したものである。
遺伝子導入装置(スーパーエレクトロポレーターNEPA21,ネッパジーン社)を用いて,CHO-K1細胞の無血清馴化株に,実施例1で得られた各hNAGLU変異体又は野生型hNAGLUをコードする遺伝子を組み込んだ発現プラスミドをそれぞれ導入し,10 μg/mL Puromycin(Thermo Fisher Scientific社)を含むCD OptiCHO培地(Thermo Fisher Scientific社)にて選択培養を行った。3~4日おきに培地交換を繰り返しながら順次培養液量を拡大し,培養中の細胞の生存率が90%を超えた時点で細胞を回収し,これをhNAGLU変異体発現バルク細胞及び野生型hNAGLU発現バルク細胞とした。
10 μg/mL Puromycinを含むCD OptiCHO培地に,実施例7で得られた各hNAGLU変異体発現バルク細胞及び野生型hNAGLU発現バルク細胞を,それぞれ2×105 cells/mLの細胞密度で播種し,37°C,5% CO2存在下で静置培養した。培養開始から9日後,培養上清を遠心分離して培養上清を回収した。
試料溶液として,実施例8で得られた培養上清を0.1% BSAを含むクエン酸緩衝液(pH4.2)で10倍希釈したものを調製した。基質溶液として,hNAGLUの人工基質である4-Methylumbelliferyl-N-acetyl-α-D-glucosaminideをクエン酸緩衝液(pH4.2)で1 mmol/Lに希釈したものを調製した。マイクロプレートに試料溶液又は標準溶液を各ウェルに25 μLずつ添加し,更に基質溶液を25 μL/well添加してプレートシェイカーで撹拌し混合した。プレートを37℃で1時間保温した後,200 mmol/L グリシン-NaOH緩衝液(pH10.7)を各ウェルに150 μLずつl添加して反応を停止させた。蛍光プレートリーダーで遊離した4-MU(4-Methylumbelliferone)の蛍光強度を測定した(励起波長355 nm,蛍光波長460 nm)。標準溶液の測定結果に基づき検量線を作成し,これに各試料溶液の測定値を内挿して,酵素活性量を求めた。酵素活性量は,各々のhNAGLU変異体について,培養中に1×106個の細胞から発現したhNAGLUの酵素活性量(nmol/h/1×106個細胞)として求めた。
図2に,実施例9で測定したバルク細胞によるhNAGLU変異体発現量の測定結果を示す。表6は,図2において棒グラフで示される酵素活性測定結果に基づく各hNAGLU変異体の発現量を,野生型の発現量を1としたときの相対値として示したものである。なお,バルク細胞の培養は4回繰り返し,それぞれについて酵素活性測定を実施した。
実施例1~10の実験結果により,hNAGLU変異体の中で,Q209R hNAGLU変異体が最も高い発現量を示すことがわかった。そこで,更なる高発現hNAGLU変異体を得るために,Q209R hNAGLU変異体に更に変異を導入した。実施例1で得られたQ209R hNAGLU変異体をコードする遺伝子を組み込んだプラスミドを鋳型として,フォワードプライマーとして配列番号42で示される塩基配列を有するMluI付加5’プライマーを,リバースプライマーとして表7に示すプライマーを用いて,表7に示すNo. 12~15のPCRを行った。表7に各リバースプライマーの塩基配列に対応する配列番号を示す。
hNAGLU変異体の一過性発現は,実施例11で精製したpCI-neoベクターにhNAGLU変異体を組み込んだプラスミドを用いて行った。コントロールとしてpCI-neoベクターに野生型hNAGLUを組み込んだプラスミドを用いた。
実施例12で得られた培養上清10 μLを,8 μLの2×Sample Buffer及び2 μLの2-Mercaptoethanolと混合し,100℃で3分間保温することで還元条件下で熱変性させた。熱変性後の試料を,0.1% SDSを含む50 mM Tris緩衝液/380 mM グリシン緩衝液(pH8.3)内に設置した5-20%ポリアクリルアミドゲルのウェルに5 μLずつアプライし,25 mA定電流にて電気泳動した。電気泳動後のゲルをOriole Fluorescent Gel Stain(バイオラッド社)に浸し,室温で90分間振とうした。ゲルを純水で洗浄した後,ルミノイメージアナライザーで蛋白質のバンドを検出した。
実施例13に記載した方法と同様に電気泳動を行い,ニトロセルロース膜と電気泳動後のゲルを,20%メタノールを含む25 mM Tris緩衝液/192 mM グリシン緩衝液に浸したブロッティングペーパーで挟み,ブロッティング装置で1.0 A,25 Vで10分間通電することで蛋白質をニトロセルロース膜に転写した。転写後のニトロセルロース膜を5%スキムミルクを含むPBSTに浸して1時間振とう後,0.4 μg/mLに希釈したMouse anti-His tag mAb溶液に浸して1時間振とうした。PBSTで膜を洗浄後,0.4 μg/mLに希釈したAnti-mouse IgG (H+L), HRP Conjugate溶液に浸して30分間振とうし,再度PBSTで洗浄した。膜の転写面にHRP検出試薬を滴下して5分間反応させ,ルミノイメージアナライザーで検出した。
試料溶液として,実施例12で得られた培養上清を0.1% BSAを含むクエン酸緩衝液(pH4.2)で10倍希釈したものを調製した。基質溶液として,hNAGLUの人工基質である4-Methylumbelliferyl-N-acetyl-α-D-glucosaminideをクエン酸緩衝液(pH4.2)で1 mmol/Lに希釈したものを調製した。マイクロプレートに試料溶液又は標準溶液を25 μL/well添加し,更に各ウェルに25 μLの基質溶液を添加してプレートシェイカーで撹拌し混合した。プレートを37℃で1時間保温した後,200 mmol/L グリシン-NaOH緩衝液(pH10.7)を150 μL/well添加して反応を停止させた。蛍光プレートリーダーで遊離した4-MU(4-Methylumbelliferone)の蛍光強度を測定した(励起波長355 nm,蛍光波長460 nm)。標準溶液の測定結果に基づき検量線を作成し,これに各試料溶液の測定値を内挿して,酵素活性量を求めた。
図3及び図4に,実施例12~15で測定した一過性発現によるhNAGLU変異体発現量の測定結果を示す。表11は,図3及びず4において棒グラフで示される酵素活性測定結果に基づく各hNAGLU変異体の発現量を,野生型の発現量を1としたときの相対値として示したものである。
以上の結果は,組換え体hNAGLUを製造する場合に,組換え体野生型hNAGLUに代えて組換え体Q209R hNAGLU変異体として製造することにより,2~5倍の生産量を得ることができることを示す。また,Q209R hNAGLU変異体に更に変異を加えて,組換え体K36E/P37S/Q209R hNAGLU変異体,組換え体L44_G45insS/Q209R hNAGLU変異体,組換え体Q209R/T320P/E321D hNAGLU変異体,組換え体K36E/P37S/L44_G45insS/Q209R hNAGLU変異体,組換え体V54I/Q209R/R620K hNAGLU変異体,組換え体L44_G45insS/V54I/Q209R hNAGLU変異体,組換え体L44_G45insS/Q209R/R620K hNAGLU変異体,及び組換え体L44_G45insS/V54I/Q209R/R620K hNAGLU変異体として製造することにより,更に組換え体hNAGLUの生産量を増加させることができることを示す。
抗ヒトトランスフェリン受容体抗体(抗hTfR抗体)とhNAGLU変異体の融合蛋白質は,以下に詳述する方法により製造することができる。
抗hTfR抗体とhNAGLU変異体の融合蛋白質は,以下の方法で製造することができる。実施例18に記載の高発現細胞株を,細胞濃度が約2X105 個/mLとなるように,CD OptiCHOTM培地で希釈し,1 Lの三角フラスコに200 mLの細胞懸濁液を加え,37℃で,5% CO2と95% 空気からなる湿潤環境で約70 rpmの撹拌速度で6~7日間培養する。培養上清を遠心操作により回収し,0.22 μmフィルター(Millipore社)でろ過して,培養上清を回収する。その培養上清に,カラム体積の5倍容の150 mL NaClを含む20 mM Tris緩衝液(pH 8.0)を添加し,カラム体積の3倍容の150 mM NaClを含む20 mM Tris緩衝液(pH 8.0)で予め平衡化しておいたProtein Aカラム(カラム体積:1 mL,Bio-Rad社)に負荷する。次いで,カラム体積の5倍容の同緩衝液を供給してカラムを洗浄した後,150 mM NaClを含むカラム体積の4倍容の50 mM グリシン緩衝液(pH 2.8)で,吸着した融合蛋白質を溶出させる。この融合蛋白質を含む溶出液のpHを1 M Tris緩衝液(pH 8.0)を添加してpH 7.0に調整する。こうして得られて溶液を融合蛋白質の精製品として,4℃又は凍結して保存する。
配列番号2:野生型hNAGLUをコードするDNA断片の塩基配列,合成配列
配列番号3:hNAGLU変異体番号1のアミノ酸配列
配列番号4:hNAGLU変異体番号1をコードするDNA断片の塩基配列,合成配列
配列番号5:hNAGLU変異体番号2のアミノ酸配列
配列番号6:hNAGLU変異体番号2をコードするDNA断片の塩基配列,合成配列
配列番号7:hNAGLU変異体番号16のアミノ酸配列
配列番号8:hNAGLU変異体番号16をコードするDNA断片の塩基配列,合成配列
配列番号9:hNAGLU変異体番号3のアミノ酸配列
配列番号10:hNAGLU変異体番号3をコードするDNA断片の塩基配列,合成配列
配列番号11:hNAGLU変異体番号4のアミノ酸配列
配列番号12:hNAGLU変異体番号4をコードするDNA断片の塩基配列,合成配列
配列番号13:hNAGLU変異体番号17のアミノ酸配列
配列番号14:hNAGLU変異体番号17をコードするDNA断片の塩基配列,合成配列
配列番号15:hNAGLU変異体番号5のアミノ酸配列
配列番号16:hNAGLU変異体番号5をコードするDNA断片の塩基配列,合成配列
配列番号17:hNAGLU変異体番号6のアミノ酸配列
配列番号18:hNAGLU変異体番号6をコードするDNA断片の塩基配列,合成配列
配列番号19:hNAGLU変異体番号7のアミノ酸配列
配列番号20:hNAGLU変異体番号7をコードするDNA断片の塩基配列,合成配列
配列番号21:hNAGLU変異体番号18のアミノ酸配列
配列番号22:hNAGLU変異体番号18をコードするDNA断片の塩基配列,合成配列
配列番号23:hNAGLU変異体番号19のアミノ酸配列
配列番号24:hNAGLU変異体番号19をコードするDNA断片の塩基配列,合成配列
配列番号25:hNAGLU変異体番号8のアミノ酸配列
配列番号26:hNAGLU変異体番号8をコードするDNA断片の塩基配列,合成配列
配列番号27:hNAGLU変異体番号9のアミノ酸配列
配列番号28:hNAGLU変異体番号9をコードするDNA断片の塩基配列,合成配列
配列番号29:hNAGLU変異体番号10のアミノ酸配列
配列番号30:hNAGLU変異体番号10をコードするDNA断片の塩基配列,合成配列
配列番号31:hNAGLU変異体番号11のアミノ酸配列
配列番号32:hNAGLU変異体番号11をコードするDNA断片の塩基配列,合成配列
配列番号33:hNAGLU変異体番号12のアミノ酸配列
配列番号34:hNAGLU変異体番号12をコードするDNA断片の塩基配列,合成配列
配列番号35:hNAGLU変異体番号13のアミノ酸配列
配列番号36:hNAGLU変異体番号13をコードするDNA断片の塩基配列,合成配列
配列番号37:hNAGLU変異体番号14のアミノ酸配列
配列番号38:hNAGLU変異体番号14をコードするDNA断片の塩基配列,合成配列
配列番号39:hNAGLU変異体番号15のアミノ酸配列
配列番号40:hNAGLU変異体番号15をコードするDNA断片の塩基配列,合成配列
配列番号41:hNAGLUをコードする遺伝子を含む塩基配列,合成配列
配列番号42:MluI付加5’プライマー,合成配列
配列番号43:Hisタグ-NotI付加3’プライマー,合成配列
配列番号44:K36E/P37S変異導入3’ プライマー,合成配列
配列番号45:L44_G45insS変異導入3’ プライマー,合成配列
配列番号46:R129Q変異導入3’ プライマー,合成配列
配列番号47:Q209R変異導入3’ プライマー,合成配列
配列番号48:E228K変異導入3’ プライマー,合成配列
配列番号49:T240V変異導入3’ プライマー,合成配列
配列番号50:T320P/E321 D変異導入3’ プライマー,合成配列
配列番号51:S505A/I506V変異導入5’ プライマー,合成配列
配列番号52:S526N/A528 T変異導入5’ プライマー,合成配列
配列番号53:D613Q変異導入5’ プライマー,合成配列
配列番号54:H204K変異導入3’ プライマー,合成配列
配列番号55:V54I変異導入3’ プライマー,合成配列
配列番号56:R620K変異導入5’ プライマー,合成配列
配列番号57:ヒトトランスフェリン受容体のアミノ酸配列
配列番号58:リンカーのアミノ酸配列の一例1
配列番号59:リンカーのアミノ酸配列の一例2
配列番号60:リンカーのアミノ酸配列の一例3
配列番号61:抗hTfR抗体の軽鎖のアミノ酸配列
配列番号62:抗hTfR抗体の重鎖のアミノ酸配列
配列番号63:抗hTfR抗体のFab重鎖のアミノ酸配列
配列番号64:hNAGLU変異体番号9と抗hTfR抗体のFab重鎖の融合蛋白質のアミノ酸配列1
配列番号65:hNAGLU変異体番号9と抗hTfR抗体のFab重鎖の融合蛋白質のアミノ酸配列2
配列番号66:抗hTfR抗体の軽鎖のアミノ酸配列をコードする塩基配列,合成配列
配列番号67:野生型hNAGLU前駆体のシグナルペプチドのアミノ酸配列
Claims (34)
- 下記の(1)~(7)からなる群から選択されるヒトα-N-アセチルグルコサミニダーゼ(hNAGLU)の変異体:
(1)配列番号1で示される野生型のhNAGLUのアミノ酸配列中36位のリシンがグルタミン酸に,かつ37位のプロリンがセリンに,それぞれ置換された配列番号3で示されるアミノ酸配列を含むもの;
(2)配列番号1で示される野生型のhNAGLUのアミノ酸配列中44位のロイシンと45位のグリシンの間にセリンが付加された配列番号5で示されるアミノ酸配列を含むもの;
(3)配列番号1で示される野生型のhNAGLUのアミノ酸配列中209位のグルタミンがアルギニンに置換された配列番号9で示されるアミノ酸配列を含むもの;
(4)配列番号1で示される野生型のhNAGLUのアミノ酸配列中228位のグルタミン酸がリシンに置換された配列番号11で示されるアミノ酸配列を含むもの;
(5)配列番号1で示される野生型のhNAGLUのアミノ酸配列中320位のトレオニンがプロリンに,かつ321位のグルタミン酸がアスパラギン酸に,それぞれ置換された配列番号15で示されるアミノ酸配列を含むもの;
(6)配列番号1で示される野生型のhNAGLUのアミノ酸配列中505位のセリンがアラニンに,かつ506位のイソロイシンがバリンに,それぞれ置換された配列番号17で示されるアミノ酸配列を含むもの;及び
(7)配列番号1で示される野生型のhNAGLUのアミノ酸配列中526位のセリンがアスパラギンに,かつ528位のアラニンがトレオニンに,それぞれ置換された配列番号19で示されるアミノ酸配列を含むもの。 - 請求項1に記載の配列番号3で示されるアミノ酸配列を含むhNAGLU変異体に対し,該アミノ酸配列の36位のグルタミン酸及び37位のセリン以外において,以下の(1’-a)~(1’-h)からなる群から選択される変異を含むhNAGLU変異体:
(1’-a)該アミノ酸配列を構成するアミノ酸残基が他のアミノ酸残基で置換されたものであり,該置換されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(1’-b)該アミノ酸配列を構成するアミノ酸残基が欠失されたものであり,該欠失されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(1’-c)上記1’-aの置換と1’-bの欠失を組み合わせたもの;
(1’-d)該アミノ酸配列中に又は該アミノ酸配列のN末端側若しくはC末端側に,1個又は複数個のアミノ酸残基が付加されたものであり,該付加されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(1’-e)上記1’-aの置換と1’-dの付加を組み合わせたもの;
(1’-f)上記1’-bの欠失と1’-dの付加を組み合わせたもの;
(1’-g)上記1’-aの置換と,1’-bの欠失と及び1’-dの付加を組み合わせたもの;及び
(1’-h)該アミノ酸配列と80%以上,85%以上,90%以上,95%以上の同一性,98%以上,又は99%の同一性を示すもの。 - 請求項1に記載の配列番号5で示されるアミノ酸配列を含むhNAGLUの変異体に対し,該アミノ酸配列の45位のセリン以外において,以下の(2’-a)~(2’-h)からなる群から選択される変異を有するhNAGLU変異体:
(2’-a)該アミノ酸配列を構成するアミノ酸残基が他のアミノ酸残基で置換されたものであり,該置換されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(2’-b)該アミノ酸配列を構成するアミノ酸残基が欠失されたものであり,該欠失されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(2’-c)上記2’-aの置換と2’-bの欠失を組み合わせたもの;
(2’-d)該アミノ酸配列中に又は該アミノ酸配列のN末端側若しくはC末端側に,1個又は複数個のアミノ酸残基が付加されたものであり,該付加されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(2’-e)上記2’-aの置換と2’-dの付加を組み合わせたもの;
(2’-f)上記2’-bの欠失と2’-dの付加を組み合わせたもの;
(2’-g)上記2’-aの置換と,2’-bの欠失と及び2’-dの付加を組み合わせたもの;及び
(2’-h)該アミノ酸配列と80%以上,85%以上,90%以上,95%以上の同一性,98%以上,又は99%の同一性を示すもの。 - 請求項1に記載の配列番号9で示されるアミノ酸配列を含むhNAGLU変異体に対し,該アミノ酸配列の209位のアルギニン以外において,以下の(3’-a)~(3’-h)からなる群から選択される変異を有するhNAGLU変異体:
(3’-a)該アミノ酸配列を構成するアミノ酸残基が他のアミノ酸残基で置換されたものであり,該置換されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(3’-b)該アミノ酸配列を構成するアミノ酸残基が欠失されたものであり,該欠失されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(3’-c)上記3’-aの置換と3’-bの欠失を組み合わせたもの;
(3’-d)該アミノ酸配列中に又は該アミノ酸配列のN末端側若しくはC末端側に,1個又は複数個のアミノ酸残基が付加されたものであり,該付加されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(3’-e)上記3’-aの置換と3’-dの付加を組み合わせたもの;
(3’-f)上記3’-bの欠失と3’-dの付加を組み合わせたもの;
(3’-g)上記3’-aの置換と,3’-bの欠失と及び3’-dの付加を組み合わせたもの;及び
(3’-h)該アミノ酸配列と80%以上,85%以上,90%以上,95%以上の同一性,98%以上,又は99%の同一性を示すもの。 - 請求項1に記載の配列番号11で示されるアミノ酸配列を含むhNAGLU変異体に対し,該アミノ酸配列の228位のリジン以外において,以下の(4’-a)~(4’-h)からなる群から選択される変異を有するhNAGLU変異体:
(4’-a)該アミノ酸配列を構成するアミノ酸残基が他のアミノ酸残基で置換されたものであり,該置換されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(4’-b)該アミノ酸配列を構成するアミノ酸残基が欠失されたものであり,該欠失されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(4’-c)上記4’-aの置換と4’-bの欠失を組み合わせたもの;
(4’-d)該アミノ酸配列中に又は該アミノ酸配列のN末端側若しくはC末端側に,1個又は複数個のアミノ酸残基が付加されたものであり,該付加されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(4’-e)上記4’-aの置換と4’-dの付加を組み合わせたもの;
(4’-f)上記4’-bの欠失と4’-dの付加を組み合わせたもの;
(4’-g)上記4’-aの置換と,4’-bの欠失と及び4’-dの付加を組み合わせたもの;及び
(4’-h)該アミノ酸配列と80%以上,85%以上,90%以上,95%以上の同一性,98%以上,又は99%の同一性を示すもの。 - 請求項1に記載の配列番号15で示されるアミノ酸配列を含むhNAGLU変異体に対し,該アミノ酸配列の320位のプロリン及び321位のアスパラギン酸以外において,以下の(5’-a)~(5’-h)からなる群から選択される変異を有するhNAGLU変異体:
(5’-a)該アミノ酸配列を構成するアミノ酸残基が他のアミノ酸残基で置換されたものであり,該置換されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(5’-b)該アミノ酸配列を構成するアミノ酸残基が欠失されたものであり,該欠失されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(5’-c)上記5’-aの置換と5’-bの欠失を組み合わせたもの;
(5’-d)該アミノ酸配列中に又は該アミノ酸配列のN末端側若しくはC末端側に,1個又は複数個のアミノ酸残基が付加されたものであり,該付加されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(5’-e)上記5’-aの置換と5’-dの付加を組み合わせたもの;
(5’-f)上記5’-bの欠失と5’-dの付加を組み合わせたもの;
(5’-g)上記5’-aの置換と,5’-bの欠失と及び5’-dの付加を組み合わせたもの;及び
(5’-h)該アミノ酸配列と80%以上,85%以上,90%以上,95%以上の同一性,98%以上,又は99%の同一性を示すもの。 - 請求項1に記載の配列番号17で示されるアミノ酸配列を含むhNAGLU変異体に対し,該アミノ酸配列の505位のアラニン及び506位のバリン以外において,以下の(6’-a)~(6’-h)からなる群から選択される変異を有するhNAGLU変異体:
(6’-a)該アミノ酸配列を構成するアミノ酸残基が他のアミノ酸残基で置換されたものであり,該置換されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(6’-b)該アミノ酸配列を構成するアミノ酸残基が欠失されたものであり,該欠失されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(6’-c)上記6’-aの置換と6’-bの欠失を組み合わせたもの;
(6’-d)該アミノ酸配列中に又は該アミノ酸配列のN末端側若しくはC末端側に,1個又は複数個のアミノ酸残基が付加されたものであり,該付加されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(6’-e)上記6’-aの置換と6’-dの付加を組み合わせたもの;
(6’-f)上記6’-bの欠失と6’-dの付加を組み合わせたもの;
(6’-g)上記6’-aの置換と,6’-bの欠失と及び6’-dの付加を組み合わせたもの;及び
(6’-h)該アミノ酸配列と80%以上,85%以上,90%以上,95%以上の同一性,98%以上,又は99%の同一性を示すもの。 - 請求項1に記載の配列番号19で示されるアミノ酸配列を含むhNAGLU変異体に対し,該アミノ酸配列の526位のアスパラギン及び528位のトレオニン以外において,以下の(7’-a)~(7’-h)からなる群から選択される変異を有するhNAGLU変異体:
(7’-a)該アミノ酸配列を構成するアミノ酸残基が他のアミノ酸残基で置換されたものであり,該置換されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(7’-b)該アミノ酸配列を構成するアミノ酸残基が欠失されたものであり,該欠失されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(7’-c)上記7’-aの置換と7’-bの欠失を組み合わせたもの;
(7’-d)該アミノ酸配列中に又は該アミノ酸配列のN末端側若しくはC末端側に,1個又は複数個のアミノ酸残基が付加されたものであり,該付加されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(7’-e)上記7’-aの置換と7’-dの付加を組み合わせたもの;
(7’-f)上記7’-bの欠失と7’-dの付加を組み合わせたもの;
(7’-g)上記7’-aの置換と,7’-bの欠失と及び7’-dの付加を組み合わせたもの;及び
(7’-h)該アミノ酸配列と80%以上,85%以上,90%以上,95%以上の同一性,98%以上,又は99%の同一性を示すもの。 - 請求項4に記載の配列番号9で示されるアミノ酸配列を含むhNAGLU変異体に対し, 以下の(8)~(15)からなる群から選択される変異を有するhNAGLU変異体:
(8)36位のリシンがグルタミン酸に,37位のプロリンがセリンに,それぞれ置換された配列番号25で示されるアミノ酸配列を含むもの;
(9)44位のロイシンと45位のグリシンの間にセリンが付加された配列番号27で示されるアミノ酸配列を含むもの;
(10)320位のトレオニンがプロリンに,321位のグルタミン酸がアスパラギン酸に,それぞれ置換された配列番号29で示されるアミノ酸配列を含むもの;
(11)36位のリシンがグルタミン酸に,37位のプロリンがセリンに,それぞれ置換され,かつ,44位のロイシンと45位のグリシンの間にセリンが付加された配列番号31で示されるアミノ酸配列を含むもの;
(12)54位のバリンがイソロイシンに,620位のアルギニンがリシンに,それぞれ置換された配列番号33で示されるアミノ酸配列を含むもの;
(13)54位のバリンがイソロイシンに置換され,かつ,44位のロイシンと45位のグリシンの間にセリンが付加された配列番号35で示されるアミノ酸配列を含むもの;
(14)620位のアルギニンがリシンに置換され,かつ,44位のロイシンと45位のグリシンの間にセリンが付加された配列番号37で示されるアミノ酸配列を含むもの;及び
(15)54位のバリンがイソロイシンに,620位のアルギニンがリシンに,それぞれ置換され,かつ,44位のロイシンと45位のグリシンの間にセリンが付加された配列番号39で示されるアミノ酸配列を含むもの。 - 請求項9に記載の配列番号25で示されるアミノ酸配列を含むhNAGLU変異体に対し,該アミノ酸配列の209位のアルギニン,36位のグルタミン酸,及び37位のセリン以外において,以下の(8’-a)~(8’-h)からなる群から選択される変異を有するhNAGLU変異体:
(8’-a)該アミノ酸配列を構成するアミノ酸残基が他のアミノ酸残基で置換されたものであり,該置換されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(8’-b)該アミノ酸配列を構成するアミノ酸残基が欠失されたものであり,該欠失されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(8’-c)上記8’-aの置換と8’-bと欠失を組み合わせたもの;
(8’-d)該アミノ酸配列中に又は該アミノ酸配列のN末端側若しくはC末端側に,1個又は複数個のアミノ酸残基が付加されたものであり,該付加されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(8’-e)上記8’-aの置換と8’-dの付加を組み合わせたもの;
(8’-f)上記8’-bの欠失と8’-dの付加を組み合わせたもの;
(8’-g)上記8’-aの置換と,8’-bの欠失と及び8’-dの付加を組み合わせたもの;
(8’-h)該アミノ酸配列と80%以上,85%以上,90%以上,95%以上の同一性,98%以上,又は99%の同一性を示すもの。 - 請求項9に記載の配列番号27で示されるアミノ酸配列を含むhNAGLU変異体に対し,該アミノ酸配列の210位のアルギニン,及び45位のセリン以外において,以下の(9’-a)~(9’-h)からなる群から選択される変異を有するhNAGLU変異体:
(9’-a)該アミノ酸配列を構成するアミノ酸残基が他のアミノ酸残基で置換されたものであり,該置換されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(9’-b)該アミノ酸配列を構成するアミノ酸残基が欠失されたものであり,該欠失されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(9’-c)上記9’-aの置換と9’-bの欠失を組み合わせたもの;
(9’-d)該アミノ酸配列中に又は該アミノ酸配列のN末端側若しくはC末端側に,1個又は複数個のアミノ酸残基が付加されたものであり,該付加されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(9’-e)上記9’-aの置換と9’-dの付加を組み合わせたもの;
(9’-f)上記9’-bの欠失と9’-dの付加を組み合わせたもの;
(9’-g)上記9’-aの置換と,9’-bの欠失と及び9’-dの付加を組み合わせたもの;
(9’-h)該アミノ酸配列と80%以上,85%以上,90%以上,95%以上の同一性,98%以上,又は99%の同一性を示すもの。 - 請求項9に記載の配列番号29で示されるアミノ酸配列を含むhNAGLU変異体に対し,該アミノ酸配列の209位のアルギニン,320位のプロリン,及び321位のアスパラギン酸以外において,以下の(10’-a)~(10’-h)からなる群から選択される変異を有するhNAGLU変異体:
(10’-a)該アミノ酸配列を構成するアミノ酸残基が他のアミノ酸残基で置換されたものであり,該置換されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(10’-b)該アミノ酸配列を構成するアミノ酸残基が欠失されたものであり,該欠失されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(10’-c)上記10’-aの置換と10’-bの欠失を組み合わせたもの;
(10’-d)該アミノ酸配列中に又は該アミノ酸配列のN末端側若しくはC末端側に,1個又は複数個のアミノ酸残基が付加されたものであり,該付加されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(10’-e)上記10’-aの置換と10’-dの付加を組み合わせたもの;
(10’-f)上記10’-bの欠失と10’-dの付加を組み合わせたもの;
(10’-g)上記10’-aの置換と,10’-bの欠失と及び10’-dの付加を組み合わせたもの;
(10’-h)該アミノ酸配列と80%以上,85%以上,90%以上,95%以上の同一性,98%以上,又は99%の同一性を示すもの。 - 請求項9に記載の配列番号31で示されるアミノ酸配列を含むhNAGLU変異体に対し,該アミノ酸配列の210位のアルギニン,36位のグルタミン酸,37位のセリン,及び45位のセリン以外において,以下の(11’-a)~(11’-h)からなる群から選択される変異を有するhNAGLU変異体:
(11’-a)該アミノ酸配列を構成するアミノ酸残基が他のアミノ酸残基で置換されたものであり,該置換されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(11’-b)該アミノ酸配列を構成するアミノ酸残基が欠失されたものであり,該欠失されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(11’-c)上記11’-aの置換と11’-bの欠失を組み合わせたもの;
(11’-d)該アミノ酸配列中に又は該アミノ酸配列のN末端側若しくはC末端側に,1個又は複数個のアミノ酸残基が付加されたものであり,該付加されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(11’-e)上記11’-aの置換と11’-dの付加を組み合わせたもの;
(11’-f)上記11’-bの欠失と11’-dの付加を組み合わせたもの;
(11’-g)上記11’-aの置換と,11’-bの欠失と及び11’-dの付加を組み合わせたもの;
(11’-h)該アミノ酸配列と80%以上,85%以上,90%以上,95%以上の同一性,98%以上,又は99%の同一性を示すもの。 - 請求項9に記載の配列番号33で示されるアミノ酸配列を含むhNAGLU変異体に対し,該アミノ酸配列の209位のアルギニン,54位のイソロイシン,及び620位のリシン以外において,以下の(12’-a)~(12’-h)からなる群から選択される変異を有するhNAGLU変異体:
(12’-a)該アミノ酸配列を構成するアミノ酸残基が他のアミノ酸残基で置換されたものであり,該置換されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(12’-b)該アミノ酸配列を構成するアミノ酸残基が欠失されたものであり,該欠失されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(12’-c)上記12’-aの置換と12’-bの欠失を組み合わせたもの;
(12’-d)該アミノ酸配列中に又は該アミノ酸配列のN末端側若しくはC末端側に,1個又は複数個のアミノ酸残基が付加されたものであり,該付加されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(12’-e)上記12’-aの置換と12’-dの付加を組み合わせたもの;
(12’-f)上記12’-bの欠失と12’-dの付加を組み合わせたもの;
(12’-g)上記12’-aの置換と,12’-bの欠失と及び12’-dの付加を組み合わせたもの;
(12’-h)該アミノ酸配列と80%以上,85%以上,90%以上,95%以上の同一性,98%以上,又は99%の同一性を示すもの。 - 請求項9に記載の配列番号35で示されるアミノ酸配列を含むhNAGLU変異体に対し,該アミノ酸配列の210位のアルギニン,55位のイソロイシン,及び45位のセリン以外において,以下の(13’-a)~(13’-h)からなる群から選択される変異を有するhNAGLU変異体:
(13’-a)該アミノ酸配列を構成するアミノ酸残基が他のアミノ酸残基で置換されたものであり,該置換されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(13’-b)該アミノ酸配列を構成するアミノ酸残基が欠失されたものであり,該欠失されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(13’-c)上記13’-aの置換と13’-bの欠失を組み合わせたもの;
(13’-d)該アミノ酸配列中に又は該アミノ酸配列のN末端側若しくはC末端側に,1個又は複数個のアミノ酸残基が付加されたものであり,該付加されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(13’-e)上記13’-aの置換と13’-dの付加を組み合わせたもの;
(13’-f)上記13’-bの欠失と13’-dの付加を組み合わせたもの;
(13’-g)上記13’-aの置換と,13’-bの欠失と及び13’-dの付加を組み合わせたもの;
(13’-h)該アミノ酸配列と80%以上,85%以上,90%以上,95%以上の同一性,98%以上,又は99%の同一性を示すもの。 - 請求項9に記載の配列番号37で示されるアミノ酸配列を含むhNAGLU変異体に対し,該アミノ酸配列の210位のアルギニン,621位のリシン,及び45位のセリン以外において,以下の(14’-a)~(14’-h)からなる群から選択される変異を有するhNAGLU変異体:
(14’-a)該アミノ酸配列を構成するアミノ酸残基が他のアミノ酸残基で置換されたものであり,該置換されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(14’-b)該アミノ酸配列を構成するアミノ酸残基が欠失されたものであり,該欠失されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(14’-c)上記14’-aの置換と14’-bの欠失を組み合わせたもの;
(14’-d)該アミノ酸配列中に又は該アミノ酸配列のN末端側若しくはC末端側に,1個又は複数個のアミノ酸残基が付加されたものであり,該付加されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(14’-e)上記14’-aの置換と14’-dの付加を組み合わせたもの;
(14’-f)上記14’-bの欠失と14’-dの付加を組み合わせたもの;
(14’-g)上記14’-aの置換と,14’-bの欠失と及び14’-dの付加を組み合わせたもの;
(14’-h)該アミノ酸配列と80%以上,85%以上,90%以上,95%以上の同一性,98%以上,又は99%の同一性を示すもの。 - 請求項9に記載の配列番号39で示されるアミノ酸配列を含むhNAGLU変異体に対し,該アミノ酸配列の210位のアルギニン,55位のイソロイシン,621位のリシン,及び45位のセリン以外において,以下の(15’-a)~(15’-h)からなる群から選択される変異を有するhNAGLU変異体:
(15’-a)該アミノ酸配列を構成するアミノ酸残基が他のアミノ酸残基で置換されたものであり,該置換されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(15’-b)該アミノ酸配列を構成するアミノ酸残基が欠失されたものであり,該欠失されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(15’-c)上記15’-aの置換と15’-bの欠失を組み合わせたもの;
(15’-d)該アミノ酸配列中に又は該アミノ酸配列のN末端側若しくはC末端側に,1個又は複数個のアミノ酸残基が付加されたものであり,該付加されたアミノ酸残基の個数が,1~10個であり,1~5個であり,又は1~3個であり,例えば,1個又は2個であるもの;
(15’-e)上記15’-aの置換と15’-dの付加を組み合わせたもの;
(15’-f)上記15’-bの欠失と15’-dの付加を組み合わせたもの;
(15’-g)上記15’-aの置換と,15’-bの欠失と及び15’-dの付加を組み合わせたもの;
(15’-h)該アミノ酸配列と80%以上,85%以上,90%以上,95%以上の同一性,98%以上,又は99%の同一性を示すもの。 - 請求項1~17の何れかに記載のhNAGLU変異体をコードする遺伝子を含んでなるDNA。
- 請求項18に記載のDNAを含んでなる発現ベクター。
- 請求項19に記載の発現ベクターで形質転換された哺乳動物細胞。
- 請求項20に記載の哺乳動物細胞を無血清培地で培養するステップを含む,hNAGLU変異体の製造方法。
- 請求項1~17の何れかに記載のhNAGLU変異体と,抗体との融合蛋白質であって,該抗体が脳血管内皮細胞上の受容体と結合することにより,該融合蛋白質が血液脳関門(BBB)を通過することのできるものである,融合蛋白質。
- 該脳血管内皮細胞上の受容体が,インスリン受容体,トランスフェリン受容体,レプチン受容体,リポタンパク質受容体,及びIGF受容体からなる群から選択されるものである,請求項22に記載の融合蛋白質。
- 該脳血管内皮細胞上の受容体が,トランスフェリン受容体である,請求項22に記載の融合蛋白質。
- 該抗体が,Fab抗体,F(ab’)2抗体,F(ab’)抗体,単一ドメイン抗体,一本鎖抗体,又はFc抗体の何れかである,請求項22~24の何れかに記載の融合蛋白質。
- 該hNAGLU変異体が,該抗体の軽鎖のC末端側若しくはN末端側の何れかに結合しているものである,請求項22~25の何れか一項に記載の融合蛋白質。
- 該hNAGLU変異体が,該抗体の重鎖のC末端側若しくはN末端側の何れかに結合しているものである,請求項22~25の何れか一項に記載の融合蛋白質。
- 該hNAGLU変異体が,該抗体の軽鎖のC末端側若しくはN末端側の何れか,又は重鎖のC末端側若しくはN末端側の何れかに,リンカー配列を介して結合しているものである,請求項22~27の何れか一項に記載の融合蛋白質。
- 該リンカー配列が,1~50個のアミノ酸残基からなるものである,請求項28に記載の融合蛋白質。
- 該リンカー配列が,1個のグリシン,1個のセリン,アミノ酸配列Gly-Ser,アミノ酸配列Ser-Ser,アミノ酸配列Gly-Gly-Ser,配列番号3のアミノ酸配列,配列番号4のアミノ酸配列,配列番号5のアミノ酸配列,及びこれらのアミノ酸配列が1~10個連続してなるアミノ酸配列からなる群より選ばれるアミノ酸配列を含んでなるものである,請求項29に記載の融合蛋白質。
- 請求項22~30の何れかに記載の融合蛋白質をコードする遺伝子を含んでなるDNA。
- 請求項31に記載のDNAを含んでなる発現ベクター。
- 請求項32に記載の発現ベクターで形質転換された哺乳動物細胞。
- 請求項33に記載の哺乳動物細胞を無血清培地で培養するステップを含む,hNAGLU変異体と抗体との融合蛋白質の製造方法。
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3192771A CA3192771A1 (en) | 2020-08-28 | 2021-08-27 | Mutant of .alpha.-n-acetylglucosaminidase |
MX2023002346A MX2023002346A (es) | 2020-08-28 | 2021-08-27 | Mutante de a-n-acetilglucosaminidasa. |
JP2022545716A JPWO2022045273A1 (ja) | 2020-08-28 | 2021-08-27 | |
IL300887A IL300887A (en) | 2020-08-28 | 2021-08-27 | α–N–ACETYLGLUCOSAMINIDASE MUTATION |
US18/022,992 US20230323326A1 (en) | 2020-08-28 | 2021-08-27 | Mutant of alpha-N-Acetylglucosaminidase |
CN202180051073.1A CN116234901A (zh) | 2020-08-28 | 2021-08-27 | α-N-乙酰氨基葡萄糖苷酶的突变体 |
BR112023003342A BR112023003342A2 (pt) | 2020-08-28 | 2021-08-27 | Mutante de alfa-n-acetilglucosaminidase de humano, ácido desoxirribonucleico, vetor de expressão, célula de mamífero, métodos para produzir um mutante de alfa-n-acetilglucosaminidase de humano e para produzir uma proteína de fusão, e, proteína de fusão |
EP21861695.1A EP4198129A1 (en) | 2020-08-28 | 2021-08-27 | Mutant of alpha-n-acetylglucosaminidase |
AU2021333365A AU2021333365A1 (en) | 2020-08-28 | 2021-08-27 | Mutant of alpha-N-acetylglucosaminidase |
KR1020237009458A KR20230056714A (ko) | 2020-08-28 | 2021-08-27 | α-N-아세틸글루코사미니다제의 변이체 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020145100 | 2020-08-28 | ||
JP2020-145100 | 2020-08-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022045273A1 true WO2022045273A1 (ja) | 2022-03-03 |
Family
ID=80353369
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2021/031431 WO2022045273A1 (ja) | 2020-08-28 | 2021-08-27 | α-N-アセチルグルコサミニダーゼの変異体 |
Country Status (12)
Country | Link |
---|---|
US (1) | US20230323326A1 (ja) |
EP (1) | EP4198129A1 (ja) |
JP (1) | JPWO2022045273A1 (ja) |
KR (1) | KR20230056714A (ja) |
CN (1) | CN116234901A (ja) |
AU (1) | AU2021333365A1 (ja) |
BR (1) | BR112023003342A2 (ja) |
CA (1) | CA3192771A1 (ja) |
IL (1) | IL300887A (ja) |
MX (1) | MX2023002346A (ja) |
TW (1) | TW202227630A (ja) |
WO (1) | WO2022045273A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117625581B (zh) * | 2024-01-24 | 2024-03-26 | 云南师范大学 | 一种N-乙酰氨基葡萄糖苷酶突变体Ea2F及其应用 |
CN117737037B (zh) * | 2024-02-07 | 2024-04-19 | 中国林业科学研究院高原林业研究所 | 一种N-乙酰氨基葡萄糖苷酶突变体De266LΔ6及其制备与应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000500972A (ja) | 1995-11-23 | 2000-02-02 | ウィメンズ アンド チルドレンズ ホスピタル | 哺乳類の合成α―N―アセチルグルコサミニダーゼおよびそれをエンコードする遺伝子配列 |
WO2012063799A1 (ja) | 2010-11-08 | 2012-05-18 | 日本ケミカルリサーチ株式会社 | 新規発現ベクター |
WO2013161958A1 (ja) | 2012-04-27 | 2013-10-31 | 日本ケミカルリサーチ株式会社 | 新規な発現ベクター |
JP2013542913A (ja) * | 2010-06-25 | 2013-11-28 | シャイアー ヒューマン ジェネティック セラピーズ, インコーポレイテッド | サンフィリポ症候群b型の処置 |
JP2017523802A (ja) * | 2014-05-14 | 2017-08-24 | ラボラトリオス デル ドクター エステヴェ ソシエダッド アノニマ | リソソーム蓄積症処置用のアデノ随伴ウイルスベクター |
WO2018124121A1 (ja) | 2016-12-26 | 2018-07-05 | Jcrファーマ株式会社 | 血液脳関門を通過する新規な抗ヒトトランスフェリン受容体抗体 |
-
2021
- 2021-08-27 CN CN202180051073.1A patent/CN116234901A/zh active Pending
- 2021-08-27 TW TW110131793A patent/TW202227630A/zh unknown
- 2021-08-27 IL IL300887A patent/IL300887A/en unknown
- 2021-08-27 CA CA3192771A patent/CA3192771A1/en active Pending
- 2021-08-27 US US18/022,992 patent/US20230323326A1/en active Pending
- 2021-08-27 EP EP21861695.1A patent/EP4198129A1/en active Pending
- 2021-08-27 BR BR112023003342A patent/BR112023003342A2/pt unknown
- 2021-08-27 JP JP2022545716A patent/JPWO2022045273A1/ja active Pending
- 2021-08-27 WO PCT/JP2021/031431 patent/WO2022045273A1/ja unknown
- 2021-08-27 KR KR1020237009458A patent/KR20230056714A/ko unknown
- 2021-08-27 AU AU2021333365A patent/AU2021333365A1/en active Pending
- 2021-08-27 MX MX2023002346A patent/MX2023002346A/es unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000500972A (ja) | 1995-11-23 | 2000-02-02 | ウィメンズ アンド チルドレンズ ホスピタル | 哺乳類の合成α―N―アセチルグルコサミニダーゼおよびそれをエンコードする遺伝子配列 |
JP2013542913A (ja) * | 2010-06-25 | 2013-11-28 | シャイアー ヒューマン ジェネティック セラピーズ, インコーポレイテッド | サンフィリポ症候群b型の処置 |
WO2012063799A1 (ja) | 2010-11-08 | 2012-05-18 | 日本ケミカルリサーチ株式会社 | 新規発現ベクター |
WO2013161958A1 (ja) | 2012-04-27 | 2013-10-31 | 日本ケミカルリサーチ株式会社 | 新規な発現ベクター |
JP2017523802A (ja) * | 2014-05-14 | 2017-08-24 | ラボラトリオス デル ドクター エステヴェ ソシエダッド アノニマ | リソソーム蓄積症処置用のアデノ随伴ウイルスベクター |
WO2018124121A1 (ja) | 2016-12-26 | 2018-07-05 | Jcrファーマ株式会社 | 血液脳関門を通過する新規な抗ヒトトランスフェリン受容体抗体 |
Non-Patent Citations (5)
Title |
---|
ADV. APPL. MATH., vol. 2, 1981, pages 482 - 9 |
ALTSCHUL SF, J MOL. BIOL., vol. 215, 1990, pages 403 - 10 |
KAN SHIH-HSIN; TROITSKAYA LARISA A; SINOW CAROLYN S; HAITZ KARYN; TODD AMANDA K; DI STEFANO ARIANA; LE STEVEN Q; DICKSON PATRICIA : "Insulin-like growth factor II peptide fusion enables uptake and lysosomal delivery of alpha-N-acetylglucosaminidase to mucopolysaccharidosis type IIIB fibroblasts", BIOCHEMICAL JOURNAL, vol. 458, no. Part 2, 1 March 2014 (2014-03-01), GB , pages 281 - 289, XP009177918, ISSN: 0264-6021, DOI: 10.1042/BJ20130845 * |
MIYAHARA M, J. BIOL. CHEM., vol. 275, 2000, pages 613 - 618 |
PROC. NATL. ACAD. SCI. USA., vol. 85, 1988, pages 2444 |
Also Published As
Publication number | Publication date |
---|---|
EP4198129A1 (en) | 2023-06-21 |
JPWO2022045273A1 (ja) | 2022-03-03 |
AU2021333365A1 (en) | 2023-03-16 |
MX2023002346A (es) | 2023-03-22 |
KR20230056714A (ko) | 2023-04-27 |
US20230323326A1 (en) | 2023-10-12 |
BR112023003342A2 (pt) | 2023-04-04 |
CN116234901A (zh) | 2023-06-06 |
TW202227630A (zh) | 2022-07-16 |
IL300887A (en) | 2023-04-01 |
CA3192771A1 (en) | 2022-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6797148B2 (ja) | 血液脳関門を通過する抗ヒトトランスフェリン受容体抗体 | |
US10899816B2 (en) | IL-15 and IL-15Rα sushi domain based immunocytokines | |
JP7232889B2 (ja) | 抗体融合蛋白質の製造方法 | |
JP6486686B2 (ja) | 単鎖抗体及び他のヘテロ多量体 | |
US20190192683A1 (en) | Cns-targeted conjugates having modified fc regions and methods of use thereof | |
EP2655624B1 (en) | Linker peptides and polypeptides comprising same | |
JP7427046B2 (ja) | Bdnfを含む融合蛋白質 | |
WO2022045273A1 (ja) | α-N-アセチルグルコサミニダーゼの変異体 | |
JP2007536933A (ja) | 抗体 | |
JP2022520998A (ja) | アルブミン結合抗体及びその使用 | |
WO2022191158A1 (ja) | 抗体-リソソーム酵素融合蛋白質の製造方法 | |
JP2024056666A (ja) | 血清アルブミンと生理活性を有する蛋白質との融合蛋白質 | |
JP2024056665A (ja) | 血清アルブミンと生理活性を有する蛋白質との融合蛋白質 | |
CN117003872A (zh) | 含有突变轻链可变区骨架的单链抗体片段 | |
JP2024056667A (ja) | 血清アルブミンと生理活性を有する蛋白質との融合蛋白質 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21861695 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022545716 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3192771 Country of ref document: CA |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112023003342 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2021333365 Country of ref document: AU Date of ref document: 20210827 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20237009458 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2021861695 Country of ref document: EP Effective date: 20230317 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 112023003342 Country of ref document: BR Kind code of ref document: A2 Effective date: 20230223 |